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Osteoporosis is a common condition affecting up to one in three women. This 
thesis has examined the genetic epidemiology of this disease, with analysis of 
postmenopausal twin pairs and unrelated women from the UK general population. 
Classical twin analysis in 87 monozygous and 95 dizygous (DZ) twin pairs 
demonstrated significant heritability for bone mineral density (BMD) at multiple skeletal 
sites, suggesting that between 60-85% of the population variance in bone mass was 
attributable to genetic factors. Within the DZ twins, a biallefic TaqI polymorphism of the 
vitamin D receptor (VDR) gene was found to be significantly associated with BMD with 
additional suggestive evidence for linkage. In this group, however, a Fokl polymorphism 
mapping to the 5' region of the gene was neither associated nor linked with bone mass. 
Analysis of 1,003 unrelated women also demonstrated a familial tendency to 
osteoporosis and fracture risk. Women with a positive family history of osteoporotic 
fracture in a female first-degree relative had reduced bone density at both spine and hip 
when compared to women with a negative history. Risk of fracture was increased three- 
fold in those with a positive family history, with strong evidence of site specificity for 
wrist ftacture. A polymorphism of the type I coUagen la gene was associated with 
reduced BMD and increased fracture risk, whilst an interleukin-I receptor gene 
polymorphism was found to be associated with rates of menopausal bone loss. Negative 
results were observed with the oestrogen and VDR gene polymorphisms, although the 
VDR TaqI polymorphism was independently associated with risk of knee and spine 
osteoarthritis. 
In conclusion, these results demonstrate that osteoporosis is under significant 
genetic control with a complex inheritance pattern. Several genes appear to act on 
differing bone-related traits with preliminary evidence for interaction between genes and 
with other co-morbid disease states. 
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CHAPTERI 
INTRODUCTION AND BACKGROUND 
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I. I Summary 
Osteoporosis, is a common skeletal disease characterised by low bone mass. 
deterioration of skeletal architecture and an increased susceptibility to fragility fracture. 
Approximately one in three women wiH experience an osteoporotic fracture during their 
lifetime, with the male lifetime risk being 25% of that observed in females. Bone mineral 
density (BMD) in later life is the strongest predictor of subsequent fracture, and is a 
composite value determined positively by the peak BMD achieved during skeletal growth 
and negatively by both age- and menopause-related bone loss. This chapter examines the 
aetiology of osteoporosis and the epidemiological risk factors associated with low BMD 
and fracture risk. A comprehensive review of genetic epidemiological studies related to 
osteoporosis is presented, utilising data from both family- and twin-based studies. With 
a hypothesis that genetic factors play a central role in the determination of bone mass, a 
discussion is given on likely candidate genes that may play a key regulatory role. The 
aim of this thesis is to Provide novel insight into the genetic epidemiology of 
osteoporosis and fracture risk in Caucasian women, and to examine the role of potential 
candidate loci in determining postmenopausal bone mass. Knowledge of the genetic 
mechanisms underlying both the attainment of peak BMD and subsequent bone loss will 
lead to an increased understanding of the disordered pathophysiology associated with 
osteoporosis and may ultimately result in improved therapeutic and diagnostic options 
for this conunon disease. 
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L2 Introduction 
The term r-costeoporosis" entered medical terminology in France and Germany 
during the last century. In its initial form it implied a histological diagnosis of porous 
bone, although this was subsequently refined to state that although bone tissue was 
present in a reduced quantity it was normally mineralised (Schapira. and Schapira., 1992). 
Clinicaffy osteoporosis is recognised by the occurrence of characteristic fractures at 
thoracolumbar spine, hip and wrist. 
A World Health Organisation (WHO) Study Group has recently attempted to 
combine both the histological and clinical definitions for osteoporosis. They state that 
osteoporosis is "a disease characterised by low bone mass and microarchitecture 
deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase 
in fracture risk" (Consensus Development Conference, 1991). Implicit in this definition 
of osteoporosis is the trait of low bone mass which can now be accurately measured non- 
invasively. The "0 (1994) has also recently proposed at a meeting of experts an 
operational definition for osteoporosis with reference to the peak young non-nal mean 
value (Table 1.1). This is based on the number of standard deviations a subject's BMD is 
above (+) or below (-) this mean peak value, and these results are expressed as a T- 
score. Using these definitions it has been possible to determine the population 
prevalence of osteoporosis at various ages, although the validity of this definition for 
males is still unclear (Table 1.2). 
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Table 1.1 Diagnostic classification for osteopenia and osteoporosis 
"0 Disease Classification BMD Measurement 
Normal T-score above -1 
Osteopenia T-score between -I and -2.5 
Osteoporosis T-score below -2.5 
Established Osteoporosis T-score below -2.5 and fragility 
fracture 
Table 1.2 Prevalence of osteoporosis at spine and hip in UK women according 
to age (Compston et al, 1995) 
Age 50-54 yrs Age 70-74 yrs 
Lumbar Spine 3.5 15 
Femoral Neck 2.0 20 
Table 1.3 Lifetime risk of common osteoporotic- related fractures in 
British men and women aged 50 years (Cooper 1996) 
Men Women 
Hip 3 14 
Vertebral (spine) 2 11 
Distal forearm (wrist) 2 13 
* Data for clinically diagnosed vertebral deformity 
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Despite these attempts to provide unifonn standards for disease definition. the 
prevalence estimates for osteoporosis remain complicated by the population reference 
ranges selected to define the mean BMD for the young normal population, the site of 
measurement and the type of machine and software used for scanning. 
Osteoporosis affects an estimated 75 million people in Europe, Japan and the 
United States (US) combined, including one in three postmenopausal women and most 
elderly people (Melton et al, 1992; Melton 1995a). Male rates of osteoporosis appear to 
be 25 % of that reported in women. The major health consequence of osteoporosis is 
that of fracture, and as stated previously the primary fracture sites are found at the long 
bones and the vertebrae. Current figures for the United Kingdom (UK) show that there 
are 60,000 hip fractures per year, 40,000 wrist (Colles) fractures and 40,000 
symptomatic vertebral fractures Per year (AGO Report, 1994). The lifetime risk for a 50 
year old woman sustaiiý an osteoporotic-related fracture is estimated at 38% (Black et 
al 1992; Cooper 1996) (Table 1.3). 
Fractures of the spine and wrist are painful and can result in skeletal defonnity. 
I-lip fracture however is responsible for much of the mortality and morbidity due to 
osteoporosis and is a leading cause of disability in elderly people. Between 12-20 % of 
patients with hip fracture wiH die within I year of the event (Keene et aL 1993), and 
mortality increases progressively with advancing age. There is also a large degree of 
morbidity associated with hip fractures as the majority of those that survive are unable to 
perform the activities of daily living unaided and a small percentage require permanent 
care m an mstitution or nursing home. Annual health costs for the care of osteoporotic 
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fractures within the UK are estimated at f942 n-ffion per year (AGO Report, 1994-, 
Dolan and Torgerson, 1998). 
1.3 Epidemiology of osteoporosis 
A risk factor is described as an attritbute associated with an increase in the risk of 
the disease. Some risk factors may be measures of the basic biologic processes that 
cause disease whilst others may merely be markers of risk, only indirectly linked to the 
pathogenesis of the disease. BMD is an established determinant of bone strength. and 
several studies have shown that it is a strong predictor of subsequent fracture (Hui et al, 
1989; Cummings et al 1990; Cummings et a] 1993). Many risk factors are thought to 
influence osteoporotic; fractures through direct effects on BMD, whilst others act 
A. 1-- 
through independent factors contributing to other facets of skeletal strength (i. e. 
architecture or quality), or by influencing the risk of falls. Many studies have identified 
epiderniological risk factors that are associated with osteoporosis and fracture at the 
population level (Cumn-fings et A 1995), although these risk factors appear too 
insensitive to act on their own as predictive tools for individual subjects (Spector et al, 
1992) (Table 1-4). It remains to be determined, however, whether any of these risk 
factors can be modified in an effective manner to significantly reduce the incidence of 
osteoporosis and the healthcare burden and cost associated with fracture. 
Most risk factors for osteoporotic fracture faH into six main categories: age or 
age-related, environmental, hormonal, chronic diseases, physical characteristics of bone, 
and racial and genetic factors. 
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Table 1.4 Crude relative risks for osteoporotic hip fracture associated with 
epidemiological risk factors in 9516 white women (Cummings et a[, 
1995) 
Measurement 
(comparison or unit) 
Relative risk 
(95% confidence intervals) 
Age (per 5 yrs) 1.4 (1.2-1.6) 
History of maternal hip fracture (vs, none) 1.8 (1.2-2.7) 
Increase in weight since age 25 (per 20%) 0.8 (0.6-0.9) 
Height at age 25 (per 6 cm) 1.3 (1.1-1.5) 
Self-rated health (per I-point decrease) 1.6 (1.2-2.1) 
Previous hyperthyroidism (vs none) 1.7 (1.2-2.5) 
Current use of benzodiazepines (vs no current use) 1.6 (1.1-2.4) 
Current use of anticonvulsant drugs (vs no current use) 2.0 (0.8-4.9) 
Current caffeine intake (per 190mg/day) 1.2 (1.0-1.5) 
Walking for exercise (vs not walking for exercise) 0.7 (0.5-1.0) 
On feet :! ý 4hr/day (vs >4 hr/day) 1.7 (1.2-2.4) 
Inability to rise from chair (vs ability) 1.7 (1.1-2.7) 
Lowest quartile for distal depth perception (vs other three) 1.4 (1.0-1.9) 
Low-frequency contrast sensitivity (per I SD decrease) 1.2 (1.0-1.5) 
Resting pulse > 80 beats/min (vs :! ý 80 beats/min) 1.7 (1.2-2.4) 
Any fracture since age of 50 (vs none) 1.5 (1.1-2.0) 
Calcaneal BMD (per I SD decrease) 1.6 (1.3-1.9) 
# Health was rated as poor (I point), fair (2 points), or good to excellent (3 points) 
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1.3.1 Risk factors - Age 
As previously demonstrated in Table 1.2, the prevalence of osteoporosis defined 
using BMD criteria increases with age. During childhood and adolescence there is rapid 
linear and appositional skeletal growth, the fomier reaching a maximum in the latter half 
of the second decade of life. Peak bone mass is attained during the third decade of life, 
With age-related bone loss commencing during the fourth decade. This loss continues 
throughout fife and is accelerated in women at the time of the menopause (Figure 1.1). 
Overall it is estimated that approximately 50% of trabecular bone and 35% of cortical 
bone mass are lost over a lifetime in women, with losses in men approximately two-thirds 
of these amounts. 
The common osteoporotic fractures also increase with age and show 
characteristic incidence profiles that are site specific (Figure 1.2). Hip fractures increase 
exponentially after the age of 70 years, with the average age for a hip fracture in the UK 
being 79 years. This is due to both age-related reductions in bone strength and to an 
age-related increase in the risk of falling. Winner et al (1989) demonstrated that whereas 
one in tbree women aged 80-84 years had Men in the previous year, this figure had risen 
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Vertebral fi-actures are commonly asymptomatic and prevalence estimates can 
only be obtained by radiological survey of the thoracolumbar spine although there 
remains a lack of a universally accepted definition for vertebral deformity. In a 
population sample of 762 women from the USA Melton et al. (1993) showed that the 
prevalence of one or more vertebral deformities increased from 7.6% at age 50-54 years 
to 64.3% in those aged 90 years and over. Recent data from the European Vertebral 
Osteoporosis (EVOS) Study has also examined prevalent vertebral deformities in 15,570 
males and females aged 50-79 years from 19 European countries (O'Neill et al, 1996). 
Prevalence rates increased with age in both sexes, though the gradient was steeper in 
women (Table 1.5). 
Table 1.5 Prevalence of vertebral deformity by age and sex group in 
the EVOS Study (O'Neill et al, 1996) 












50-54 16.5 11.5 0,70 9.9 5.0 0.51 
55-60 18.5 14.6 0.79 11.4 7.6 0.67 
60-64 21.0 16.8 0.80 12.8 9.9 0.77 
65-69 20.9 23.5 1.12 12.1 13.4 1.11 
70-75 20.7 27.2 1.31 13.2 17.0 1.29 
75-79 29.1 34.8 1.20 18.1 24.7 1.36 
EasteU et aL 1991 # McCloskey et al, 1993 
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Distal. forearm fractures display a different incidence pattern to that of the other 
osteoporotic fractures. The incidence rates for wrist fractures increase linearly from age 
40-65 years and then plateau in women, whereas in males the incidence rernains at a 
constant low rate between 20 and 80 years. 
1.3.2 Risk factors - Hormonal 
LIZI Oestrogen 
Osteoporosis occurs more commonly in women than in men, with female fracture 
rates increasing markedly after the menopause. These differences probably occur 
because of sex differences in peak BMD and because of women experiencing accelerated 
bone loss at the time of the menopause. This indicates the importance of oestrogen in 
the determination and maintenance of BMD in women, although the importance of this 
hormone on the male skeleton has also been demonstrated by recent case reports (Smith 
et al, 1994; Morishirna et al, 1995; Bilezikian et aL 1998). 
The association between osteoporosis and oestrogen was first described in 1941 
when it was noted that 40 of 42 women with osteoporotic fractures were 
postmenopausal (Albright et al, 194 1). Subsequently the associations between 
oopherectomy and accelerated bone loss (Meema et al, 1965; Nordin et al, 1968), and 
the beneficial effects of oestrogen were observed (Meema et al, 1975; Lindsay et al, 
1980). Bone mass has been positively associated with parity (Alderman et al, 1986) and 
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use of the oral contraceptive (Lindsay et al, 1986), but results have not been consistent 
between studies. Hypo-oestrogenic states that occur in anorexia nervosa and athletic 
amenorrhoea are also associated with low bone mass and increased fracture risk, 
although the pathogenic role of oestrogen deficiency has not been definitely established 
in these conditions. At the onset of the menopause there is an increase in bone turnover 
that results in net bone loss (Stepan et al, 1987). Bone turnover can be assessed 
indirectly by measurement of biochemical markers of bone formation and resorption 
found in serum and urine, and studies show that treatment with hormone replacement 
therapy (HRT) causes these markers to return to premenopausal levels (Johansen et al, 
1988; Uebelhart et al, 1991). 
L3. Z2 Testosterone 
Testosterone deficiency has been reported to occur in up to 30% of men with 
spinal osteoporosis, (Jackson et al, 1987) and is a significant risk factor for hip fracture 
in elderly males (Jackson et al, 1992). Androgen receptors have been demonstrated in 
vitro in human osteoblasts and osteoblast-like ceRs, as weH as in bone marrow stromal 
cells and osteoclast-like multinucleated cells (Vanderscheueren and Bouillon, 1995). 
The recent findings of low BMD in men with mutations in either oestrogen receptor 
(ER) or aromatase genes, suggests that local aromatisation of testosterone to oestradiol 
with direct oestrogen action on bone via its receptor rmy also be necessary for nonml 
male bone homeostasis (Smith et al, 1994; Morishima et al, 1995; Bilezikian et aL 1998). 
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L3. Z3 Thyroxine 
Bone mass is reduced in patients with thyrotoxicosis, with the detrimental effects 
of thyroid hormones on the skeleton being more marked in women compared to rnen 
(Rosen et al, 1992; Daimond et aL 1994). The decrease in BMD associated with 
thyrotoxicosis is reversible with effective treatment, although a previous history of 
thyroid disease is still associated with increased hip fracture risk in elderly women 
(Cummings et aL 1995). Thyroid hormones increase bone remodelling and directly 
stimulate osteoblast production of markers such as alkaline phosphatase (ALP) and 
osteocalcin (OC) (Mosekilde et aL 1990; Sato et al, 1987; Rizzoli et aL 1986). Despite 
this micreased osteoblastic activity, the enhanced bone formation cannot compensate for 
the thyroid-induced increase in bone resorption 
L3. Z4 Parathyroid hormone 
Parathyroid hormone (PTH) regulates the levels of calcium and phosphate M 
blood by modulating the activity of specific cells in bone and kidney. Patients with 
hyperparathyroidism show reduced BMD prinwily at cortical but not trabecular bone 
sites. Past history of hyperparathyroidism has also been shown to be a risk factor for hip 
fracture in the elderly (Cummings et aL 1995). PTH stimulates bone resorption, 
although this effect is not a consequence of direct action of PTH on the osteoclast as it 
does not respond to this hormone in isolation. This suggests that the presence of 
osteoblasts or osteoblast-derived factors is necessary for PTH-induced resorption. PTH 
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also has complex effects on bone formation, being able to both stimulate and inhibit bone 
collagen and matrix synthesis (Canalis et aL 1989; Canalis et aL 1994). 
1.3.3 Risk factors - Environmental 
The incidence of wrist and hip fractures exhibits a marked seasonal variation. 
The variation for wrist fractures is seen in Northern Europe but is not apparent in 
Southern European countries, and is clearly associated with an increased risk of falls in 
the winter months due to icy conditions. The seasonality in hip fractures is observed 
world-wide in both men and women, although the majority of hip fractures occur indoors 
and are not directly related to slipping on icy surfaces. They may therefore be a 
consequence of either a cold induced reduction in neuromuscular response to a faHs or to 
reduced vitamin D levels due to low sunlight exposure in the winter months. 
There is wide variation in the incidence of hip fractures within populations of a 
given race and gender. The Mediterranean Osteoporosis Study (MEDOS) suggested 
that hip fracture rates differed both between and within countries, with an II -fold 
variation (Elffors et al, 1994), although some of these differences are likely to be due to 
sampling and selection bias. In the USA, Jacobsen (1990) studied age-adjusted hip 
fracture rates in white women aged above 65 years from over 2,000 counties. Risk of 
fracture was negatively associated with increasing northern latitude, water hardness and 
hours of January sunlight, and positively associated with poverty levels, proportion of the 
land in farms, and the proportion of the population with fluoridated water. Compared to 
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the hip fracture data, the EVOS Study showed a much smaUer geographical variation for 
vertebral deformity (O'Neill et al, 1996). This may reflect the additional requirement for 
falls in the pathogenesis of hip fracture, although it my simply be a result of a better 
study design with less bias. 
L3.3.1 Calcium 
Calcium is a vital component of normal functioning bone and comprises about 
22% of skeletal weight. At birth the skeleton contains around 25 g of calcium, rising to 
1,000-1,200 g at skeletal maturity (Widdowson 1981). Infants double their skeletal mass 
in the first year of fife, and up to 40% of adult skeletal mass is accrued during 
adolescence. Estimates suggest that a mean calcium intake of 175 mg/day is required 
during the growth years to ensure adequate skeletal development. Matkovic et al (1979) 
compared bone mass in two populations from Croatia that had differing dietary calcium 
intakes. Subjects in the high calciwn intake area had greater peak BMD and maintained 
this benefit throughout life. In a study of calcium supplementation in pre-pubertal twins, 
Johnston et al (1992) demonstrated the beneficial effects of calcium on BMD in the twin 
receiving the supplement. Cununings and Nevitt (1997) have recently published their 
results from a meta-analysis of 23 epidemiological studies examining the relationship 
I- - between dietary calcium intake and osteoporotic fracture. Pooled results suggest a 
modest 4% reduction in hip fracture risk per 300mg/day increase in dietary calcium 
levels. 
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L3.3.2 Calcium absorption 
Calcium absorption through the gastrointestinal tract is dependent on the level of 
dietary intake. At low dietary intakes, calcium absorption occurs mainly via a 1.25- 
dihydroxyvitamin D3 [1,25-(OH)2D3] dependent active transport mechanism. At levels 
of calcium intake greater than 400 milligrammes (mg) per day, calcium is absorbed 
passively (Sheikh et al, 1988). Studies in older populations have shown that intestinal 
calcium absorption decreases with age in both males and females (Gallagher et al, 1979, 
Slovik et al, 198 1), although some have shown conflicting results (Christiansen and 
Rodbro, 1984). Ageing may alter the metabolism of calcium and vitamin D in a number 
of ways. There is an age-related decline in dermal production of 7-dehydrocholesterol, 
the precursor of pre-vitan-ýn D3,, so that synthesis of vitamin D3 is reduced (MacLaughlin 
and Holick, 1985). Intake of vitamin D, exposure to sunlight, renal production of 1,25- 
(01-1)2D3, intestinal absorption of calcium, and the ability to adapt to a low calcium diet 
may all be impaired in the elderly (Tsai et al, 1984; Reid et al, 1986; Bouillon et a], 
1987). Ebeling et, al (1992) have also shown that a decrease in the concentration of 
vitamin D receptors (VDRs) in intestinal mucosa with age in women may also contribute 
to impaired intestinal responsiveness to endogenous 1,25-(OH)2D3. As a consequence, 
secondary hyperparathyroidism often occurs with ageing and can contribute significantly 
to bone loss. Vitamin D levels have been shown to vary both between and within 
populations (McKenna 1992; van der Wielen et al, 1995), exhibiting a marked 
seasonality with lower levels seen in the winter mnths. These findings could account 
for some of the geographic and seasonal variation seen in osteoporotic fracture rates. 
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L3.3.3 Smoking 
Smoking has been reported to be a risk factor for osteoporotic, fractures at the 
hil, r), spine and wrist (Daniell 1976; Williams et al, 1982; Seeman et al, 1983). In the 
Study of Osteoporotic Fractures (SOF), current smokers have been shown to have a 2- 
fold increased risk of hip fracture compared to non-smokers or former smokers 
(Cummings et al, 1995). A recent meta analysis of 29 cross sectional studies has also 
conformed a cumulative effect of smoking on reductions in BMD and increases in hip 
fracture risk with age (Law and Hackshaw 1997). 
Smoking is, however, associated with other diseases that may impact on hip 
fracture risk. Adjustment for effects such as poorer health, weight loss, reduced 
quadriceps muscle strength, and reduced exercise levels diminished significantly the risk 
of fracture associated with current smoking (Cumniings et aL 1995). There is, however, 
evidence from other studies that smoking does have a direct influence on BMD 
independent of these other associations (Law and Hackshaw, 1997). Slemenda et al 
(1989) have shown that in premenopausal women, smoking causes reduction in BMD 
which is more marked at skeletal sites with a high trabecular bone content such as the 
lumbar spine and distal radius. Hopper and Seeman (1994) studied 41 female twin pairs 
(21 identical, 20 non-identical) discordant for smoking status. The smoking twin had 
lower BMD than the non-smoking twin in each pair, even after adjustment for potential 
confounders such as weight, age at menopause, caffeine intake, dietary calcium intake 
and exercise levels. This effect was most marked at the lumbar spine, with a mean 
reduction of 9.3%, compared to a reduction of 5.8% from the femoral neck. A dose 
response effect was also observed at the lumbar spine, with a decrease in BMD of 2% 
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for every I O-pack-year habit of smoking. Smoking was associated with increases in 
serum follicle stimulating hormone (FSH) and leutinising hormone (LH), and reductions 
in serum PTH. 
The mechanism by which smoking reduces BMD is uncertain and several theories 
have been proposed. Smoking is associated with alterations in reproductive function and 
a slightly earlier menopause of one to two years, and this may contribute to the 
reductions in BMD (Baron et aL 1990). Smokers also appear to experience more rapid 
bone loss in the early postmenopausal years (Krall and Dawson-Hughes 1991). Hirota et 
al (1993) have shown that smokers have a four-fold increased risk of osteonecrosis of 
the femoral head, suggesting that smoking may cause vasoconstriction and reduced 
blood supply to the femoral neck. Smoking may also have a direct toxic effect on bone 
cells. Lastly, elderly smokers have been shown to have an increased risk of falling 
(Nelson et al, 1994), and this may explain why the risk of hip ftacture associated with 
smoking is greater than that Predicted by the reductions observed in BMD- 
L3.3.4 Otherfactors 
Many other environmental factors have been found to be associated with low 
BMD in epidemiological studies, although results are not always consistent between 
studies. Excess alcohol is associated with reduced BMD and accelerated bone loss 
(Slemenda et al, 1992), although mild-moderate intake has been shown to have beneficial 
effects on bone mass at both spine and hip (Holbrook and Brett-Connor, 1993). Current 
caffeine intake has been associated with increased risk of hip fracture (Cummings et al, 
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1995), with evidence of an interaction between age and dietary intake of both calcium 
and caffeine (Massey 1991). 
1.3.4 Risk factors - Chronic diseases 
There are coRections of heterogeneous conditions that can be associated with 
increased bone loss, low bone mass and osteoporotic fracture (Table 1.6). In some of 
these diseases the causal relationship with osteoporosis is established such as with 
thyrotoxicosis, Cushing's disease, severe hyperparathyroidism and hypogonadism. In 
other conditions, the link with osteoporosis may be mediated through several disease- 
and therapy-related mechanisms such as in rheumatoid arthritis, gastrointestinal disease, 
organ transplantation and prolonged inunobilisation. Finally, in some conditions the 
causal relationship and aetiology remain unknown. 
1.3.5 Risk factors - Physical characteristics of bone 
When studying individuals with and without fractures there is still considerable 
misclassification and overlap of low and normal bone density results, with an average of 
only 0.5 standard deviations (SD) between cases and controls. In addition, and more 
importantly, BMD still fails to explain a considerable portion of the variance in fracture 
risk (Ott 1993; Marshall et al, 1996). Since the pathophysiology of osteoporosis 
includes both loss of bone mass and an alteration of trabecular microstructure, it has 
been suggested that measurement of other facets of bone strength such as the structure, 
elasticity and composition may improve fracture prediction. 
41 
Table 1.6 Recognised causes of secondary osteoporosis 
Endocrine 




" Diabetes mellitus 
Amenorrhoea 
" Amenorrhic athletes 












" Coehac disease 
" Inflanunatory bowel disease 
" Alcoholism 
" Pregnancy associated osteoporosis 
" Immobilisation 
" Rheumatoid arthritis or other connective tissue disease 




L3.5.1 Bone size 
Current absorptiometry methods to measure BMD measure the bone mineral 
content (BMC) within a given area. The measurement is therefore an areal density and 
not a true volumetric density,, and the correction of BMC for area removes some but not 
aH of its dependency on bone size. Bone size may be an important and independent 
predictor for osteoporotic fracture. Mazess et al (1994) reported that Z-scores for area] 
BMD of the lumbar spine were significantly better than calculated volumetric Z-scores in 
discriminating between patients with vertebral fracture and age-matched control subjects. 
By contrast in SOF, Cummings et al (I 994a) showed that areal BMD and estimated 
volumetric bone density of the hip both had similar predictive values for hip fracture. 
L3.5.2 Hip geonwtry 
Faulkner et al (1993) have also shown that hip geometry is predictive of hip 
fracture, with an increased risk of 1.7 for each SD increase in the measurement of hip 
axis length (HAL). This risk was independent of the association between hip geometry 
and height. Reid et al (1994) have demonstrated in elderly women from New Zealand 
that the mean HAL and femoral neck length measurements have increased over a 40 year 
period (1950s to 1990s). This increase was equivalent to approximately I SD and could 
explain the increase in hip fracture rates that have been observed over this time period. 
The authors speculate that this increase in geometric hip size may be due to improved 
nutrition before and during puberty, although the possibility of cohort effect cannot be 
excluded. 
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L3.5.3 Bone structure and architecture 
Quantitative ultrasound (QUS) is believed to provide a non-invasive measure of 
bone structure and is based on the theory that when sound waves pass through porous 
material such as bone they are scattered and absorbed and travel in a manner that 
depends on the elasticity, stiffness, volume and density of the material (Abendschein and 
Hy, att, 1970; Antich 1993). Current machines give figures for broadband attenuation 
(BUA) and velocity of sound (VOS) through bone. In vitro studies have shown that 
QUS parameters are highly correlated with structural and architectural components such 
as trabecular volume fraction and thickness, trabecular number, yield strength and load- 
bearing capacity (Gluer et al, 1994; Bouxsein et al, 1995). A large number of in vivo 
studies in humans assessing the relationship between QUS and bone mass and/or fracture 
have also now been reported. Correlation coefficients between QUS and BMD have 
ranged from r=0.14 to 0.88, with most studies finding correlations in the r=0.40 to 
0.70 range (Gregg et al, 1997). These findings suggest that QUS is not a direct 
surrogate measure of BMD, and may represent a measure of bone structure. At least 27 
cross-sectional studies have demonstrated lower QUS measurements in women with 
prevalent osteoporotic fractures compared to age-matched controls (Gregg et al, 1997). 
Odds ratio of spine and hip fractures ranged from 1.4 to 3.7 for each SD decrease of 
either BUA or VOS (Bauer et al, 1995; Gluer et al, 1996). Longitudinal studies have 
also provided support that QUS is a measure of future osteoporosis, and fracture risk 
(Porter et al, 1990; Heaney et al, 1995; Huang C et aL 1998). A large French population 
study in the elderly demonstrated that QUS measurement were also of greater predictive 
value for hip fracture than BMD (Hans et al, 1996). 
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1.3.6 Risk factors - Racial and genetic factors 
There is a wide variation in the prevalence of osteoporosis and in osteoporotic 
ýC. tracture rates between ethnic and racial groups (Melton 1995b). Variation in 
environmental factors such as diet, physical activity and exposure to ultraviolet fight have 
been suggested as possible reasons for these differences, although none of these factors 
seems sufficient to fully explain the observed differences. This suggests that genetic 
factors may play an important role in determining these racial and ethnic differences. 
Osteoporotic fracture rates are increased in those of Northern European descent, 
with the highest rates being observed in Scandinavia (Offors et al, 1994). The 
significantly lower incidence of hip fracture among blacks was first noted by Gyepes et a] 
(1962), with subsequent work confiaming that Blacks in the US and Africa have fewer 
vertebral and hip fractures than whites (Moldawer et al, 1965; Solomon 1979; Farmer 
et aL 1984; Kellie et aL 1990). 
This difference in fracture rates has been assumed to be due in part to Blacks 
having higher BMD compared to whites, with a mean increase of 8% (range 4-12%) 
(Cohn et al, 1977). This racial difference has been shown in one study to exist already 
during childhood (Bell et al, 199 1) and at least from puberty onward (Luckey et al, 
1989). The mechanism by which BMD is greater in Blacks remains, however, unknown. 
Various studies have explored differences in hormone concentrations (Meier et al, 1992; 
Dawson-Hughes et al, 1993; Kleerekoper et al, 1994), calcium metabolism (Clemens et 
al, 1982; BeH et al, 1985; Meier et aL 1991; BeR et aL 1993), body mass (Ortiz et a], 
1992), and body composition (Nelson et al, 1991). As noted previously, current 
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measures of BMD using dual energy xray absorptiometry (DXA) are two-dimensional 
areal measurements rather than true "density" values. Although BMD reduces the 
influence of bone size on BMC by normalising values for areal projection, it does not 
account for changes in bone thickness and remains therefore confounded by bone 
geometry. Racial differences in BMD may therefore be attributed to differences in bone 
and skeletal size. Studies have shown that the racial differences in BMD reduce 
considerably when statistical corrections were made for body size (Nelson et al, 1991; 
Tobias et aL 1994; Davis et aL 1994), with up to 50% of the variance in BMD being 
attributable to differences in body size (Nelson et al, 1991). Simple adjustment for 
height may not be ideal as Blacks have greater leg length but shorter tnmk length than 
white, whereas Asians have the same tnmk length as whites but a shorter leg length. 
Ideally size adjustment should be done using the dimensions of the structure actually 
measured although this is not practical with the current methods for bone densitometry. 
These data suggest the importance of bone size as an important indicator of bone 
o+-r suength, although the factors responsible for the ethnic/racial differences in 
bone size 
remain to be determined. 
Ethnic differences have also been observed in hip geometry, and this may also 
contribute to the observed racial differences in hip fracture (Cummings et al, 1994b). 
Similarly, a lower risk of falling has been reported in Black elderly women compared to 
white and this may also contribute to the racial differences in hip fracture (Tinetti et al., 
1988). 
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L4 Genetic epidemiology of osteoporosis 
The observed racial differences in BMD and fracture risk support the hyWthesis 
that population specific factors may play an important role in determining risk of 
osteoporosis. This may be due to both genetic and environmental components acting 
either directly on BMD or on intermediate phenotypes related to bone mass. 
Alternatively these factors may be acting on other independent phenotypes which are 
themselves correlated with the risk osteoporosis, and fracture. The relative importance of 
genetic factors in the determination of osteoporosis and bone mass can be quantified 
tbrough the use of appropriate twin or family based studies. 
1.4.1 Family Studies in Osteoporosis 
L4.1.1 Aggregation of bone mass in nornsalfamilies 
The importance of genetic determinants of osteoporosis comes from 
observations that the disease tended to segregate within families. Early studies examined 
correlation coefficients (r) between mother-daughter pairs (Table 1.7) for non-invasive 
measurements of skeletal size and BMD using single photon X-ray absorptiometry 
(SPA). 
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Table 1.7 Summary of mother-daughter studies examining axial and 
peripheral BMD measurements 
No. mothers Mean age No. Mean age BMD measurement 
SD (yrs) daughters SD (yrs) 
Lutz (1986) 26 55 4 26 26 ±5 SPA forearm 
Sowers 34 56 10 36 31 ±9 SPA forearm 
(1986) 
Tylavasky 84 44.2 0.4 84 18.6 ± 0.1 SPA forearm 
(1989) 
Lutz (1990) 37 52 ±7 37 25 4 DPA spine and hip 




Kahn (1994) 27 49.7 ± 3.6 27 23.9 4.1 SPA forearm 
27 76.9 ± 6.7 27 49.7 3.6 
McKay 41 38.8 ± 4.4 41 11.8 2.1 DXA spine and hip 
(1994) 24 67.3 ± 6.7 24 40.0 5.4 
Jouarmy 129 41.9 3.6 98 18.1 2.0 DXA total body 
(1995) 
Lonzer 16 28 DXA spine and hip 
(1996) 
Ferrari 138 40.0 4.0 138 8.1 0.7 DXA spine and hip 
(1998) 
Danielson 207 71 .74.6 
207 48.5 ± 7.3 DXA spine, hip 
(1999) and calcaneus 
Standard error (SE) 
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Lutz et al (1986) demonstrated that radial bone mass was significantly correlated 
between mother and daughter pairs, with heritability (W) estimates of 0.57 for 
measurements of bone mass/width and 0.72 for bone mass. In a study of similar size and 
design, however, Sowers et al (1986) observed no familial correlation in forearm bone 
mass. Tylavsky et al (1989) reported significant correlations in radial bone mass at both 
mid (r = 0.34) and distal (r = 0.32) sites, that remained significant after adjusting for age 
and body mass index (BNff). Kahn et al (1994) studied 27 triads of mother, daughter 
and grandmother for possible genetic influence on distal and proximal forearm BMD. At 
the proximal site a significant correlation was found between the mother-grandmother 
pairs (r =: 0.47), and although the mother-daughter correlation was 0.33 this failed to 
reach statistical significance due to the small numbers in the study. Significant 
correlations between the three generations were found, however, for measures of 
skeletal size, obesity and muscle strength in the hand. 
Lutz and Tesar (1990) first observed familial correlations in BMD at the spine 
and hip in a study of 37 mother-daughter pairs using dual photon absorptiomerty (DPA). 
Correlations coefficients ranged from 0.38 to 0.59, and were higher for premenopausal 
mothers and their daughters compared to the postmenopausal mothers and their 
daughters. KraIl and Dawson-Hughes (1993) studied BMD measuremnts at several 
skeletal sites in 40 mother-daughter pairs. Significant correlations were seen at all sites, 
ranging from r=0.30 for Itunbar spine BMD to r=0.54 for total body BMD. A second i 
3 generation study also found significant correlations for BMD values at the spine and 
hip between 24 grandmother-mother pairs and 41 mother-daughter pairs (McKay et al., 
1994). No significant correlations were observed however for BMD values between the 
18 grandmother-daughter pairs even after adjustment for age. A lower mother-daughter 
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correlation in total body BMD of r=0.24 was observed by Joanny et al (1995), and 
probably reflects the fact that values were adjusted for body mass and other 
environmental confounders. Ferrari et al (1998) examined both spine and hip BMD 
measurements in prepubertal daughters and their menopausal mothers. BMD was 
significantly correlated between the mother-daughter pairs (r = 0.22 to 0.36), 
demonstrating that 18-37% of BMD was directly determined by maternal descent. In 
the study by Danielson et al. (1999), mothers were recruited from the SOF study and 
results were stratified according to the disease status of the mother: incident peripheral 
fracture or prevalent vertebral fracture, low BMD but no fracture (i. e. femoral neck 
BMD T-score < -2.5), or normal BMD (i. e. femoral neck BMD T-score > -1.6). In 
total, 78 mother-daughter pairs were classified as "normal" and the correlations in BNfD 
measurements for these pairs ranged from r=0.16 at the femoral neck to r=0.28. 
Heritability estimates for this group were not presented, although pooled estimates 
independent of maternal disease status are given for premenopausal (h' range: 50-63%) 
and postmenopausal daughters (W range: 34 - 48%). 
The genetic similarity of mother-daughter and sister-sister pairs is identical, with 
each subject from a pair sharing on average 50% of their genes with the other family 
member. The correlation in BMD values within sibs would therefore be expected to be 
similar for that observed for mother-daughter pairs. Indeed, the closer matching of age 
and menopausal status within female siblings compared to mother-daughter pairs would 
I- - be expected to give a "truer" representation of the genetic component acting on BMD. 
A small early study in 29 female sibling pairs (mean age 60 ± 14 yrs) identified a 
significant correlation in crude forearm BNM (r = 0.48), although alter adjustment 
so 
and/or stratification for age and menopausal status this was no longer significant 
(Sowers et aL 1986). Further work from this group has also examined the correlation in 
hip BMD measurements between premenopausal siblings (Sowers et al, 1992). In total 
data were available from 137 families with the following composition: 2 sisters (n = 96 
families), 3 sisters (n = 31), 4 sisters (n = 7), 5 sisters (n = 2), and 7 sisters (n = 1). 
Variance component analysis was consistent with a polygenic inheritance model for 
adjusted hip BMD (adjusted for age and BNH), with heritability estimates ranging from 
0.67 at the femoral neck to 0.45 at the trochanteric site. No data from lumbar spine 
measurements was presented. 
These studies using data from female first-degree relatives all show a consistent 
genetic component to BMD. In the absence of data suggesting inheritance of 
nutochondrial DNA or imprinting (both giving rise to matemal transmission). an 
autosomal disease transmission is expected. This would imply that the genetic factors 
acting on BMD would be expected to be contributory from both parents, and that 
genetic effects would be observed in mother-son in addition to mother-daughter pairs. 
Comparison of male-female sibling pairs may be affected by the sex differences in BMD 
acquisition, skeletal size and body fat distribution, and appropriate statistical adjustments 
need to be utilised. To date, four studies have examined the coffelations in BMD 
between members of nuclear families (Krall and Dawson Hughes, 1993; McKay et 4 
1994; Jouanny et. al, 1995; Lonzer et al, 1996), and the details of these studies are 
summarised in Table 1.8. Krall and Dawson-Hughes (1993) also present data for 40 
daughter-son pairs, although correlations were only significant for os calcis BMD (r = 
0.45). 
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Table 1.8 Correlation of BMD measurements across family members 
Mother/ Mother/ Father/ Father/ Midparent/ Midparent/ 
Daughter Son Daughter Son Daughter Son 
Krall (1993) 
Total body 0.54 0.57 0.11 0.24 0.46 # 0.54 4# 
Lumbar spine 0.30 0.28 0.16 0.24 0.34 0.37 
Femoral neck 0.40 0.47 # -0.12 0.31 0.22 0.58 
McKay (1994) 
Lumbar spine 0.34 # 0.25 - - - - 
Femoral neck 0.31 # 0.22 - - - - 
Jouanny(1995) 
Total body 0.24 # 0.30 0.29 0.18 0.29 0.18 
Lower (1996) * 
Lumbar spine 0.58 # 0.83 ## 0.86 #4 
Pooling of results for sons and daughters in this stud 
#p<0.05 ##, p<0.0 1 ** p<0.001 
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Overall, these data would support an autosomal genetic contribution to the 
inheritance of BMD. Differences observed within studies could suggest some sex- 
specific genetic factors acting on BMD. Differences observed across studies could 
reflect population-specific genetic components acting on BMD, although they rnay have 
arisen because of differences in the sample sizes and ages of the nuclear families, and 
U- 
because of population specific envirom-nental exposures. 
L4.1.2 Segregation analysis of the inheritance of bone mass 
Data from family based studies has also allowed segregation analysis to be 
performed. This aflows the inheritance pattern for BMD to be modeUed and may 
subsequently aid the identification of specific loci having effects on the deterniination of 
BMD. 
Guegen et al (1995) have further analysed the data from the 129 French nuclear 
families described by Jouanny et al. (1995). Segregation analysis rejected the monogenic 
inheritance model for BMD and was reported to be consistent with a strong polygenic 
component. The maximum heritability for BMD in this study was 84% which was seen 
at age 26.4 years, with heritability values of 63.2% (14 years) and 33.8% (53 yrs) being 
observed at the extremes of the age distribution for the study population- This variability 
did not appear due to a change in the genetic component with age but was because of an 
increase in the individual specific variability after the age of 26.4 years, suggestIng that 
the correlation between BMD in two relatives is a function of the ages of each individual 
in the pair. 
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In contrast to this study suggesting a polygenic inheritance modeL segregation 
analysis from 302 pedigrees in rural Turkmenia. has indicated the possibility of a major 
gene effect on BMD variance (Livshits et aL 1996). BMD was measured from hand 
radiographs, with a composite score made for cortical and trabecular bone. The best 
fitting segregation model suggested the presence of a single gene explaining 50-60% of 
total variance in BMD, with two co-dominant alleles where the frequency of the aflele 
determining the higher BMD was between 0.30 and 0.38 in this Turkmenian population. 
Additional evidence that low spine BMD may also be under a dominant, monogenic 
mode of inheritance comes from data in seven pedigrees with familial osteopenia (total 
number of subjects = 143, number with spinal osteoPenia = 37) reported by Spotila et al 
(1996), A bimodal distribution to age-adjusted spine BMD values was observed, with 
simulation data suggesting a disease allele frequency of 0.0 1. 
L4.1.3 Aggregation of bone mass infamilies with osteoporosis 
The family studies previously described have predominantly all examined BMD 
correlations within nonnal subjects. To address the issue that genetic factors may 
contribute speci-ficaUy to low bone mass and fracture, several studies have examined 
these coffelations in families with evidence of osteoporosis, and these are summarised in 
Table 1.9. All these studies suggest that there may be site specific genetic factors 
influencing low bone mass and fracture at the spine and hip. Evans et at (1988) failed to 
show any reduction in BMD measured at the os calcis using quantitative computerised 
tomography (QCT) in the first-degree relatives of subjects with vertebral osteoporosis, 
r-"4 
although this may merely have been a power issue as this measurement result %vas offly 
available in 19/35 relatives. Reductions in BMD were found to be greater at the spine 
compared to femoral neck (7% vs 5%) in daughters of women with vertebral 
osteoporosis (Seeman et al, 1989), and similarly the reductions in BMD were also 
greater at the femoral neck compared to lumbar spine in daughters of women -,, vith hip 
fracture (Seeman et al, 1994). In the study by Cohen-Solal et al (1998) all probands 
were male with a predominance of vertebral fractures. Although the greatest reduction 
in BMD in first-degree relatives was observed at the spine a significant decrease was 
also seen at the hip. Danielson et al (1999) studied 72 mother-daughter pairs where the 
mother had either a prevalent vertebral fracture or an incident fracture of the hip, 
radius/ulna or humerus. It is not possible to determine the number of mothers that fefl 
into each of these categories, although overall daughters of the women with any fracture 
had significant reductions in BMD across afl measured sites. The mother-daughter 
correlations in BMD within this fracture group were also higher than had been observed 
in the women with "normal" BMD, ranging from r=0.30 at the femoral neck to r=0.48 
at the calcaneus. The lumbar spine correlation was only r=0.28, although matemal 
spinal BMD values could have been affected by the presence of prevalent vertebral 
deformity. 
In the absence of chnical or radiographical evidence of osteoporosis and/or 
fracture, two cross-sectional studies have utilised reported family history of disease to 
examine whether BMD was reduced in subjects with a positive family history of 
osteoporosis (Tylavsky et al, 1989; Soroko et al, 1994). These results are sununarised in 
Table 1.10. 
r% FN 
Table 1.9 Family studies of BMD measurements in relatives of 
patients with osteoporotic fracture 
Study 
Evans Seeman Seeman Cohen-Solal Danielson 
(1988) (1989) (1994) (1998) (1999) 
No. probands 25 25 74 38 72 
Sex ratio (F: M) 19: 6 25: 0 74: 0 0: 38 72: 0 




Mean age ± SD 60 ± It 67.9 ± 1.5 4 72.9 ± 1.1 9 50.3 ± 11.4 70.8 ± 4.1 
ofprobands 
No. relatives 35 32 41 73 72 
Sex ratio (F: M) 24: 1 32: 0 41: 0 41: 32 72: 0 
Relationship to Siblings Daughters Daughters Siblings (S) Daughters 
proband Offspring Offspring (0) 
Mean age ± SD 43 ± 10 36.9 ± 1.4 # 44.2 ± 2.0 # 43.5 ± 12.4 (S) 47.1 ± 8.0 
of relatives 27.3 ± 5.4 (0) 
BMD QCT spine DXA spine DXA spine DXA spine DXA spine 
measurements QCT calcaneus DXA hip DXA hip DXA hip DXA hip 
SXA calcaneus 
BMD reduction 1.7 SD - spine 0.7 SD - spine 0.4 SD - hip 1.3 
SD - spine 0.5 - 0.75 SD 
in relatives 0.3 SD - hip 1.0 SD - hip 
#± SE Compared to age-matched controls 
1% 
Table 1.10 Cross-sectional studies examining BMD in women with reported 
family history of osteoporosis 
Study 
Tylavsky (1989) Soroko (1994) 
No. subjects (N) 84 877 
Mean age ± SD (yrs) 18.6 74.4 ± 7.4 
Definition of family history Relationship Relationship 
e Maternal 9 Parental, Sister 
History History 
* Osteoporosis 9 Osteoporosis 
Fracture site Fracture 
e Hip, Spine, Colles 9 Any bone age > 50 
No. with positive history 20 454 
BMD measurement Radius Spine/Hip 
Reduction in BMD associated Distal: ý 2.0 % (NS) Spine: ý 3.0 % (P = 0.02) 
with positive family history Mid: ý1.7 % (NS) Hip: ý 1.9% (P = 0.07) 
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The relationship between family history of osteoporosis and/or fracture and 
reduced BMD was greatest at the spine and appeared specificaUy associated , Nllth 
paternal history of disease (Soroko et al, 1994). Potential limitations to these studies 
include the fact that family history was self-reported and was not able to be validated. 
Because of the subjects' age, spine BMD measurements may have been artefactuafly 
elevated due to the presence of aortic calcification and degenerative spinal disease. The 
negative findings of Tylavsky et al (1989) also reflect the small sample size and modest 
Power of the study as the magnitude of reduction in BNO seen with a positive family 
history was similar to that observed by Soroko et al (1994). 
L4.1.4 Family studies of osteoporoticfracture 
Studies examining the genetic effect on fracture are limited due to the age of 
disease onset and the low annual incidence of fracture-estimated at 1-2 women per year 
sustaining a vertebral fracture for every 100 women aged 65-70 years with low BMD (T 
score < -2.5) (Seeman & Hopper, 1997). Most data have therefore been derived from 
reported family history of fracture in subjects who have already experienced an 
osteoporotic fracture. To date, four cross-sectional and three prospective studies have 
examined the relationship between self-reported family history of osteoporosis and/or 
fracture and individual risk of fracture (Tables 1.11 and 1.12). All these studies are 
limited by the fact that fracture defuiftion in the relatives was self-reported, whilst in the 
cross-sectional studies differential recall of family history between fracture cases and 
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The studies by Soroko et al (1994) and MaUrnin et al (1994) demonstrate that 
any increase in fracture risk associated with a reported fimiily history is modest. They 
also suggest that it is a paternal history of osteoporosis and/or fracture rather than a 
maternal history that is specifically associated with this increased risk. The number of 
males with osteoporosis is small and this could have affected the results. The small stu4 
by Gardsell. et al (1987) showed, however, no difference in the prevalence of fractures In 
daughters of women with vertebral fracture when compared to controls with a negative 
family history. 
The three prospective studies have aH shown an increased fracture risk in women 
reporting a positive family history of hip fracture (Cummings et al, 1995; Torgerson et 
al, 1996) and wrist fracture (Fox et al, 1998). The 2-fold increased fracture risk 
observed by Cummings et al (1995) appeared independent of a subjects' bone mass and 
of a positive maternal history for other types of fracture associated with falling. This 
could suggest a genetic component to hip fracture risk that is acting on factors other 
than BMD and faff-related mechanisms. The study by Torgerson et al (1996) is limited 
because index case fractures were ascertained only by questionnaire with no validation 
process, and because traumatic fractures were included in the analysis. It is also unclear 
why details on hip fractures in maternal grandmothers are only included. Assuming a 
genetic component to fracture risk, one would anticipate that the risk would be greater 
with a parental history compared to that in observed in grandparents as parents and 
off-spring share on average 50% of their genes whereas grandparents and grandcHdren 
share on average only 25% of their genes. 
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In summary, therefore, family studies have shown familial resemblance in BMD 
measurements at various skeletal sites and are consistent with a major genetic 
component acting on bone mass. First-degree relatives of subjects with osteoporotic 
fracture have reduced BMD compared to age-matched controls in a site-specific ffianner. 
Family history of fracture, particularly of the hip, also appears to be associated with an 
increased fracture risk that again appears site specific and independent of BMD. Famil, \l 
studies are, however, confounded inherently by the age differences between parents and 
their children, particularly with regard to age-related phenomena such as BMD, and by 
possible major differences in environmental and life-style factors operational during the i 
development of peak BNM. It is because of these problems that twin studies have 
recently been utilised to aid in the identification of genetic factors underlying the 
attainment of BMD and the development of osteoporosis. 
62 
1.4.2 Twin Studies 
Because twins are matched for age and also commonly for environment, twin 
studies provide a powerful resource for the quantification of the genetic effects acting on 
complex traits such as osteoporosis. Identical, or monozygous (MZ), twins share 100 
% of their genes, and any phenotypic differences within MZ pairs must be due to 
environmental differences acting between members of a pair. Non-identical. or dizygous 
(DZ), twins share on average 50 % of their genes, and differences within these twin pairs 
must be due to both a combination of environmental and genetic differences between 
subjects. Comparison of the degree of similarity in phenotypes between both MZ and 
DZ twins gives an indication of the genetic component acting on the trait (Falconer 
1981). 
L4.21 Twin studies examining bone mass 
The first twin study in osteoporosis was described by Smith et al (1973) where 
bone mass and bone width were measured in the distal third of the right radial n-ýdshafi 
using SPA. The study's subjects included both young (age range 5-18 years) and adult 
(age range 44-55 years) twin pairs. The variance in radial bone mass and width within 
the younger DZ pairs was four times greater than the variance within MZ twin pairs, 
providing evidence for a significant genetic influence on both traits with heritability 
estimates of 0.75 (bone mass) and 0.77 (bone width). In the adult twins the within-pair 
variance in the DZ pairs also exceeded the variance within MZ pairs, although heritability 
estirnates were reduced, 0.49 (bone mass) and 0.45 (bone width). These data suggested 
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a significant genetic determination of bone mass which appeared stronger in younger 
subjects. The intra-pair differences in bone mass also appeared to increase with age In 
both the MZ and DZ twins, although this change was only significant in the case of DZ 
twins. A major limitation to this study was that the analysis in the younger twins pooled 
data from both male and female same-sexed twin pairs, as the sample size precluded sex 
specific analysis. In addition, data were also included on three pairs of Negro twins. 
This early work has been confirmed and extended by several workers (Table 
1.13). In a small study of same sexed twins Moller et al (1978) examined metacarpal 
morphometry, demonstrating that the mean intra-pair variances of both total and cortical 
width was 4-5 times higher in DZ than in MZ pairs with an estimated heritability of 
between 0.7 to 0.8. Again, the small sample size resulted in data for male and female 
twin pairs being pooled. 
Dequeker et. al. (1987) published the first twin study to examine BNID 
measurements at both peripheral (distal radius) and axial (lumbar spine) sites. Results 
were stratified by age (below and above 25 years). A significant genetic effect was 
demonstrated only for radial BMC in the older twins (8 MZ, 5 DZ pairs), with a 
ka 
heritability estimate of 0.75, whereas spinal BMD exhibited a strong genetic component 
with heritability estimates of 0.88 only in the younger twin pairs (8 MZ, 9 DZ pairs). 
Although the authors interpret these results to suggest that genetic and environmental 
factors may have differing effects on the peripheral and axial skeleton that are age 
dependent, it is more probable that the study was severely limited by the small number of 
subjects in each age group. In addition, although a twin pairs are reported to be sex- 
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matched no details are given on whether results were pooled for males and females and 
whether fernale twins were concordant for menopausal status. 
The results from other twin studies that have examined BMD at different sites are 
surnmarised in Tables 1.13 and 1.14. The consistent finding of quantitative evidence for 
genes influencing BMD is unlikely if many genes are involved in the inheritance of the 
trait (Cavalh-Sforza & Bodmer, 1971). These data would therefore suggest that 
relatively few genes might be involved in the inheritance of BMD. Bivariate analysis of 
BMD in premenopausal twins has also been reported to be consistent with one gene or a 
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Table 1.14 Heritability estimates for BMD from twin studies 
Pocock (1987) Slemenda (1991) Flicker (1995) Arden (1996a) 
Lumbar spine 
" rMZ 0.92 0.85 0.74 0.68 
" rDZ 0.36 0.33 0.33 0.29 
*h2 0.92 1.05 0.82 0.78 
Femoral neck 
" rMZ 0.73 0.81 0.74 0.61 
" rDZ 0.33 0.37 0.52 0.19 
*h2 0.73 0.88 0.44 0.84 
Ward's triangle 
" rN4Z 0.85 0.80 0.73 0.47 
" rDZ 0.36 0.38 0.31 0.22 
eh2 0.85 0.84 0.84 0.51 
Distal radius 
" rw 0.71 * 0.78 0.67 # 0.63 
" rDZ 0.50 * 0.43 0.62 # 0.32 
4, h2 0.42 * 0.70 0.10 # 
0.61 
Total body 
" rMZ - - 0.76 
0.63 
" rDZ 0.37 
0.25 
h2 0.58 0.76 
Distal radius BMC 
# Total forearm BMD 
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In summary, cross-sectional twin studies have shown consistently that the 
correlations for BMD are greater in MZ compared to DZ twin pairs and are consistent 
with a significant genetic component to the variance in BMD. These studies give. 
however. 
) little indication as to how genetic factors control the underlying physiological 
mechanisms that regulate the attainment of BMD. 
LAZ2 Twin studies examining bone turnover 
Mother-daughter studies have previously suggested a genetic influence over 
serum calcium levels (Lutz 1986), with heritability estimates for ionised, ultrafiltrable and 
total calcium being 0.93,0.92 and 0.67 respectively. To date, four studies in two 
different samples of adult twins have examined for genetic effects on osteoblast function 
and bone turnover in general. 
In a study of pre- and postmenopausal twins (39 MZ pairs, 31 DZ pairs) Kelly et 
al (1991) observed that up to 80% of the variance in serum OC levels, a marker of bone 
formation, was attributable to genetic factors. Importantly, in DZ twins, within-pair 
differences in osteocalcin were significantly related to within-pair differences in BMD at 
both the lumbar spine and femoral neck. The twin with the higher osteocalcin value was 
found to have the lower BMD measurement at both skeletal sites. In this study, 
however, no genetic effect was demonstrated for urinary markers of bone resorption (the 
hydroxyproline: creatinine and calcium: creatiiýe ratios). 
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Further studies in these same twins (with only smaH additions to numbers) using 
more recent markers of both formation and resorption have also shown a strong genetic 
component on bone turnover (Tokita, et aL 1994; Harris et aL 1998). Again, within-pair 
differences in PICP and ICTP in DZ pairs predicted differences in lumbar spine BMD. 
findings that were independent of their OC levels (Tokita et al, 1994). Multivariate 
analysis also suggested that the genes specifically influencing BAP only accounted for 
16% of the total genetic variance at the lumbar spine and 4% at the femoral neck, 
suggestmg the potential loci influencing BNM and BAP appear largely independent 
(Harris et aL 1998). Whether the same were true for genes controlling the other markers 
of bone turnover was not clear. 
Garnero et. al (1996a) in a larger study of postmenopausal twins (61 MZ pairs, 59 
DZ pairs) with measurements on a wide range of biochemical markers demonstrated 
more modest effects, finding that genetic contribution was greatest in markers that did 
not change markedly at the time of the menopause. In addition, in this study only within- 
pair differences of urinary type I collagen cross-linked N-telopeptide (a marker of bone 
resorption) was predictive of BMD at spine and hip. 
In summary, these data suggest a genetic contribution to ceUular processes that 
are involved in bone homeostasis. Population studies have suggested that biochemical 
markers of bone turnover may be predictive of subsequent rates of bone loss 
(Christiansen et al, 1987; Christiansen et al, 1993), although these findings have not been 
replicated in all studies (Keen et al, 1996). Extrapolation of these positive findings to the 
twin studies on bone turnover could, however, suggest a genetic contribution to rates of 
postmenopausal bone loss. 
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1.4.2.3 Twin studies examining rates of change in bone mass 
Only two twin studies have examined rates of change in BMD with conflicting 
results. In a cohort of 46 elderly (age range 60-71 years) male twins (25 MZ and 21 
DZ), Christian et al (1989) found no evidence for a genetic effect on change in forearm 
bone mass, with two measurements taken over a 16 year period. Within-pair 
correlations (rMZ/rDZ) for the rates of change in foreamn BMD were significant for 
both zYgosities, (rMZ = 0.35; rDZ = 0.43), although the correlations were not greater in 
the MZ compared to DZ twin pairs. These data suggested that factors common within 
twin pairs such as common environmental influences might be important in determining 
age-related bone loss in males. Further work from the same group also showed that 
these correlations were, reduced by 25-35% after adjustment for smoking, alcohol use, 
dietary calcium intake and exercise levels (Slemenda. et al, 1992). 
Conflicting results have been presented by Kelly et al (1993) in a longitudinal 
study over 1-5 years in male and female twins (16 MZ and 16 DZ pairs). rMZ values 
were greater than rDZ for the percentage rates of change in lumbar spine BMD. Similar 
but weaker effects were also seen at the trochanteric and Ward's triangle sites although 
not at the femoral neck. The authors suggest that the genetic effect on rates of change 
in bone mass may therefore be greater at trabecular rather than cortical bone sites. 
There are, however, several concerns about the findings of this study. The number of 
subjects in this study is small and the stability of the analytical models is therefore 
questionable. The twins were predominantly premenopausal and rates of change in 
BMD were small, ranging from -0.02 %/yr at the spine and -1/13 %/yr at the trochanter. 
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Given that BMD was measured using DPA with coefficients of variation ranging from 
2.6 % to 4.1 % across the skeletal sites, it is debatable whether these rates of change 
were significant given the short duration of the study. 
In summary, to date twin studies have not revealed any clear genetic contribution 
to age or menopause related bone loss. Larger longitudinal studies in postmenopausal 
twins wifl be required to test this hypothesis. 
L4.24 Twin studies examining osteoporoticfracture 
To date only one study has specifically examined the genetic influence on 
osteoporotic fractures (Kannus et aL 1999). This study examined data from 2308 MZ 
and 5241 DZ pairs, with fractures sustained over the age of 50 years being derived from 
hospital coding. Despite the large sample size, only 786 fracture subjects were 
identified, representing only 5.2% of the total. With a 25-year prospective study this 
figure appears low and suggests incomplete ascertainment. Because of this small 
number, fractures across all sites were pooled, and it was not possible to undertake site- 
specific analysis. In addition, spinal fractures would have been clinical and probably 
symptomatic, as radiological surveY was not undertaken in all subjects. Although the 
results overall were reported not to support a significant genetic contribution to fracture 
risk, sex-specific analysis did suggest a genetic conthbution in male twins. Further 
studies will be required to address this issue in more detail. 
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1.5 Candidate gene studies in osteoporosis 
As has been illustrated, osteoporosis is a complex disease that has been shown to 
have a strong genetic component. The specific genetic elements to consider m such a 
disease model include: 
1) The number of genes involved 
2) The frequency of the predisposing afleles 
3) The respective effects attributable to specific alleles 
The combined effects of aRelic interactions 
5) The background or enviromnental influence on the aflele effects. 
As osteoporosis is a disease of later life there is little segregation analysis data 
from disease affected pedigrees to indicate the mode of transn-dssion. Most data have 
either been acquired from twin studies or through quantitative trait analysis within large, 
normal pedigrees. Varying segregation models have been proposed (Geugen et al, 1995; 
Lipshits et al, 1996; Spotila et al, 1996), although it is now believed that several genes 
with frequent alleles having relatively small effects and interacting with environmental 
factors are likely to account for most of the genetic component of the disease (Pocock et 
al, 1987; Slemenda et al, 1991). At present there is no strong evidence to support a 
single gene effect on bone mass within the general population. Rare nionogeruc 
disorders (i. e. osteogenesis imperfecta) associated with a considerable increase in 
fracture risk in affected individuals are only observed in a tiny proportion of patients With 
osteoPorosis (Spotila et aL 1991; Spotila et al, 1994). 
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At any given genetic locus many different forms of a gene representing individual 
mutations may exist, and these are termed alleles. Many genes have one or several 
alleles represented at high frequencies in populations and such loci are said to be 
polymorphic. Typicafly a gene is defined as being polymorphic when its mst frequent 
allele has a population frequency of less than 0.95, although a less stringent criterion of 
0.99 is sometimes used (Ott 1992). This allows for the wide variation in the phenotypic 
expression of genetic traits that is observed: some alleles being associated directly with 
disease processes, while others contribute to the "normal" genetic variation seen in all 
populations. At the deoxyribonucelic. acid (DNA) level, the most common 
polymorphisms are generally based on single nucleotide changes, resulting in a biallelic 
system. Two other types of polymorphism also occur within the human genome. 
Variable number tandem repeats (VNTRs) occur because of variable nwnbers of short 
oligonucleotide sequences. These VNTRs are much more polymorphic than single 
nucleotide substitutions (Nakamura et al, 1987), although they occur less frequently 
throughout the genome. MicrosateRites consist of base pair (bp) repeats of short 
sequences (up to 6 bp) and exhibit wide variability (Weber and May, 1989). Most of the 
microsateflite polymorphisms identified to date have been based on dinucleotide repeats 
(dC-dA).. 
Genetic association studies will allow the comparison of candidate gene 
polymorphisms between patients and appropriate controls (Lander and Schork, 1994). 
Candidate genes can be tested for association with major traits such as BMD or fracture, 
and in addition they can also be tested against intermediate phenotypes such as bone 
turnover and other local, cellular processes. Knowledge of bone pathophysiology 
provides insight into the large number of proteins that are actively involved in 
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maintenance of skeletal integrity and the regulation of bone homeostasis. The genes that 
encode these proteins are therefore all potential candidate genes for the genetic 
regulation of BMD, and polymorphisms of these genes may contribute to the population 
variation of BMD and subsequent risk of osteoporosis. 
In this thesis, four candidate genes have been examined for polymorphic 
association with BMD and risk of osteoporosis. The background to the work on these 
candidate genes is presented in the next sections. 
1.5.1 Vitamin D receptor 
Vitamin D3,, or cholecalciferoL is a steroid prohormone made in the skin by 
ultraviolet irradiation of 7-dehydrocholesterol. Metabolism in the fiver and kidney 
converts cholecalciferol. to the active metabolite calcitriol, 1,25-(OH)2D3. Although 
1,25-(OH)2D3 functions as an active hormone with diverse actions in a variety of tissues 
and cell types, most work to date has concentrated on its physiological regulation of 
calcium and phosphate horneostasis by bone, intestine and kidney. This is mediated 
through the VDF, (DeLuca 1992) although recent studies have indicated that 1,25- 
(OH)2D3may also influence ceflular processes through a second, non-genomic pathway 
that is not dependent on its receptor (Swain et aL 1993). 
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L5.1.1 Structural organisation of the vitamin D receptor 
The VDR is a member of the steroid, thyroid and retinoic acid receptor 
superfamily (Mangelsdorf et aL 1995). AU these receptors have a conserved structure. 
with the principal functional domains that effect the receptor's action including those for 
hormonal ligand binding, heterodimerisation, DNA binding/nuclear localisation, and 
transcriptional activation (Figure 1.3). Comparison of VDR protein sequence across 
species reveals significant similarity. The greatest degree of conservation occurs in those 
domains of known functional significance. 
The human VDR (hVDR) possess a conserved DNA binding domain consisting 
of two zinc finger motifs (residues 24-90). This structural motif is similar to the helix- 
turn-hefix DNA binding motif found in a number of other proteins that carry out related 
regulation of transcription. Within the intervening sequence of the two zinc fingers is a 
cluster of five basic amino acids (residues 49-55). This finding is unique to the VDR 
class of steroid hormone receptors. This cluster of amino acids is believed to play 
important roles in the regulation of DNA binding (Rastinejad et al, 1995) and nuclear 
localisation (Hsieh et al, 1998). In addition,. this segment includes ser-5 1, a site of hVDR 
phosphorylation by protein kinase C that could result in modulation of both DNA- 
binding and nuclear localisation of VDR in vivo (Hsieh et al, 1991; Darwish et 4 1993). 
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L5.1.2 Molecularfunction of the vitamin D receptor 
The classical mechanism of action for 1,, 25-(OH)2D3 involves binding of the 
vitamin to its intraceflular receptor, localisation of the figand-receptor complex to the 
nucleus of the cell and interaction with a specific regulatory nucleotide sequence within 
chromosomal DNA. This complex association then induces the transcription of specific 
messenger RNA (mRNA) coding for proteins which carry out the cellular functions of 
vitamm D (Darwish and DeLuca 1993). Phosphorylation of specific serine residues in 
the DNA binding domain of the VDR appears to also be required prior to activation of 
transcription (Darwish et al, 1993). Carlberg et al (I 993a., 1993b) identified two classes 
of vitamin D response element that are activated either by VDR binding as a homodimer 
(i. e. VDRNDR) or as a heterodimer (i. e. VDR with retinoid X receptor or other nuclear 
10- 
tactors). The motif GGGTGA arranged as a direct repeat with a spacing of six 
nucleotides, or as a palindrome without spacing, or as an inverted palindrome with a6 
nucleotide spacing confers induction of transcription mediated by VDR alone. The 
second class of element activated by the heterodimer complex comprises a6 nucleotide 
half-site direct repeat (GGTCCA, AGGTGA or GGGTGA) separated by 3 bp, this 
spacing contributing to the specificity of the response element to its respective receptor. 
The actions of vitamin D on skeletal bone remodelling have been extensively 
studied (DeLuca et al, 1992). Vitamin D stimulates osteoblast production of OC, and 
serum levels of this protein are used as an indicator of osteoblast function and of bone 
formation. The cloning of the human OC gene allowed the identification of a vitamin D 
response element approximately 500 bp upstream of the promoter (Morrison et al. 
1989). 
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L 5.1.3 Chromosomal location and structural organisadon of the h VDR gene 
The hVDR was initially cloned by Baker et al (1988), and has been localised to 
chromosome 12ql2-14 by somatic ceR hybridisation (Labuda et al, 1992; Szpirer et al. 
1991). It is interesting to note that the gene for psuedodeficiency vitamin D rickets 
(PDDR) due to a deficiency in 25-hydroxycholecalciferol- I -hydroylase maps to the same 
region. Labuda et al (1991) used a biallelic polymorphism and a VDR cloned DNA 
(cDNA) probe to demonstrate linkage between the VDR locus and the PDDR locus Ood 
score 1.94). In addition, no recombination was observed between the VDR locus and 
the type 2 collagen al (COL2AI) gene (Iod score 1.94). 
Nfiya, moto et al (1997) characterised the hVDR gene and its promoter by 
isolating lamda-phage and cosmid clones spanning more than 100 kilobases (kb). The 
chromosomal hVDR gene encompasses approximately 75 (kb) of genon-& DNA and 
contains II exons (Figure 1.3). The non-coding 5' end of the VDR gene includes exons 
I A, IB and I C, while its translated product is encoded by the additional 8 exons (2-9). 
Three unique mRNA isoforms are produced as a result of the differential splicing of 
exons 1B and IC. The DNA sequence upstream of exon IA is GC-rich and does not 
appear to contain a TATA box, although several binding sites for the transcription factor 
SP I and other activators have been noted. The bulk of the leader sequence of 115 
nucleotides is contained in the first exon (Baker et al, 1988). Exon 2 contains the 
remainder of the leader sequence, the translation initiation codon and the first of the two 
zinc finger structures. A polyrnorphic sequence within exon 2 also determines the 
presence or absence of an alternative translation start site, resulting in a hVDR protein 
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truncated by 3 amino acids. Exon 3 contains the second finger. thus completing the 
DNA binding domain of the VDR- Exons 4-6 comprise the nucleotide sequence for the 
"hinge" portion of the VDR molecule and are located in a cluster. A unique feature of 
the hVDR gene is the presence of an additional exon (5) that is not found in the nuclear 
receptor genes and encodes residues 155-194. This region of the VDR protein is more 
expansive than the corresponding segment in the other nuclear receptors, suggesting that 
the VDR may have acquired a novel exon of unknown function as it diverged from the 
other nuclear receptors during evolution (NEyamoto et al, 1997). The final three exons 
are also located in a cluster and encode the ligand-binding domain. Exon 9 is the largest 
of the VDR exons and contains the final 250 nucleotides of coding sequence as well as 
3.2 kb of 3' non-coding sequence (Baker et al, 1988). Two polyadenylation signals 
AATAAA are present 25 bp and 70 bp upstream of the poly-A tafl respectively. 
L5.1.4 Hereditary disorders associated with mutations in the VDR gene 
In total, 18 point mutations have been described in hereditary vitamin D resistant 
rickets patients (Figure 1.3). Single base-pair mutations within exons coding for the 
DNA binding domain result in disrupted action of 1,25-(014)2D3, and present 
phenotypicaRy as hereditary vitamin D resistant rickets (Yagi et aL 1993). A n-iissense 
mutation in exon 3 causing an amino acid substitution (Arg to Gln at amino acid position 
77) has been reported in two affected siblings with hereditary vitamin D resistant rickets 
(MaHoy et a], 1994). This region codes for the base of the second zinc finger that is 
critical for DNA binding of the receptor. Missense mutations in the hormone-binding 
domain of the VDR gene have also been described. A substitution of Leu to Arg at 
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amino acid position 271 results in a receptor which has reduced binding affinity. with 
expression analysis demonstrating that gene transcription could be elicited by the mutant 
VDR only in the presence of a 1,000-fold higher concentration of 1,25(OH)2D3 
(Kristjansson et al, 1993). Several truncated forms of the VDR have also been 
recognised in patients with hereditary vitamin D resistant rickets (Wiese et A 1993) 
where nucleotide substitutions produce premature stop codons resulting in messenger 
RNA transcripts that lack the fuff hormone binding domain. 
L5.1.5 VDR nufl mice 
VDR knockout mice have recently been created by two groups (Yoshizawa et al. 
1997; Li et al, 1997). Heterozygotes appeared normal, whereas homozygous VDR -/- 
mice displayed a phenotype similar to HVDRR. Homozygous mice were born normal. 
subsequently developing symptoms and signs of rickets/osteornalacia and secondary 
hyperparathyroidism after weaning. These included low bone mass, hypocalcaen-L, 
hypophosphataemia, elevated PTH, and a 10-fold elevation in 1,25-(OH)2D3 coincident 
with extremely low 24,25(01-1)2D3. Affected homozygotes either died within 15 weeks 
or exhibited near normal survival rates for up to 6 months, differences that may have 
been attributable to variations in either diet or enviromnent. Partial phenotypic rescue of 
the VDR knockout mice was possible with dietary manipulation of the blood calcium and 
phosphate levels. PTH was normalised and bone mineralisation was greatly improved 
with these measures, although alopecia and skin changes such as den-nal cysts persisted. 
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L5.1.6 Restrictionfragment length polymorphisim in the VDR gene 
The cloning of the human cDNA allowed identification of restriction fragment 
length polyrnorphisms (RFLPs) within the gene. Faraco et al (1989) identified an APal 
RFLP at the human VDR gene locus with bands at either 7.9 kb or 3.0 kb. Co-dominant 
inheritance of this dimorphism was demonstrated in one family of 7 individuals Two 
further RFLPs were detected by Morrison et al (1992) using the restriction 
endonucleases BsmI and EcoRV and a 2.1 kb VDR cDNA probe. The RFLPs were 
coded as "Ad' (Apal), "Bb" (BsmI), and "Ee" (EcoRP), where the upper case letter 
signifies absence of the restriction site and the lower case letter signifies presence of the 
site. The genotypes of 182 unrelated individuals were assessed using all three VDR 
RFLPs and this demonstrated a strong degree of co-association indicating linkage 
disequilibriurn (LD) at this locus. The RFLPs were highly associated such that genotype 
"AX' was found with "BB" and "EE" at frequencies of 83% and 92% respectively. 
Correspondingly, genotype "aa" was found with "bb" and "ee" at frequencies of 61% 
and 72% respectively, Hustmyer et al (1993) detected an additional VDR RFLP using 
the restriction endonuclease TaqI and a 1.4 kb full length cDNA of the VDR open 
reading frame. For the TaqI enodonuclease, two variant bands were detected at 2.0 kb 
and 2.2 bb. Mendelian inheritance was demonstrated in one family of 8 individuals. In 
this study Hustmyer et al (1993) found that the RFLPs differed between American white 
Caucasians, Blacks and Asians (Table 1.15). 
The most informative RFLPs (BsmI, ApaI and Taq]) were subsequently mapped 
to the 3' region of the gene using Sau-3A restriction sub-fragments of the VDR cDNA 
(Morrison et al, 1994). The BsmI and ApaI sites he within intron 8 and do not alter the 
VDR messenger RNA sequence, whiIst the TaqI site is within exon 9 (Figure 1.3). It is. 
however, a synonymous codon change (i. e. ATT to ATC) and does not alter the amino 
acid sequence (isoleucine) at this position. There was, on average, 98% concordance for 
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the haplotypes BAt and baT (Morrison et al, 1994). A microsatellite pol,, -(A) repeat has 
also been mapped to the 3'-untranslated region (UTR), approximately I kb upstream of 
the poly(A) tail (Morrison et al, 1994). Multiple (ý! 12) allehc variants of this 
microsatellite have been detected and classified into two groupings, long (L) and short 
(S), based upon the length of the repeat (Ingles et al, 1997a; 1997b). The L grouping 
appears significantly linked to the TaqI T allele. 
Near the 5' region of the hVDF, a FoU restriction endonuclease site has been 
identified (Saijo et al, 1991; Gross et, 1996). The presence of the restriction site dictates 
the expression of the 427-residue, MI isofonn of the VDR (so named because it contains 
an ATG methionine translational start site corresponding to codon #1). An evolutionary 
more recent polymorphism has been reported in which the ATG codon #1 and the FokI 
restriction site are changed, causing a 424-residue isofonn of the receptor to be 
translated (Gross et al, 1998). 
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Table 1.15 Summary of frequencies of polymorphisms at the VDR locus in 
different racial groups 




ApaI American Caucasians 153 0.56 0.44 
_ 
Faraco et al 1989 
Australian Caucasians 256 0.49 0.51 Morrison et al 1992 
American Caucasians 85 0.50 0.50 0.48 Hustmyer et al 1993 
American Blacks 19 0.45 0.50 0.05 0.63 Hustmyer et al 1993 
American Asians 16 0.22 0.78 0.31 Hustmyer et al 1993 
BsmI Australian Caucasians 182 0.44 0.56 Morrison et al 1992 
American Caucasians 85 0.44 0.56 0.55 Hustmyer et al 1993 
American Blacks 19 0.21 0.79 0.42 Hustmyer et al 1993 
American Asians 16 0.06 0.94 0.12 Hustmyer et a] 1993 
EcoRV Australian Caucasians 255 0.49 0.51 Morrison et a] 1992 
American Caucasians 85 0.49 0.51 0.46 Hustmyer et al 1993 
American Blacks 19 0.32 0.68 0.63 Hustmyer et al 1993 
American Asians 16 0.22 0.78 0.31 Hustmyer et al 1993 
TaqI UK Caucasians 190 0.40 0.60 Spector et al 1992 
American Caucasians 85 0.39 0.61 0.48 Hustmyer et al 1993 
American Blacks 19 0.21 0.79 0.42 Hustmyer et al 1993 
American Asians 16 0.03 0.97 0.06 Hustmyer et al 1993 
N= number of subjects studied Al= absence of restriction site A2 = presence of 
restriction site 
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L5.1.7 h VDR gene polynwrphism and osteoporosis 
The OC gene on chromosome I has a VDR hormone response element in its 
promoter region, and 1,25-(OH)2D3 is known to induce OC protein synthesis (Morrison 
et al, 1989). Production of OC may be regulated by functionally different alleles of the 
VDR gene on chromosome 12, given that Kelly et al. (199 1) had shown high heritability 
estimates for circulating levels. In an association analysis Morrison et al (1992) 
demonstrated that VDR RFLPs predicted circulating osteocalcin levels in 182 unrelated 
subjects, with these results being independent of age or menopausal effects. Morrison et 
al (1994) subsequently examined the relationship between VDR gene alleles and bone 
mass at spine and hip in a study of 64 MZ and 49 DZ female twin pairs. VDR genotype 
was assigned using the polymerase chain reaction (PCR) and restriction endonuclease 
digestion with the enzymes BsmI, ApaI and TaqI. VDR genotype was specifically 
associated with BMD at the spine and to a lesser extent at the hip in this group, with the 
allele "B" (or "t") contributing to low bone mass in an additive or co-dominant model. 
The magnitude of the effect due to the BsmI RFLP was approximately I SD of the age- 
matched population distribution. It was subsequently estimated that the VDR locus 
might explain up to 75% of the genetic variation in BMD. A similar relationship was 
seen in 311 randomly selected unrelated women, with the 'ýBB" genotype having about 
10-15% (equivalent to I SD) lower spine MM compared to "bb" individuals. The 
"BB" genotype was over represented in those women with BMD measurements 2 SD 
below the peak adulthood value (i. e. T score <-2). Extrapolation of the cross-sectional 
data suggested that women with the low BMD genotype could reach the fracture 
threshold up to II years earlier than the other individuals. 
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Preliminary functional data from the report by Morrison et al (1994) using 
minigenes and heterologous promoter and reporter constructs showed increased 
luciferase activity associated with the haplotype BBAAtt compared to bbaaTT. These 
differences were suggestive of either increased mRNA synthesis or stability. There were. 
however, many differences in the sequences used between the constructs (i. e. point 
mutations, insertions and deletions), and any one of these variations could have affected 
the in vitro mRNA concentrations. 
1.5.2 Oestrogen receptor 
Oestrogen action is mediated by oestrogen receptors (ER), ERcc and ERP, which 
have unique tissue distributions and different affinities for oestrogen agonists and 
antagonists. The first report of the presence of ERcc in bone tissue was made by Eriksen 
et al (1988) in a study of human cells of osteoblast lineage using Northem blot analysis. 
L5.21 Chromosomal location and structural organisation of the ER a gene 
Walter et al (1985) cloned and Greene et al (1986) sequenced a cDNA for the 
entire translated portion of the mRNA for the ER of MCF-7 human breast cancer cells. 
The cDNA contains 1,785 nucleotides and encodes a protein of 595 amino acids 
(predicted molecular weight 66,182). The genomic organisation of the ER gene was 
subsequently described 2 years later (Ponglikitmongkol et A 1988), consisting of 8 
exons, spanning 140 kb (Figure 1.4). 
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The position of the introns appears highly conserved, being remarkably similar to 
one of the chicken thyroid hormone receptor genes. The human ERcc gene was initiafly 
mapped to chromosomal region 6q24-27 using in-situ hybridisation (Gosden et al, 1986). 
Menasce et al (1993) using yeast artificial clones (YAQ and fluorescence in situ 
hybridisation subsequently provided more accurate localisation to 6q25.1. 
A highly conserved 66-amino acid region of the oestrogen and glucocorticoid 
receptors, which corresponds to part of the receptors' DNA-binding domain (region Q. 
determines the specificity of target gene recognition. This region contains 2 subregions 
(CI and CII), encoded by two separate exons that are analogous to "zinc fingers"'. 
Mader et al (1989) showed, through the study of a chimeric EF, that 3 amino acids 
located on the C-tem-final side of the Cl finger played a key role in this specificity. 
L5.22 Hereditary disorders associated with mutations in the human ERa 
gene 
The finding of an important fimctional role for oestrogen and its receptor in the 
human male skeleton is highlighted in the report by Smith et al (1994) who described a 
28 year old male with an oestrogen receptor mutation. The subject presented with 
marked osteoporosis and biochemical evidence of increased bone turnover. Other 
phenotypic characteristics included tall stature with incomplete epiphyseal closure, 
bilateral axillary acanthrosis nigricans and biochemical evidence of insulin resistance with 
impaired glucose tolerance. Serum sex hormones and pituitary hormones also indicated 
primary resistance to oestrogen. Molecular analysis subsequently revealed that the 
patient was homozygous for a C--+T mutation at codon 157 in exon 2 which introduced 
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a premature stop codon (TGA). This was in the A/B domain of the ER protein and 
would be expected to yield a severely truncated protein with no functional activity. 
L5.23 ER a nuff mice 
ER-knockout mice have been generated by disruption of exon 2 of the murine ER 
gene (Lubahn et aL 1993). Homozygous, knockout mice have been shown to have 
reductions in BMD of 20-25% when compared to wild-type mice (Korach 1994). These 
findings were seen in both male and feniale mice, suggesting a role of oestrogen in the 
development and maintenance of bone mass in the male skeleton. 
L5.24 Restriction fragment length polymorph isms in th e ER a gen e 
Gross structural mutations within the human ERcc gene appear rare, although a 
large number of variant and/or atypical receptor transcripts and proteins have been 
described, particularly in primary breast cancers and established breast cancer cell lines. 
Variant mRNAs that appear to arise from alternate splicing of the primary ER transcript 
have been described which lack exon 2,3,4,5 or 7 (Table 1.16). Other splice variants 
include ones containing six additional bp from the 5' of intron 2 (Fuqua et al, 1993), 
those lacking the 3' nine bp of exon 4, those containing an additional I kb of intron 5, 
and various insertions of approximately 130 bp in exon 5 homologous to the alu gene 
family (Graham et al, 1990). Functional data on these variants suggests that this altered 
splicing of the ER mRNA may contribute to the clinical behaviour of the tumours and 
perhaps could serve as a prognostic factor. 
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Table 1.16 Oestrogen receptor RNA splice variants from breast cancer 
tumours and cell lines 
Deleted exon Source ER activity Reference 
2 T47D cells Unknown Wang et al, 1991 




Wang et al, 1991 
McGuire et a]. 1991 
4 MCF-7 and ZR75-1 cells Unknown Pfeffer et al, 1993 
5 ER7/PR' human tumours Constitutive function Fuqua et a], 1991 
7 T47D cells 
ER71PR+ human turnours 
Non-functional 
Dominant-negative 
Wang et al, 1991 
Fuqua et al, 1992 
Sequence variation in non-malignant somatic cells has also been examined and 
several common polymorphisms have been identified. Using RNAse protection assays, 
Garcia et al (1988) identified a genetic polymorphism within the mRNA region encoding 
the amino terminal portion of the ER protein. Subsequent direct sequencing identified 2 
mutations (Garcia et al, 1989), although the C--*T substitution at position 257 was 
subsequently shown to be artefactual (Taylor et al, 1992). The mutation at position 261 
is a synonymous change and does not alter the amino acid sequence. An early small 
study (Taylor et al, 1992) showed the frequency of the of the ER "B-variant" allele to be 
0.04 in Caucasians (n = 22) and 0.07 in Blacks (n = 7). A subsequent study (Schmutzier 
et al, 1991) showed an identical allele frequency of 0.06 in both women with breast 
cancer (n = 300) and in those with no history of breast cancer (n = 183). No fink 
between ER genotype and tumour histology and expression of ER could be 
demonstrated. The B-variant genotype has been associated with an increased rate of 
spontaneous abortion in women with a history of breast cancer (Lehrer et 4 1990). 
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although this finding has not been confirmed in case-control study of women with a 
history of repeated miscarriage (Taylor et al, 1993). A small study in women (n = 88) 
has also suggested an association between the B-variant aflele and hypertension (Lehrer 
et al, 1993). In this study there were 21 subjects who were heterozygous for the 
polymorphic allele, giving an inffited frequency of 0.12. This is double that observed in 
other studies and could suggest selection bias and an unrepresentative study sample. 
A PvuIl polymorphism was identified by Castagnoli et al (1987) using Southern 
blot analysis. Mendelian inheritance was demonstrated in two Italian families. Hill et al 
(1989) found no difference in the allele frequencies of the ER PvuH polymorphism 
between DNA samples from human breast turnour samples (n = 188) and blood from 
healthy controls (n = 53). The allele frequencies were also shiilar to those observed by 
Castagnoli et al (1987). Presence of the 1.6 kb allele (aHele 1) appeared to be associated 
with reduced ER expression by breast tumour cefls. The 1.6 kb aflele was also found to 
correlate with an older age of diagnosis in 59 breast cancer patients (Parl et al, 1989). In 
a larger study of 257 breast cancer patients and 145 controls, Yaich et al (1992) failed 
however to show any relationship between the PvuII polymorphism and ER expression 
on tumour cells or with patient age at diagnosis. The PvuH polymorphism has been 
mapped to intron I of the ER gene, lying 0.4 kb upstream of exon 2 (Yaich et al, 1992). 
The precise functional significance of this polymorphism on ER function and breast 
cancer is therefore uncertain. Andersen et al (1997) studied leucocyte DNA from 143 
patients with familial clustering of cancer (breast and/or ovarian). Three patients were 
found to have a germline glycine to cysteine substitution at codon 160 of the ER gene. 
This is believed to represent a polymorphism as this change was also observed in 8/729 
controls, split equally between males and females. In the 229 female controlS In NA-hom 
family history of cancer was known, I of 2 who had a sister with breast cancer was 
carrying the variant aflele. 
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A polymorphic dinucleotide, repeat (TA),, has been identified in the promoter 
region of the ER gene (del Senno et al, 1992). This mapped to position - 1174 in relation 
to exon I. Co-dominant segregation was observed in 6 families. In total, 17 alleles were 
identified in an initial analysis of 70 chromosomes from 70 unrelated Italian individuals. 
The heterozygosity index was 82%. 
1.5.3 Type I collagen al 
Type I coUagen is the major protein constituent in skin, tendon and bone, and 
consists of the same protein, containing 2 al polypeptide chains and I (x2 chain. 
Differences in the coHagens from these three tissues are a function of the degree of 
hydroxylation of proline and lysine residues, aldehyde formation for cross-linking, and 
glycosylation. 
L5.3.1 Chromosomal location and structural organisation of the COLL41 
gene 
Sundar Raj et al (1977) mapped a type I collagen gene to chromosome 17 using 
cell hybridisation and micro-cell hybridisation. Huerre et al (1982) used a cDNA probe 
in both man-mouse and man-Chinese hamster somatic ceH hybrids to demonstrate co- 
segregation of the type I collagen la (COLIAI) gene with chromosome 17, with 
subsequent in-situ hybridisation mapping this gene to chromosomal band 17q2l. 3 I- 
q22.05 (Retief et al, 1985). Tromp et al (1988) were the first group to characterise a 
M-length human COLIAI cDNA. The COLIAI gene exhibits structural similarity with 
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collagens type 1 cc2, type 11 and 111, showing a characteristic structure of a large number 
of relatively small exons (54 and 108 bp) at evolutionary conserved positions along the 
length of the triple helical Glycine-X-Y portion (Boedtker et al, 1983). The X and Y 
stand for the amino acids fbHowing and preceding the glycine in the tri-peptide repeat. 
L5.3.2 Hereditary disorders associated with mutations in the COLL41 gene 
Willing et al (1993) observed that cultured dermal fibroblasts from patients with 
osteogenesis imperfecta (01) type I produced about half the normal amount of type I 
procollagen. This is because of a decreased COLIAI mRNA synthesis, indicating a 
possible defect in this gene in the majority of patients with type 1 01. In a survey of 40 
unrelated probands with 01 type I where no causative mutation was known, no 
promoter region mutations were identified with little evidence of sequence diversity 
(Willing et al; 1995). A large number of mutations and deletions have, however, been 
described within the coding region of the al and a2 type I coUagen genes, and 
Kuivanienu et al (1997) surnmarised. the sequence data on 317 apparently unrelated 01 
patients. Most mutations of the type I collagen genes were single bp changes and either 
changed the codon of a critical amino acid (63%) or led to abnormal mRNA splicing 
(13%). Most of the amino acid substitutions were those of a bulkier amino acid 
replacing the obligatory glycine of the repeating Gly-X-Y sequence of the collagen triple 
helix. Many patients with milder 01 showed evidence, however, of a null allele due to a 
premature stop mutation in the mutant mRNA transcript. 
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L5.3.3 COLL41 gene mutations and osteoporosis 
Spotila et al (1991) have identified a single bp mutation (G--ýA) in the a2 chain 
of type I coffagen, causing an amino acid change at codon. 661 of glycine to serine. This 
mutation was found in a 52 year-old Caucasian woman with low bone mass, thoracic 
vertebral fracture and 5 previous fragility fractures from the ages of 8 to 35. The patient 
also exhibited signs that may have been attributable to mild 01 (i. e. slight evidence of 
blue sclerae and mild hearing loss). This mutation was observed in her three sons (age 
range 24-31 years) who had each sustained one to four fractures as adolescents, although 
it was not present in DNA samples from the patient's mother (no DNA sample was 
available from the father) nor in a ftwther 54 unrelated individuals. A subsequent study 
(Spotila et al, 1994) examined for coding sequence defects in both the coRagen type I cc I 
and a2 genes in 26 subjects (21 female, 5 male). All subjects had low BMD, a positive 
family history of osteoporosis, and an absence of metabolic bone disease or clinical 
features to suggest 01. In addition to the sequence defect already observed (Spotila et 
al, 1991), two unrelated subjects (32 year old female and a 16 year old boy) were found 
to be heterozygous for a G-+C mutation that altered the proline codon at position 27 of 
the aI chain to alanine. To study the frequency of this substitution in a larger 
population, DNA was isolated from 81 normal individuals and a further 37 women with 
postmenopausal osteoporosis. None of these individuals exhibited this G-)-C mutation. 
Four other sequence variants were observed, although these occurred with equal 
frequency in the osteopenic and normal populations: alanine to profine at positionCL2 (I )- 
459, T/C in the asparganine codon at position (X2(l)-3 of the N-telopeptide, A/C in the 
proline codon at position (X2(l)-392, and T/C at codon CC2 (1)-955 (Constantinou et al, 
1990; Strobel et al, 1992). 
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L5.3.4 COLL41 gene polymorphisim and osteoporosis 
Mutations within the protein-coding region of type I collagen that cause gross 
structural changes therefore appear rare in postmenopausal osteoporosis. Sequence 
changes in regulatory regions of the type I collagen gene may, however, predispose to 
osteoporosis with alterations in type I collagen synthesis and metabolism Screening the 
COLIAl transcriptional control regions by PCR-SSCP in a sample of 50 sub ects, Grant 
et al (1996) identified 3 polymorphisms in the first intron. Two of these were rare with 
allele frequencies of approximately 0.04 and 0.03. The third, common polymorphism 
had an allele frequency of 0.22 and represented a G-+T substitution at the first base of a 
consensus site for the transcription factor SpI in the first intron (nucleotide 2046). The 
functional significance of this polymorphism on type I collagen synthesis is as yet 
uncertain, although preliminary data suggests that the rarer allele is associated with an 
increase in transcriptional activity (Grant et al, 1998). This polymorphism has recently 
been associated with reduced spinal bone mass and an increased risk of prevalent 
vertebral fracture in two populations from Aberdeen and London (Grant et al, 1996). 
1.5.4 Interleukin-1 receptor antagonist 
Oestrogen deficiency is associated with an increase in local production of various 
cytokines and growth factors within the bone marrow and bone cells, and these 
inflammatory factors appear to play an important role in the development of 
postmenopausal osteoporosis, (Ralston, 1994). Interleukin I (IL-1) is a powerful 
stimulant of bone resorption and a well-recognised inhibitor of bone formation 
(Dinareflo, 1991). IL-1 is a powerful stimulant of bone resorption, activating mature 
osteoclasts indirectly via a primary effect on osteoblasts and inhibiting osteoclast 
apopotosis. Monocytes of patients with "high turnover" osteoporosis, the histological 
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hallmark of postmenopausal osteoporosis, secrete increased amounts of IL- I (Pacifici et 
al, 1993). Subsequent observations have shown that this postmenopausal increase in IL- 
I activity results from an effect of oestrogen on the production of both IL-1 and its 
receptor antagonist IL-lra. Animal studies have also revealed that treatment with IL-lra 
blocks the ex vivo osteoclast formation induced by ovariectomy (Kitazawa et al. 1994). 
The IL- I ra protein binds to IL- I receptors and competes with both IL- I cc and IL- IP 
without detectable IL-1 agonist effects. This results in the biological activity of these 
two cytokines being neutralised in physiological and pathophysiological 
immune/inflammatory responses. 
IL-Ira levels are elevated in the blood of patients with a variety of immune, 
infectious and traumatic conditions. Two forms of the protein exist through alternative 
splicing of 2 different first exons. 
L5.4.1 Chromosomal location and structural organisation of the IL-IRN gene 
The human interleukin I receptor antagonist gene (IL- I RN) was first cloned by 
Carter et al (1990), and subsequently mapped to chromosome 2q using somatic 
rodent/human cell hybrids (Steinkasserer et al, 1992). The gene consists of 4 exons. 
Using a YAC containing the IL-IRN gene as a probe in fluorescence in situ 
hybridisation, Patterson et al. (1993) more accurately assigned the IL-IRN gene to 
2q 14.2. The genes for interleukin I a, interleukin 10, and the interleukin I receptors also 
map to the chromosomal region 2q, supporting the view that an early gene duplication 
event resulted in the creation of an interleukin I gene family. 
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L5.4.2 Polymorphisnu of the IL-IRNgene 
Early Ympping studies of the IL-IRN gene utilised the presence of polý, Tnorphic 
length variation within the second intron (Steinkasserer et al, 1992). Direct sequence 
analysis by Tarlow et al. (1993) demonstrated that this polymorphism was caused by a 
variable copy number of an 86 bp sequence (Figure 1.5). In total, 5 alleles were 
identified comprising between 2 and 6 repeats. The 4-repeat (allele Al) and 2-repeat 
(affele A2) alleles appear most common, while the other alleles occur at a combined 
frequency of less than 5% (Tarlow et aL 1993; Blakernore et al, 1996). The A2 allele 
has been found to be associated with a more severe clinical outcome in several 
inflammatory diseases, including systemic lupus erythematosus (Blakemore et al, 1994), 
Graves disease (Blakemore et al, 1995), ulcerative colitis (Mansfield et al, 1994), lichen 
sclerosus (Clay et al, 1994) and alopecia areata (Tarlow et al, 1994). Blakemore et al 
(1996) have also demonstrated an association between the IL- I RN A2 allele and diabetic 
retinopathy. The functional significance associated with the 86-bp VNTR is uncertain, 
although the polymorphic sequence may have direct effects as it is reported to contain 
three potential protein binding sites; an a-interferon silencer A, a 0-interferon silencer B 
and an acute phase response element (Tarlow et al, 1993). 
Additional single nucleotide polymorphisms have also been identified throughout 
the IL- I RN gene (Figure 1.5). 
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At the onset of this thesis limited results on the association between candidate 
genes and osteoporosis were available. Although preliminary evidence was available for 
the VDR and COLIAl genes, these findings were limited to reports from a single study 
in each case. Cross-sectional association studies also only allow the candidate gene to be 
tested for association with baseline BMD, but provide little insight into 
pathophysio logical processes. Assessment of longitudinal data may determine. however, 
whether the candidate gene is specifically associated with bone turnover, rates of bone 
loss or fracture incidence, thereby providing a possible fimctional mechanism. 
In the absence of a major gene effect on BMD, it is important to simultaneously 
examine several candidate genes in the same population. This allows assessment of 
evidence for interactions between genes acting on BMD and contributing to fracture risk. 
98 
L6 Thesis aims 
The main aims of this thesis are outlined below. 
1. To examine the candidacy of VDR gene polymorphisms on osteoporosis risk 
a) To attempt to replicate the original twin studies findings results from 
Morrison et al. (1994) in a different population of Caucasian, 
postmenopausal twins 
b) To extend the association between VDR genotype and BMD to unrelated 
women from the general population 
C) To examine for association between VDR genotype and longitudinal rates of 
bone loss, and osteoporotic fracture 
2. To examine the candidacy of other genes on osteoporosis risk 
a) To study the PvuII and XbaI ER gene polymorphisms for association with 
BMD and bone loss in unrelated women 
b) To examine the COLIAI gene polymorphism. for association with BMD 
and fracture in a case-control study, thereby attempting to replicate the 
findings of Grant et al (1997) 
C) To assess the IL- I RN VNTR genotype for association with and BMD 
and bone loss in unrelated women 
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3. To examine for evidence of locus interactions on BMD and other 
intermediate disease-related traits 
a) Analysis of genotype data (VDF, COLIA 1, EF, EL- I RN) against 
osteoporotic phenotypes in both twins and unrelated women 
4. To examine for a genetic association between osteoporosis and osteoarthritis 
a) Analysis of VDR genotype against risk of osteoarthritis at spine and knee 
in unrelated women 
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CHAPTER 11 
METHODS OF INVESTIGATION 
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II. I Summary 
This chapter presents details of the subjects who have been studied in this thesis 
and also of the methods utilised in the molecular and statistical analysis. Data on feniale 
twins and from a population-based cohort of unrelated women were available at St. 
Thomas' Hospital for this study. Information regarding the selection and recruitment of 
these subjects, and of how they compare to women from the UK general population is 
given. All women completed a detailed osteoporosis risk factor questionnaire and the 
infonnation obtained via this route is discussed. Full details are also given for the 
equipment used in the measurement of BMD in aff subjects. 
In total, four candidate genes were analysed (VDR, ER, IL- I RN and COLIA I). 
Details of the polymorphisms studied and the molecular biological detection methods 
used are presented. 
Heritability analysis was conducted in the MZ and DZ twins using standardised 
techniques. A modified sib-pair linkage analysis within the DZ pairs was used to 
examine for evidence of linkage between the candidate locus and the trait of interest (i. e. 
BMD). Candidate genes were tested for association with disease-related traits within the 
population cohorts using standard statistical methods. The underlying models and 
statistical assumptions for these tests are discussed in detail. 
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A2 Subjects 
11.2.1 Twin study 
Female twins were studied from the St. Tbomas' Adult Twin Register. This 
study was established in 1992 by Dr. Tim Spector to initially study the genetic effects on 
complex rheumatic diseases such as osteoporosis and osteoarthritis. The study's aims 
have since expanded to include an understanding of the genetic basis for a wide range of 
age-related phenotypes across multiple organ systems. Twins were initiafly obtained 
from a small registry at the Institute of Psychiatry, London University, although the 
majority of twins were subsequently recruited directly via national media campaigns. 
Female twins in the age range 45-70 were invited to attend and assist with research into 
osteoporosis and osteoarthritis. The zygosity of the twins was determined using a validated 
questionnaire and in doubtful cases this was confirnrd using muhiplex DNA fingetphnfing. 
Zygosity testing was performed at the Institute of Molecular Medicine using three 
polymorphic markers: VNTRs of the apolipoprotein B and heavy chain inununoglobulin 
genes, and a chromosome 16 microsateflite (D16S292). Probabihty of zygosity was 
calculated by sequential analysis, with this method providing accuracy of > 99%. AH subjects 
also completed a detailed nurse-administered risk factor questionnaire (Appendix A). 
11.2.2 Population study 
Clinical data and biological samples were utilised from women who were 
participating in the Chingford Study. This study was established in 1988 under the 
guidance of Dr. Tim Spector and Dr. David Doyle to study the longitudinal 
epidemiology of osteoarthritis and osteoporosis. In 1988 women in the age range 45-64 
had been selected from a large single general practice in Chingford, North-East London 
(total of 11,000 registered patients) to participate in a longitudinal epidemiological study 
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of rheumatic diseases. 1,353 women were found to be in the age range specified, and of 
these 78% (1,003) agreed to participate. The area is predominantly middle class, 98% 
are white and the population similar to United Kingdom normals in terms of height. 
weight, Smoking status, hysterectomy rates and use of HRT. Fasting blood and urine 
samples were obtained on all women at each visit and stored at -20* until required for 
analysis. All women also completed a questionnaire designed specifically to assess risk 
factors for osteoporosis and osteoarthritis (Appendix B). Subjects have been reviewed 
annuaffy by the same observer (Dr. Debbie Hart). 
11.2.3 Definition of menopausal status 
In both studies, premenopausal status was defined as a subject with regular 
menstruation. If hysterectomy without oopherectomy had been performed this was 
confirmed by measurement of serum sex hormones - FSH, LH and oestradiol. 
Postmenopausal status was defined as absence of menstruation for ý! 12 months and was 
confirmed in all cases by measurement of female sex hormones, with increases in FSH 
and LH, and a serum oestradiol < 100 pmol/l. 
11.2.4 Consent 
Women in both the twin and population based studies gave their informed 
consent to participate in these studies, and the relevant study protocols were approved 
by the Local Ethical Committee. 
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11-3 Bone Mineral Density Measurements 
11.3.1 Twins 
BMD was measured using DXA with a Hologic QDR-2000 (Hologic Inc.. 
Walthan-4 MA). Measurements were taken at the lumbar spine (LI-L4). hip (femoral 
neck, Ward's triangle, total hip and inter-trochanteric regions), forearm (3 regions: 
ultradistal, distal and mid-third) and total body BMC. 
11.3.2 Population study 
In the Chingford Study, BMD was measured using DXA with a Hologic QDR- 
1000. Annual measurements had been taken at the lumbar spine and femoral neck over a 
six-year period in A women. 
11.3.3 Reproducibility 
Daily quality control for the Hologic machines was performed using standard 
spine phantoms. ReproducibilitY in vivo was assessed with duplicate measures in 12 
healthy female volunteers. The coefficient of variation was 0.8 % at the lumbar spine. 
1.4% at the femoral neck, at the forearm and total body. 
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11.3.4 Definition of osteoporosis 
Based on WHO disease criteria (WHO, 1994), subjects were classified as having 
osteoporosis at either the spine or hip if their BMD was less than 2.5 standard de-N iations 
below the mean peak young adulthood value for that site. The Hologic database , vas 
used as the reference range for this calculation. 
11.3.5 Rates of change in BMD 
Annual measurements of BMD were available on women from the population 
cohort. In calculating the rate of change in BMD, it was assumed that the expected 
change in BMD was linear with time for each subject with variation in slopes and 
intercepts from subject to subject. The deviations of the measured BMD for a subject 
from the expected BMD were expected to have a zero mean and constant variance and 
to be uncorrelated. Under these assumptions a linear regression equation, where BMD is 
a dependent variable expressed as a linear function with time (in years), was fitted for 
individual subjects. Under this model, the annual percentage change in BMD for each 
subject was then derived by dividing the regression slope by the intercept at time zero. If 
hormonal treatment or other treatments known to affect bone metabolism such as 
steroids, bisphosphonates, calcium or vitamin D was initiated during the study pefiod, 




Assessment o osteoporoticfractures tf 
Peripheral fractures 
At their initial examination, all women from the Chingford population study reported 
their personal history of fracture for the I 0-year period preceding the study onset (1978- 
88). Because of the cohort's age range (45-64 years) all reported fractures had been 
sustained after the attainment of peak bone mass. Osteoporotic fractures sustained by 
these women were defined as fractures at the wrist and hip that had occurred after 
minimal trauma. The circumstances under which the fracture had occurred were detailed 
in a postal questionnaire. Major traumatic fractures were classified if they had occurred 
following a road traffic accident, a fall from the height of a chair or greater, or a fall 
down a ffight of stairs. Peripheral fractures in these subjects had been previously 
validated by examination of the subjects' medical records (Arden et al, 1996b). 
11.4.2 Vertebral fractures 
At their baseline assessment all 1003 women underwent radiological survey of 
their thoracic (T4-TI2) and lumbar (LI-L4) spines using standardised procedures. Spine 
fractures, which are mostly asymptornatic, were assumed to be osteoporotic in origim 
Fractures were defined with morphometric analysis using a semi-automated digitiser and 
a validated algorithm (McCloskey et al, 1993). Fracture was defined as at least two 2 
SD deformities or one 3 SD deformity of either anterior or posterior vertebral body 
16, ý height. These criteria have been shown to be associated with low BMD 
in population 
studies and are equivalent to more stringent cut-offs used by other groups (Eastell et al, 
199 1; Black et al, 199 1). 
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H. 5 Molecular studies 
11.5.1 General Reagents 
Molecular biology and analytical grade chemical reagents were obtained from the 
f0flowing suppliers: BioRad Ltd (Richmond CA, USA), Intemational Biotechnologies 
Inc OBI; New Haven, CT, USA), and the Sigma Chemical Co (Louis, MO, USA). 
Enzymes for molecular biology were purchased from Boehringer Manheim (Manheim, W 
Germany), Pharmacia. LKB Biotechnology (Uppsala, Sweden) or from Prornega 
Corporation (Maddison, WI, USA). 
111.5.2 Solutions and buffers 
(i) Tris saturated phenol: liquefied phenol saturated with O. IM Tris-HCL pH 8.0. 
(H) TBE: 50mM Tris-HCI, 40mM boric acid, ImM EDTA, pH 8.0 
(iii) TE: lOmM Tris-HCI, ImM EDTA, pH 8.0 
(iv) Red ceff lysis buffer: 15mM NH4CL, I OmM NaHC03. ImM EDTA, pH 8.0 
(V) Leucocyte lysis buffer: lOmM Tris-HCL 0.2% SDS, 5OmM EDTA, pH 8.0 
11.5.3 Genomic DNA extraction 
Peripheral whole blood was taken into EDTA tubes (2 x 10ml). Tubes were 
centrifuged for 10 n-ýinutes in a bench top centrifuge. The buffy coats were coRected, 
pooled and resuspended in normal saline (0.9 % NaCl) and centrifuged as above to 
minimise red cell contamination. The washed, pooled buffy coat was resuspended in red 
cell lysis buffer at 4'C for 20 minutes to lyse any residual red blood cells. The intact 
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leucocytes were then centrifuged again as above and the peUet resuspended in I ml of 
normal saline. 2ml of leucocyte lysis buffer were then added to lyse the leucocý-tes 
producing a viscous crude lysate. This crude preparation could be stored at -201C prior 
to the DNA extraction process if necessary. 
DNA extraction utilised a phenol/chloroform method. Briefly, to each crude 
leucocyte lysate was added 50 gl (10mghnl) of proteinase K (Boehringer Manheirn, W. 
Germany) and 250 W 10% SDS. Each sample was incubated at either 65'C for 1-4 
hours or at 37'C overnight. 1.5ml of equilibrated phenol and 1.5n-d of 24: 1 
chloroform/isoatnyl were added to each sample. Samples were then mixed, centrifuged 
and upper phase transferred to a clean tube. This extraction process was repeated. Then 
3ml of chloroform/isoamyl (24: 1) were added to the pooled upper phase that was again 
centrifuged before the upper phase was again transferred to a clean tube. Adding 2.5 
volumes of 100% ethanol to the pooled upper phases precipitated DNA and tubes were 
then placed at -201C for I hour. The precipitate was removed by centrifugation, washed 
with 70% ethanol, and subsequently air dried prior to dissolving in Iml of TE. DNA 
concentration and purity was measured by absorbane at 260 and 280 nanometers, with 
readings of 1.6 to 1.8 indicating that the DNA was of sufficient purity for subsequent 
analysis. 
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U. 5.4 The polymerase chain reaction 
The PCR exploits certain features of DNA replication. DNA polymerase uses 
single-stranded DNA as a template for the synthesis of a complementary new strand. 
This single strand DNA template can be produced by heating double stranded DNA 
(dsDNA) to temperatures near boiling. DNA polymerase also requires a smaU section of 
ds-DNA to initiate ("prime") synthesis, and the starting point for the DNA synthesis can 
therefore be specified by supplying an oligonucleotide primer that anneals to the template 
and that specific point. Both DNA strands can serve as templates for synthesis provided 
that an oligonucleotide primer is supphed for each strand. The net result of a PCR is, 
therefore, that by the end of n cycles the reaction will contain a theoretical maximum of 
2'ds-DNA molecules that are copies of the DNA sequence between the ofigonucleotide 
primers. 
The starting material for PCR is genomic DNA. To this are added DNA 
polymerase, specific oligonucleotide primers5 and a mixture of all four deoxynucleotide 
(dNTP) precursors. The reaction mixture then undergoes a series of cyclical temperature 
changes to amplify the DNA region of interest (Figure 11.1). The annealing temperature 
is the key variable in determining the specificity of the PCF, and temperatures and times 
used wifl vary depending on the sequence to be amplified. 
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Figure 11.1 The PCR Cycle 
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11.5.5 Restniction fragment length polymorphisms 
Single bp polymorphisms occurring at the recognition sites for restriction 
endonucleases (usually a small sequence of 4 to 6 bp) can be identified by analysis of the 
size of DNA fragments after digestion with the specific enzyme. A biaHelic RFLP wifl 
have one allele where the restriction site is present and the DNA is cleaved into 2 smaller 
fragments, and one where the site is absent and the DNA will not be cleaved. Early 
studies used restriction endonuclease digestion of genomic DNA with radiolabefled 
cDNA probes to identify polymorphic variants. PCR has now aflowed the amplification 
of smaller and specific regions flanking the RFLP site. This has allowed the DNA 
fragments (often <I kb) to be easily visualised using gel electrophoresis. 
11.5.6 Gel Electrophoresis 
Agarose (IBI) gels (1-2 %) in TBE buffer (50mM Tris-HCI, 40mM boric acid, 
IniM EDTA, pH 8.0) were prepared containing 0.5 ytg/ml ethidium, bromide. PCR 
products or digested PCR products were separated using a Biorad gel apparatus at 100 
V for I hour. AI kb DNA marker was used to size DNA fragments for all gels. To 
visualise DNA, gels were transilluminated under ultraviolet light and photographed. 
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H. 6 Detection of candidate genes using PCR 
11.6.1 Vitamin D receptor gene 
H. 6.1.1 TaqI genotype 
Oligonucleotides 
Primers sequences 5'-CAG AGC ATG GAC AGGGAG CAA G-3' and 5'-GCA 
ACT CCT CAT GGC TGA GGT CTC A-3' producing a 740 bp fragment. 
PCR conditions 
Reactions were performed in 20 ýtl containing 200 ng of genomic DNA, 20 pmol 
of each primer, 200 ýM dNTPs, 50mM KCL, lOmM Tris (pH 9.0 at 250C), 0.1% 
Tritoe X-100,2. OmM MgC12 and I unit Taq DNA polymerase (Promega Corporation). 
Each sample was subjected to an arnplification cycle in a Corbett Research FTS-1 
Thermocycler (Corbett Research, NSW, Australia) as follows: 
Step 1: 3 min at 940,1 min at 620,2 min at 72'. 
Steps 2-6: 20 sec at 94'. 20 sec at 62'. 1 min at 72'. 
Steps 7-47: 5 sec at 94', 5 sec at 62', 30 sec at 72'. 
Step 48: 3 n-fin at 720. 
Restriction dimest conditions 
The restriction endonuclease TaqI recognises the sequence TýCGAA. A 10 pl 
aliquot of each PCR product was digested with 5 units of TaqI (Promega Corps) in a 
total volume of 20 [LI (I mM Tris-HCI [pH 7.4], 30mM KCI, I OpM EDTA, I 00pM 
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DTT, 0.5mg/ml BSA, 5% glycerol) at 65' for I hour. The invariant TaqI site in the 
PCR product acted as an internal control for the enzyme digest. The digested products 
were then separated using gel electrophoresis and a 2% agarose gel. 
AUcle designation for the TaqI RELP associated with VDR 
The banding pattern for the TaqI restriction enzyme is shown in Figure 11.2. The 
afleles were coded as "T" and 'T',, where the upper case signifies absence of the 
polymorphic restriction site and the lower case presence of the site. In homozygous 
ati absence of the TaqI site (TT) the enzyme digestion of the 740 bp PCR product at the 
invariant TaqI site yields 245 bp and 495 bp bands. Homozygous presence of the TaqI 
site (tt) yields fragments of 205 bp, 245 bp and 290 bp. Heterozygotes for the TaqI 
R-FLP (Tt) exhibit fragments at 490 bp, 290 bp, 245 bp and 205 bp. 
11.6.1.2 FokIgenotype 
Oligonucleotides 
Primer sequences 5'-GAT GCC AGC TGG CCC TGG CAC TG-3' and 5'-ATG 
GAA ACA CCT TGC TTC TTC TCC CTC-3' producing a 272 bp PCR product. 
PCR conditions 
13- 
Reactions were performed in a 20 jil volume, containing 200 ng of genon-& 
DNA, 20 pmol of each primer, 200 [tM dNTPs, 50mM KCL, I OmM Tris (pH 9.0), 
2. OmM MgC12 and I unit Taq DNA polymerase (Promega Corporation). Each sample 
was subjected to an amplification cycle in a Corbett Research FTS- I Thennocycler 
(Corbett Research, NSW, Australia) as follows: 
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Stepl: 3 min at 950,1 min at 65', 1 min at 74'. 
Steps 2-6: 20 sec at 95', 30 sec at 65", 30 sec at 740. 
Steps 7-37: 5 sec at 95', 5 sec at 65', 15 sec at 74'. 
Step 38: 3 min at 740. 
Restriction digest conditions 
A 10 ýd aliquot of each PCR product was digested with 5 units of FokI (Promega 
Corporation) in a total volume of 20ýtl (ImM Tris-HCI [pH 7.4], 5mM NaCl, 10ýM 
EDTA, 100ýM DTT, 0.5mg/ml BSA, 5% glycerol) at 371 for 3 hours. The digested 
products were then separated using gel electrophoresis, and a 2% agarose gel. 
Aflele desianation for the FokI RFLP associated with VDR 
The restriction endonuclease Fokl recognises the sequence GGATG, and 
therefore detects the presence of the ATG sequence. The absence of the Fokl site, 
indicated as 'T', therefore demonstrates that the first ATG site is absent. Presence of 
the FAI site, indicate by 'T', will result in cleavage of the 272 bp PCR product by the 
restriction endonuclease to yield two fragments of 198 bp and 74 bp. Individuals 
homozygous for the FF genotype exhibit a single uncut fragment of 272 bp, while 
homozygotes for the ff genotype have two fi-agments of 198 and 72 bp. The 
heterozygote Ff genotype has all three bands (Figure 11.3). 
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Figure 11.2 Allele banding pattern 
for the Taqj VDR RFLP 
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M =1 marker for sizing 
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11.6.2 Oestrogen receptor gene 
Oýhgonucleotides 
Primers sequences 5'-CTG CCA CCC TAT CTG TAT CTT TTC CTA TTC 
TCC-3' and 5'-TCT TTC TCT GCC ACC CTG GCG TCG ATT ATC TGA-3' 
producing a 1.3 kb PCR product. 
PCR Conditions 
D- 
Reactions were perfonned in 20 pl containing 200 ng of genornic DNA, 20 pmol 
of each primer, 200 pM dNTPs, 50mM KCL, I OmM Tris (pH 8.3), 2. OmMMgCI2 and 5 
units Taq DNA polymerase (Promega Corporation). Each sample was subjected to an 
amplification cycle in a Corbett Research FTS- I Thermocycler as follows: 
Stepl: 5 min at 940,1 min at 640,1 min at 72'. 
Steps 2-3 1: 20 sec at 94*, 20 sec at 62*, 1 min at 72*. 
Step 32: 3 min at 720. 
IRIkestriction diaest 
A 10 gl aliquot of each PCR product was digested with either 5 units of PvuH or 
aI (both Promega Corps) at 37' for I hour. The digested products were then ' AV 
separated using gel electrophoresis and a 1.2% agarose gel. 
Allele desianation for RFLPs associated with ERa 
Coding for ERct gene alleles uses a similar nomenclature to that used for the 
VDR gene, such that the upper case letter signifies absence of the poly-morphic 
restriction site and the lower case letter presence of the site. The banding pattern for the 
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PvulI restriction enzyme is shown in Figure HA The "p" afiele produced fragments of 
0.85 kb and 0.45 kb. A similar pattern was also observed for the Xbal genotypes. -,. Nith 
the 'Y' allele having fragment sizes of 0.9 kb and 0.4 kb. 
11.6.3 Type I Collagen al gene 
Oligonucleotides 
Primer sequences 5'-TAA CTT CTG GAC TAT TTG CGC ACT TTT TGG-3' 
and 5-GTC CAG CCC TCA TCC TGG CC-3' were utilised to amplify a region within 
the first intron of the COLIAl gene. The underlined bases in the reverse primer 
represent mismatched bases that introduce a Ball restriction site in polymorphic alleles 
with the G--*T substitution. 
PCR Conditions 
PCR reactions were perfonned in 25 ýil containing 200 ng of genornic DNA, 20 
pmol of each primer, 200 jiM dNTPs, 50mM KCL, I OmM Tris (pH 8-3), 1.5mMM9CI2 
and 5 units Taq DNA polymerase (Prornega Corporation). Each sample was subjected 
to an amplification cycle in a Perkin Ehner 480 Thermocycler (Perkin Elmer, Foster City, 
CA5 USA) to produce a 264 bp product as follows: 
Step 1: 3 min at 94' 
Steps 2-36: 1 min at 94', 1 min at 60', 1 min at 72' 
Step 37: 3 min at 72" 
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I? a Ivestriction diaests 
A 10 ýtl aliquot of each PCR product was digested with 5 units of MscI (Promega 
Corps) in a buffer containý 150 mM TRIS-HCI (pH 7.5), 250 mM NaCl and 35 mM 
MgCl2at 37* overnight. Msd is an isoschizomer of BaII, with both enzymes recognising 
the sequence TGGýCCA. The digested products were then separated using gel 
electrophoresis and a 3% agarose gel. 
Allele designation for RFLPs associated with COLIAI 
Afleles were coded as "S" for presence of the guanine residue and "s- for the 
rarer thymidine residue. The "s" affele resulted in two fragments of 246 bp and 18 bp, 
although the latter was not detectable with a 3% agarose gel. The "S" allele represented 
non-digestion of the PCR product as was of size 264 bp. Banding patterns for the 
COLIAI polymorphism are shown in Figure H. 5. 
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Figure 11.4 Allele banding pattern for the PvuII ER RFLP 











Figure 11.5 Allele banding pattern for COLIA1 RFLP 
marker for sizing 
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11.6.4 Interleukin I receptor antagonist gene 
Ofigonucl&otides 
Primer sequences 5'-CTC AGC AAC ACT CCT AT-3' and 5'-TCC TGG TCT 
GCA GGT AA-3' were used to amplify a variable number tandem repeat in intron 2 of 
the IL- I RN gene. 
PCR Conditions 
PCR reactions were performed in a total volume of 20 ýtl, containing 200 ng of 
genomic DNA, 20 pmol of each primer, 200 [tM dNTPs, 50mM KCL, I OmM Tris (pH 
8.3), 5. OmM MgC12 and I unit Taq DNA polymerase (Promega Corporation). Each 
sample was subjected to an amplification cycle in a Corbett Research FTS-1 
Therynocycler as follows: 
Step 1: 1 min at 960 
Steps 2-3 1: 1 min at 941,1 min at 600,2 min at 700 
Step 32: 3 min at 72' 
Allele designation for RFLPs associated with ILI RN 
The fmal PCR products were analysed on 1.2% agarose gels. Previous work in 
70 unrelated individuals (Tarlow et al, 1993) had identified 5 alleles at this locus. Alleles 
were classified according to their relative size on gel electrophoresis (Figure 11.6). 
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11-6.5 Quality control 
All PCR reactions contained a negative control that contained no DNA. This 
was to ensure that aH the PCR ingredients were not contaminated with exogenous DNA. 
In addition, all "runs" included samples of known genotype to ensure consistency of the 
endonuclease digestion. 5-10 % of samples were repeated for internal consistency. 
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Figure 11.6 Allele banding pattern 
for IL-lRN VNTR 
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11-7 Statistical Analysis 
11.7.1 Heritability analysis 
Heritability is defined as a ratio of variances (V), specifically, the ratio of the 
genetic variance (i. e. that attributable to genotypic or allefic differences among 
individuals) to the total Phenotypic variance in the population. The observed phenotypic 
population variance (Vp) is partitioned into components reflecting the differences in 
unobserved genetic (g) and environmental factors (c = common, e= unique), both of 
which must be estimated from covariances or correlations among relatives. This 
approach assumes a linear model where the trait is a linear function of genetic and 
environmental factors. If the genotypes and environment are independent, the total 
variance of the trait can be defined as: 
Vp = Vg + Vc + Ve 
From this breakdown, broad sense heritability can be written as: h' = Vg/Vp 
The classical twin model assumes that MZ twins share 100% of their genes, and 
therefore any intrapair variations in a measured trait may be due to environmental 
factors. DZ twins are no more alike than full sibs and share on average 50% of their 
genes, hence their intrapair variations must be due to both environmental and genetic 
factors. The twin model also assumes that (1) both sets of twins have been sampled from 
the same gene pool, (2) that environmental sharing is similar for both MZ and DZ twins, 
and (3) that the variance due to epistasis, is negligible. Under these assumptions a 
comparison of the correlation between MZ and DZ twins provides an estimate of the 
relative contribution of genetic factors in the total variation of a quantitative trait. To 
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statistical. ly estimate this component of genetic variance, the total variance of a 
quantitative trait is partitioned into two components: one due to within (intrapair. W) 
vanation and one due to between (interpair, B) variation by performing analysis of 
variance (ANOVA). Intraclass correlations for MZ pairs and DZ pairs are then 
estimated: 
(B-W)/(B+W). 
Heritability estimates were calculated using the computer programme 
TWINAN90 (Williams et al, 1992). The broad sense heritability estimate was calculated 
as twice the difference of the MZ and DZ intraclass correlations [i. e. 2(rMZ-rDZ)] 
(Falconer, 1960). 
Because co-twins in the same pair tend to share environment as well as genes, 
. heritability estimates could be spuriously increased. This is particularly true if the 
enviromnental sharing is greater within MZ twin pairs than it is within DZ pairs. To 
avoid this potential bias of differential environmental covariance, trait values were 
adjusted for environmental variables by means of multiple regression analysis. Separate 
equations were developed for MZ and DZ twins to allow for the potential differential 
effects of the enviromnental variables in the two groups of twins. On the basis of these 
equations a predicted value was calculated for each trait value. A residual value was 
calculated as the difference between the observed and predicted trait values, and these 
standardised residuals were then used in the adjusted heritability analysis. 
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11.7.2 Modified linkage analysis 
To assess the contribution of candidate gene polymorphisms on BMD within the 
DZ twins, modified sib-pair linkage analysis was performed. Intra-class correlations in 
BMD were calculated using the programme TWINAN90, as described previously, for 
DZ twins concordant or discordant for genotype. Results were deemed suggestive of 
linkage at the trait locus if the rWc.,, dým was significantly greater than the rDZdiscordant- 
ustment for potential confounders was also performed as previously described for the 
heritability analysis. 
Classical sib-pair analysis detennines whether each sib pair shares 0,1 or 2 alleles 
identical by descent (IBD) at a locus of interest. For a quantitative trait, sib pairs should 
show a correlation between the magnitude of their phenotypic difference and the number 
of alleles shared IBD (Haseman and Elston, 1972). Modifications to this classical 
method of analysis were required for several reasons. Firstly, parental genotype 
information was not available for the DZ twins and it was not possible to accurately infer 
their IBD status. Analysis was therefore based on identical by state (IBS) sharing that is 
less powerffil than IBD analysis (Bishop and Williamson, 1990). As the candidate gene 
polymorphisms examined were biallelic, DZ twins were simply classified as being either 
concordant or discordant for their IBS sharing. Secondly, the original report by 
Haseman and Elston (1972) examined the squared intra-pair difference in trait values, 
regressing this value against the number of alleles shared IBD. Squaring of the intra-pair 
difference can, however, magnify errors due to extreme outlying values, and use of crude 
values provides a more reliable estimate. As the quantitative trait of interest in this 
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analysis was BMD, which is known to be affected by environmental factors, the use of 
the TWINAN90 programme to calculate the rDZcmcordant/dixordam values also aflowed 
adjustment to be made for these potential confounders. 
11-7.3 Testing for Hardy Weinberg equilibrium 
In a large random-mating population with no selection, mutation or migratiorL 
the gene frequencies and the genotype frequencies are constant from generation to 
generation. A population with such constant gene and genotype frequencies is described 
as being in Hardy Weinberg equilibrium (Hardy, 1908; Weinberg, 1908). For a gene 
with two alleles with frequency p and q (1-p), Hardy Weinberg equilibrium (HWE) is 
maintained if- 
p2+ 2pq +q2 == I 
Testing for HWE was made using Chi-squared analysis, comparing the observed 
genotype frequencies against those expected under random mating. 
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11.7.4 Association analysis 
11.7.4.1 Analysis of variance 
Risk factors for quantitative traits cannot cause the trait but they can affect its 
mean value and variation. It is possible to model the effect of risk factor xi to individual 
j's phenotype ýj, by a regression coefficient Pi through an equation such as: 
ýi = (X + Eßi xii 
In the simplest genetic case, known as a "measured genotype approach", non- 
genetic variables are treated as nuisance variables with an additive action on the 
phenotype, and regression is used to adjust the trait value for these variables. Genotypic 
risk factors can be treated as qualitative data, set to I if an individual has a particular 
genotype and zero if otherwise. After adjustment, the deviation that remains is what is 
hoped to be explained by the genotype, and represents a categorisation of the data that 
can be analysed using analysis of variance (ANOVA). 
H. 7.4.2 Analysis of trait means 
Knowledge of genotype information allows the study population to be grouped 
according to their underlying genotype. It is possible to test one's data against the null 
hypothesis that there is no difference in the trait means (p) of the genotypes using 
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Student's t-test. For a biallefic locus with two alleles (1/2) the null hypothesis (H,, ) 
would be: 
HO: 9 11 - ýt 12 :: ý ýt22 
At loci with multiple alleles several issues need to be considered. Unless datasets 
are large the number of individuals in each genotype group will be small and this may 
reduce the power to identify a difference in mean trait values across the groups. 
Genotype groups may also be pooled to allow testing of differences in trait means 
associated with carriage versus non-carriage of a particular allele under both dominant 
and recessive inheritance models. In these circumstances there may be a large number of 
potential groupings and comparisons made, and at present it is not clear if statistical 
ustments for these multiple comparisons in the form of the Bonferroni correction 
factor is necessary or appropriate (Altshuler et al, 1998; Perneger 1998). 
H. 7.4.3 Odds ratios 
In a case control study, the frequency of the different genotypes is compared 
between individuals who have the outcome measure of interest (cases) and a swnple of 
individuals who do not (controls). Measures of odds ratio (OR) can be calculated as 
follows and closely approximate those of relative risk obtained from cohort studies when 
the disease or outcome measure is rare (Rothman 1986). 
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Table U. 1 Calculation of the odds ratio from a case-control study 
Genotype Frequency in cases Frequency in controls Odds ratio 
NN - -- ---------- ---- ... A, B, 
NS A2 B2 A2B, /AIB2 
SS A3 B3 A3B, /AIB3 
N: normal allele S: susceptibility allele 
The OR equals unity when there is no association between the exposure and the 
disease. If the OR is greater than unity, then the rate of the disease amongst the exposed 
is greater than non-exposed. If however the OR is below unity then the rate of disease in 
the unexposed group is greater. The contingency tables outlined above can 
accommodate a variety of data stratifications and other complications. 
Confidence limits of the OR are used to represent the statistical uncertainty 
involved and give an impression as to the magnitude of the effect. This aids 
differentiation between statistical and scientific significance. To calculate the confidence 
interval the standard error of the OR has to be calculated using maximum likelihood 
estimation. The 95% confidence interval incorporates the range of values from mean - 
(1.96xSE) to mean + (1.96xSE). 
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H. 7.4.4 Analysis of confounding 
Confounding can occur when an association between a risk factor and disease 
can be explained by a factor associated with both the disease and the risk factor 
(Mettinen and Cook, 1981). A confounder must satisfy the following conditions: i) that 
it is associated with both the study disease and the exposure factor under study, and ii) 
that the confounder is extraneous to the two main variables (disease and exposure) but 
can distort their relation. A factor cannot be considered a confounder if it lies on the 
causal pathway between exposure and outcome or if it determines the presence of an 
exposure variable but has no direct effect on outcome. In the analysis of data, 
confounding can be seen when the OR is altered after adjustment for another factor. 
Confounding can be handled in the analysis by matching, stratification and/or use 
of multivariate models. Stratification provides a direct way by which biased comparisons 
due to confounding can be ehminated. The major limitation of stratification is, however, 
the number of strata that can be analysed simultaneously, as the greater the number of 
strata the less the numbers of subjects in each cell. Schlesselman (1982) has estimated 
that 1280 cases and 1280 controls would be needed to examine the joint effects of 7 
dichotomous variables with stratification. Logistic regression modelling can be expanded 
to include the effects of quantitative and qualitative variables simultaneously. Dose 
response relationships can be defined using a linear regression model: 
ax 
where y is the disease probability, x the exposure variable, and a and b are parameters to 
be estimated. This model assumes, however, a linear relationship between the probability 
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of disease and the exposure variable. Logistic regression mdels the relationship 
between disease probability and exposure as linear on a logit scale: 
y== --gxp(a+bjx I+ (exp (a + bx) 
The above equation can also be expanded to include several variables 
simultaneously 
In P (Y = I)- a+ bix, + b2x2 
I- P(Y = 1) 
where xi, x2,... N, represent n independent variables used to Predict the probability of 
disease. 
Values for the regression coefficients bi can be obtained using maximum 
likelihood procedures and these can be interpreted in terms of the OR, computed as OR 
= exp (b. ), for each risk factor after adjustment for the effects of other variables. 
H. 7.4.5 Interaction analysis 
Interaction or effect modification has to be considered as it can be influenced 
greatly by the process of adjustment for confounding. If the impact of a risk factor on 
the outcome varies across different values of a third variable, then "statistical interaction" 
or effect 'ýnodification exists". This third variable could be either an enviromnental 
exposure (i. e. dietary calcium intake) or an independent genetic marker. Although 
methods exist for dealing with interaction in logistic regression (Kelsey et al. 1986), 
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simple adjustment for such a third variable may mask important biological relationships. 
Stratification may reveal useful information (Ottman 1990) althougii., as discussed, large 
sample sizes would be required. In many instances the models are simplistic using a 
. Ill. bia-lic gene polymorphism at a single locus and a single dichotomous environmental 
exposure (present vs absent). 
H. 7.4.6 Sensitivity and specificity 
Measuring commonly assesses the accuracy of a diagnostic procedure as follows: 
1) sensitivity (the proportion of true positives correctly identified) 
specificity (the proportion of true negatives correctly identified). 
These concepts can be applied to various methods of ascertainment such as the 
reporting of a Positive family history for disease or carriage of a disease risk genotype. 
Table U. 2 Sensitivity and specificity 
Disease status 
Test status + 
+a 
c 
Sensitivity (se) = a/(a + c) Specificity (sp) = d/(b + d) 
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H. 7.4.7 Positive and negative predictive values 
Another important concept is the predictive value of a test. The positive 
predictive value (PPV) refers to the fraction of persons classified as having the disease or 
trait by the test who actuaUy do have the trait. The negative predictive value (NPV) 
refers to the fraction of subjects classified as not having the disease by the test whom 
actually do not have the trait. PPV and NPV are functions of sensitivity, specificity, and 
the frequency (prevalence) of the underlying trait in the population tested. The rarer the 
trait, the lower the PPV will be for any given level of sensitivity and specificity. Unless 




P (disease +I test +) 
(se) x (a) - ---- (se) x (g) + (I - sp) 
P (disease -I test -) 
- 
(5p) xG- P--) - (I - se) x (g) + (sp) x(I - g) 
where g is the frequency of the disease or trait in the population. 
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11.7.5 Hardware and software 
The data were entered on an IBM compatible 880-Megabyte hard disc computer. 
The basic statistical calculations including frequencies, tabulations, ANOVA and 
Student's t-test were all Perfornied using the statistical programme STATA (Stata 
Corporation, TX, USA). Intra-class correlations for the MZ and DZ twins were 
computed using the analysis programme TWINAN90 (Williams et al, 1992). 
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CHAPTER III 
FAMILIAL AGGREGATION OF BONE MINERAL DENSITY AND 
OSTEOPOROTIC FRACTURE RISK 
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III. I Summary 
In this chapter data have been examined to determine the genetic component to 
BMD and fracture risk in women from the UK population. 
A classical twin analysis was perfonned to assess the genetic contribution to 
BMD at multiple sites (lumbar spine, hip, forearm and total body) in 87 MZ pairs and 95 
DZ postmenopausal twin pairs. Within-pair correlations in BMD were highest in the 
MZ pairs compared to the DZ pairs at a sites, with heritability estimates ranging from 
0.60 to 0.98. These findings were independent of confounders such as age, weight, 
menopause duration, smoking status and HRT use. 
Data are also presented from a population-based analysis of unrelated women 
where familial history of an osteoporotic fracture in a female first-degree relative was 
used as a surrogate measure of genetic susceptibility. BMD was modestly reduced by 
0.4 SD at both the spine and the hip in those with a positive family fracture history,, 
when compared to those with a negative history. Family history of any osteoporotic 
fracture was also associated with an increased total risk for fracture, and site specific 
analysis showed that a positive family history of wrist fracture was associated with a 
four-fold increased risk of fracture at this site. These increases in risk remained after 
adjustment for BMD, suggesting that other genetic factors may also contribute towards 
this familial risk associated with osteoporotic fracture. 
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111-2 Introduction 
In Chapter 1, data from family and twin studies demonstrated that genetic factors 
ap ear to play a central role in the regulation of bone mass. These findings are, Ip 
however, specific to the populations that have been studied and at the onset of this thesis 
only limited data were available regarding the genetic contribution to bone mass in 
women from the UK There was also little data regarding the familial segregation of 
fracture, with most studies concentrating prhmrily on hip fracture risk (Cummings et A 
1995). 
In this chapter there were two main aims. Firstly, classical twin analysis was 
used to study the simflarity in bone mass measures between MZ and DZ postmenopausal 
twms from the UK. This would provide an estimate of the broad heritability for BMD at 
multiple skeletal sites in the UK population, thereby allowing comparison with other 
published studies. The second aim was to examine the genetic contribution to fracture 
risk, although as the number of prevalent fractures in the twin group was too small for 
accurate analysis a population-based analysis was performed. In this, a positive family 
history of osteoporotic, fracture in female first-degree relatives (i. e. mother and/or 
sisters) was used as a measure of genetic susceptibility to fracture. In these unrelated 
women from the general population reported family history was then examined for 
association with low BMD and fracture risk at multiple sites. 
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111-3 Methods 
IU. 3.1 Twins 
109 white Caucasian female DZ twin pairs were studied. These subjects were 
aged 50-69 years of age and were healthy and not known to be suffering fi7om any 
disease affecting bone metabolism. In total, 96 DZ pairs were concordant for 
postmenopausal status and were included in the analysis. In one pair, one twin suffered 
from an eating disorder and she and her co-twin were subsequently excluded from the 
analysis due to gross discordance in their body weight (65 kg vs 142 kg). 97 healthy 
NEZ female pairs were also included in the analysis, of which 87 pairs were concordant 
for postmenopausal status. BMD measurements at the lumbar spine, hip, forearm and 
total body were available on all subjects. 
111.3.2 Population study 
Data were available from all 1003 women participating in the Chingford 
population study. At their initial assessment all subjects had been asked in the nurse- 
administered questionnaire about a history of osteoporotic fractures occurring at either 
hip or wrist in a female first degree relative aged > 35 years. These fractures were self- 
reported and it was not possible to validate fractures occurring in the subjects' relatives. 
Women reporting a history of wrist or hip fracture occurring in either a mother and/or 
sister were classified as having a positive family history for osteoporotic fracture. BMD 
measurements at the lumbar spine and femoral neck were available on all subjects. 
Details of prevalent vertebral fractures and validated peripheral fractures for the I O-N, ear 
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period prior to the study's commencement (1978-1988) were also availab)e on afl 
women. 
111.3.3 Statistical analyses 
In twin subjects, the intraclass correlations for BMD measures within MZ and DZ 
pairs were calculated, with heritability estimates derived using the Falconer equation. 
Adjustment for potential confounders was performed using linear regression. 
In the population-based analysis, differences in demographic variables between 
subjects with a positive family history for fracture and those with a negative history were 
compared by an unpaired t-test for normally distributed variables and by a Mann- 
Whitney U-test for non-parametric variables. Categorical variables were analysed using 
a X2 test. Multivariate analysis was performed using logistic regression to estimate the 
odds ratio and 95% test based confidence intervals for sustaining a fracture by family 
history fracture status. The sensitivity, specificity, PPV and NPV for family history of 
fracture as a predictive tool were also assessed. 
111.4 Results 
111.4.1 Twin analysis 
Full clinical data were available on 87 MZ and 95 DZ pairs. No significant 
differences in baseline characteristics were observed between the two zygosities (Table 
111.1), although the MZ twins tended to have lower weights, a reduced use of HRT and a 
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reduced frequency of smoking. The means and variances for BMD at all skeletal sites 
were siniflar for MZ and DZ twins. The intra-class correlations in BMD v. -ere 
significantly higher in the MZ twins compared to the DZ twins at all sites (Figure 111.1). 
with significant Falconer heritability estimates (Table HI. 2). These findings were all 
essentially unaltered after adjustment for potential confounders (i. e. age, weight, 
menopause duration, HRT use, smoking status). 
Table 111.1 Mean characteristics (SD) of 174 MZ and 190 DZ postmenopausal 
twins 
Variable MZ twins 
(n - 174) 
DZ twins 
(n=190) 
Age (yrs) 59.7(4.6) 58.7(5.5) 
Height (cm) 160.2(5.7) 162.1(6.2) 
Weight (kg) 62.5(9.2) 65.1(11.2) 
BMI (kg/m2) 24.4(3.4) 24.8(4.4) 
Age at menopause (yrs) 49.2(4.4) 48.9(4.9) 
Years since menopause (yrs) 10.5(6.4) 9.9(7.4) 
No. ever use of HRT (%) 65(37) 85(45) 
Median duration of HRT use (months) 24 (6,48)* 24 (6,48)* 
No. ever smoked (%) 66(38) 99(52) 
interquartile range 
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Table 111.2 Falconer heritability estimates for BMD at various skeletal 
sites from data in 87 MZ and 95 DZ postmenopausal twin 
pairs 
Site Heritability estimate 
Lumbar spine 0.76 
Femoral neck 0.63 
Ward's triangle 0.68 
Total hip 0.65 
Total body 0.98 
Distal. radius 0.73 
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IIL4.2 Population analysis 
Cross-sectional data were available on all 1003 women from the Chingford 
Study, mean age (SD) of 54.2 (6.0) years. A history of hip fracture in female first- 
degree relatives was reported in 44 subjects (39 maternal and 5 sibling fractures). At the 
wrist 107 fractures were reported (83 maternal and 24 sibling), with 6 subjects having a 
hfistory of fracture at this site in both their mother and a sister. In total, a positive family 
history of any osteoporotic fracture in either a mother and/or sister was reported in 138 
of the 1003 women. 
gMily fracture history and BMD Rvelationshni between f 
When compared to those with a negative family history of fracture, BMD was 
significantly reduced in those with a positive history at spine and hip: spine, mean 
difference (95% Cl) of 0.04 gkmý (0,0.08), p-0.02, and at the hip, mean difference 
0.03 g/cn? (0,0.05), p=0.02 (Table 111.3). Overall, the prevalence of established 
osteoporosis was 9.9 % at the lumbar spine and 2.5 % at the femoral neck. The risk of a 
subject having spinal osteoporosis, was increased in those with a positive family fracture 
history when compared to those with a negative history, with an odds ratio (95% Cl) of 
1.82 (1.08,3.05), p=0.02. A similar trend was also seen at the hip although this was 
non-significant, with an odds ratio of 1.72 (0.63,4.71), p=0.29. 
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Relationsbip between &, P22ýy fracture histojy and fracture risk 
In total, 119 non-vertebral fractures were reported. After validation and 
exclusion Of fractures due to major trauma there were 51 validated fragility fractures at 
appendicular sites including 16 at the wrist and 6 at the hip. From the radiological 
survey of the thoracolumbar spine, 41 prevalent vertebral deformities consistent with 
fracture were also identified. In total therefore, 60 subjects were found to have 
validated evidence of prevalent osteoporotic fractures at either the spine, hip or wrist, 
with one woman having fractures at both hip and spine whilst a further two women had 
fractures at both the spine and wrist. 
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Table 111.3 Mean characteristics (SD) of 1003 women according to the presence 
or absence of a family history for osteoporotic fracture (hip and/or 
wrist) in a female first-degree relative 
Variable Positive Family Negative Family P- value 
History History 
(n =: 13 8) (n= 865) 
Age (yrs) 54.2(6.2) 54.2 (6.0) 0.99 
No, postmenopausal 102(74%) 622(72%) 0.64 
subjects (%) 
Time past menopause 8.0(5.4) 8.6(6.0) 0.29 
(yrs) 
BMI (kg/m) 25.4(4.5) 25.6(4.3) 0.54 
No. ever use of HRT 31(22%) 207(24%) 0.70 
No. ever smoking 61(44%) 402(46%) 0.63 
Lumbar spine BMD 0.94(0.16) 0.98(0.16) 0.02 
(g/cm) 
Femoral Neck BMD 0.74 (0.12) 0.77 (0.12) 0.02 
(g/cm) 
No. subjects with 14(10%) 46(5%) 0.03 
osteoporotic fractures 
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A positive family history of any fracture was associated with an increased total 
risk for osteoporotic fracture, with adjustment for BMD and other potential confounding 
variables having little effect on the odds ratio (Table 111.4). This increase in risk 
associated with the positive family history appeared related to appendicular fractures 
rather than vertebral deformity/fracture, and site-specific analysis showed that a positive 
family history of wrist fracture was associated with a 4-fold increased risk of wrist 
fracture (Table 111.5). Again, this increase in risk remained significant after adjustment 
for BMD. There was, however, no significant relationship between a positive family 
history of wrist fracture and prevalent fracture status at either the spine or hip. There 
was also no apparent relationship between a positive family history of hip fracture and 
risk of prevalent fracture at spine, hip or wrist. Specifically, the risk of prevalent hip 
fracture in those with a positive family history of hip fracture was not significantly 
increased, crude OR - 3.83 (0.44,33.49). The wide confidence intervals of this 
estimate reflect the fact that the number of hip fractures in subjects and their first-degree 
relatives was small and the model is potentially unstable. The results relating family 
history of fracture to risk of fracture were also essentially unaltered if all reported 
osteoporotic fractures were included rather than including only those which had been 
validated. 
The sensitivities, specificities, PPV and NPV of family fracture history for 
assessment of spinal and hip osteoporosis, and for any osteoporotic fracture at the wrist. 
hip and spine are shown in Table IH. 6. Site-specific analysis at the wrist showed that for 
a positive family history of wrist fracture the sensitivity to predict prevalent wrist 
fracture was 5%, the specificity 98.8%, the PPV 31.3% and the NPV 90.3%. 
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Table 111.4 Odds ratio (95% CI) for fracture risk associated with a positive 
family history 
Fracture site in OR OR 
study subjects (Crude) (Adjusted*) 
Any fracture 2.02 2.00 
(n = 60 subjects) (1.02,3.78) (1.04,3.83) 
Spine 1.20 1.11 # 
(n = 41 subjects) (0.52,2.74) (0.48,2.59) 
Appendicular 3.04 2.70 
(n 22 subjects) (1.21,7.59) (1.05,6.92) 
Wrist 2.91 2.54 
(n 16 subjects) (0.99,, 8.50) (0.85,7.65) 
Hip 3.17 2.72 
(n =6 subjects) (0.57,17.45) (0.48,15.26) 
adjusted age, hip BMD, BMI 
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Table 111.6 Sensitivity, Specificity, Positive Predictive Value (PPV), and 
Negative Predictive Value (NPV) of Family Fracture History 
for risk of osteoporosis and osteoporotic fracture 
Sensitivity Specificity PPV NPV 
Spinal Osteoporosis 15.2 91.0 21.2 87.1 
Hip Osteoporosis 20.3 84.2 17.0 86.9 
Any Osteoporotic Fracture 10.1 94.7 23.3 86.8 
Spine Fracture 16.3 86.3 54.3 50.8 
Hip Fracture 33.3 86.4 14.6 99.5 
Wrist Fracture 31.3 86.5 3.6 55.3 
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111.5 Discussion 
111.5.1 Twin study 
The results presented in this chapter demonstrate that genetic factors contribute 
significantly to the variance in BMD at multiple skeletal sites in postmenopausal twins 
from the UK. The heritability estimates at spine, hip and forearm are similar in 
magnitude to those observed in studies of younger (Pocock et al, 1987) and older twins 
(Flicker et al, 1995), and also demonstrate a strong genetic correlation in the variance of 
total body BMD. 
Compared to those obtained from studies in younger twins (Pocock et al, 1987), 
the rMZ estimates in these older twins are reduced at predominantly trabecular bone 
sites (lumbar spine: 0.74 vs, 0.92, Ward's triangle: 0.71 vs 0.83). There was however 
little difference noted at cortical bone sites (femoral neck: 0.76 vs 0.73, distal radius: 
0.71 vs 0.71). This suggests that unique environmental influences may become 
increasingly important with age at the trabecular sites rather than at the cortical bone 
sites. The finding that this site-specific reduction was not so apparent in the DZ twins 
may also suggest a stronger effect of the common environment within twin pairs on 
trabecular compared to cortical sites. 
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Limitations 
The classical twin analysis makes 3 main assumptions: the trait means and 
variances are equal between the MZ and DZ pairs, equal common-environment betvveen 
MZ and DZ pairs, and no evidence of gene interaction or epistasis. Slemenda et a] 
(1991) have previously discussed the limitations of twin model and how results maý, be 
affected. In the data from this analysis, the mean values for the BMD measures were 
similar between the twin pairs (see Table 111.1) and the TWINAN90 programme 
formally assesses the assumption of equal trait variances. The results did not suggest the 
presence of interaction or epistasis as the heritability estimates did not exceed 1.00 and 
the rMZ was not significantly greater than twice the rDZ value. Although the heritability 
estimates were essentially unaltered by adjustment for environmental confounders it is 
not possible to exclude the possibility of differences in the common environment 
between the zygosities. 
The finding that the broad heritability estimates for BMD were similar to those M 
twin studies of different age ranges, does not imply that the genetic factors acting on 
bone mass are constant with time. Even if the genetic variance actuaffy increased with 
acre the broad sense heritability could decrease with age if the variation in non-genetic 45 5, 
factors increased more rapidly with age. Cross-sectional studies also cannot exclude the 
possibility of different genes being expressed during development, dependent on factors 
such as age, puberty or menopausal status. 
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111.5.2 Population study 
In this cohort of women, history of fracture in a female first-degree relative Nvas 
associated with a two-fold increased risk of osteoporotic fracture. This increase in risk 
appeared site specific, as a four-fold increased risk of wrist fracture was observed in 
subjects where a mother and/or sister had previously sustained fractures at this site. 
These data support a strong genetic component on factors associated with osteoporotic 
fracture, particularly at the wrist. 
The results demonstrate that a history of osteoporotic fracture in a female first- 
degree relative is associated with a reduction in BMD at both spine and hip. The 
difference in BMD between the family history groups was equivalent to 0.4 SD at each 
skeletal site, and similar in magnitude to that observed in previous studies (Evans et al, 
1988; Seeman et al, 1989; Tylavsky et al, 1989; Soroko et al, 1994; Seeman et al, 1994). 
The data also suggest site specificity in genetic risk as a positive family history 
for appendicular fracture was associated with wrist and/or hip fractures but not with 
spinal fractures. It was not possible to analyse whether site specificity was also apparent 
for vertebral fractures as most vertebral fractures are asymptornatic and to accurately 
identify these in female first-degree relatives would have required radiological screening. 
Evidence for site specificity is also suggested by observations from other studies. Data 
from the SOF Study reported that in elderly women incident hip fracture risk was 
increased 2-fold in those with a positive maternal history of hip fracture. Other types of 
matemal fracture associated with falling did not, however, increase the risk of hip 
fracture (Cummings et al, 1995). In addition, further work from this group has recently 
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shown that parental history (both mother and father) of wrist fracture was associated 
with an increased risk of incident wrist fracture, whereas a family history of hip fracture 
was not associated with any increased risk (Fox et aL 1998). These increases in wrist 
and hip fracture risk were also independent of a subject's BMD at both the radius and 
hip respectively. A sibling history of wrist fracture was not associated with any increase 
in incident wrist fracture risk. Torgerson et al (1996) have also shown in a2 year study 
of 1,857 perimenopausal women (age range 47-51 years) that the risk of any setf- 
reported appendicular fracture was increased Mold in those with a maternal 
grandmother history of hip fracture. This increase in risk also appeared independent of a 
subject's BMD. Due to the younger age of this cohort no hip fractures were observed 
during the study period. In the EVOS Study, a parental history of hip fracture was not 
associated with an increased risk of prevalent vertebral deformity in women, although a 
modest association was observed between maternal history of hip fracture and vertebral 
deformity in men (Diaz et aL 1997). Other work has suggested that these deformities 
are more likely to be traurnatic in aetiology and the importance of ffimily history in this 
instance is therefore unclear (O'Neill et al, 1996; Silman et al, 1997). 
The finding that the increase in r ct-ure risk associated with a positive family fa 
history was unaltered after adjustment for BMD would suggest that common within 
family factors (both genetic and environmental) other than BMD may be contributing to 
the familial clustering of fracture risk. Bone structure and architecture have been shown 
to be under genetic control independent of BMD (Arden et A 1996), and have also been 
demonstrated to be independent predictors of hip fracture in elderly populations (Hans et 
al, 1996; Faulkner et al, 1993). As family history data were based on appendicular 
fractures at the wrist and hip, this may indicate a possible familial component to the risk 
I 
-% 
of falling with the genetic effect mediated through factors such as muscle strength and 
proprioception (Arden and Spector, 1997) 
Linfitations 
The study design used in the population-based analysis, being retrospective in 
design, is subject to several potential limitations. Prevalent fractures were determined by 
reported history and subsequently validated from patients' medical records. The 
validation process of these reported fractures has been described in detail previously 
(Arden et al, 1996). In total, 100% of reported hip fractures were validated and 66% of 
reported wrist fractures. The main reason that fractures could not be validated was that 
subjects had either died or moved away from the area and it was not possible to access 
their medical records. The proportion of reported fractures that were not subsequently 
validated did not, however, differ between the family history groups. Previous work has 
also shown that although elderly women tend to over-report fracture, self-report is 
accurate for fractures of the hip, wrist and humerus (Nevitt et al, 1992). The results 
were also essentially unaltered if all reported fractures rather than just validated fractures 
were analysed, although self-report of any fracture is less reliable (Nevitt et al, 1992). 
Only fractures relating to low trauma incident were studied in this analyses, although 
recent studies have also suggested that all trauniatic fractures may be associated with 
reduced BMD (Sanders et al. ) 1998). 
As with other studies utilising reported history of fracture in a relative (Soroko et 
al, 1994; Mallmin et al, 1994; Cummings et aL 1995; Torgerson et al, 1996. Diaz et al, 
1997), the estimates of family history were based on recall only. It was therefore not 
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possible to determine whether differential recall bias in the reporting of family history 
was apparent between the subjects with and without prevalent fracture. Reporting of 
osteoporotic fracture in family members may have been biased by the subjects' 
awareness of their own fracture status, with fracture cases having better recal This is 
particularly valid given that prevalent rather than incident fractures were assessed. In 
case-control studies it is difficult to measure the magnitude of recall bias in obtaining 
famfly history. Several studies have suggested that the ability of individuals to recall the 
presence of diseases in their own relatives may be quite limited (Schull and Cobb, 1969; 
Napier et al, 1972; Hastrup et al, 1985). If the rate of misclassification in reporting 
family information were the same between cases and controls (i. e. nondilYerential) the 
estimated odds ratio would be underestimated. When, however, there is differential 
recall between cases and controls then the estimated odds ratio will differ. If cases over- 
reported positive family history then the estimated odds ratio would be falsely elevated, 
whereas if they under-reported positive family history compared to controls, then the 
estimated odds ratio would be lower than its true value. 
Although differential recall bias cannot directly be excluded, no significant 
differences in either HRT or calcium/vitamin D use were observed between the family 
history groups. This suggests that at the time of the study's onset use of currently 
available treatments for osteoporosis was not influenced by knowledge of fan-ffly history. 
At the time of completing the questionnaire all women were also unaware of their DXA 
BMD result, and only women with an age-matched Z-score of < -2.0 were subsequently 
notified as being a risk of osteoporosis. 
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Family history of disease should not, however, be considered as a sýnple 
attribute of a person. Family history depends on many factors such as the number of 
relatives, the biological relationship between the index case and their relatives, the age 
distribution of relatives, and the disease frequency within the general population. 
Osteoporotic fractures occur in later life and there is little evidence that this disease 
would therefore influence reproductive fitness or fan-ffly size. Oestrogen exposure and 
increased parity have, however, been shown to be protective for osteoporosis in some 
studies (Alderman et al, 1986), suggesting that relatives from large sibships may have a 
lower risk for developing osteoporotic fracture. This would result in a downward bias in 
the frequency of positive family history among osteoporotic cases. Conversely, with 
large sibships and a common disease such as osteoporosis, the probability of finding at 
least one affected relative of a case will be intrinsically greater than that of controls, even 
in the absence of any underlying difference in genetic risk. For example, the probability 
of an index case having a negative family history in a sibling is (I - k)', where k is equal 
to the population risk and n is the number of siblings. For a disease with a population 
frequency of 5% to 10%, then it would obviously be quite possible to find one or mre 
affected relatives by chance alone in large sibships. A deficiency of this study was that 
detailed infonmtion on the number of sisters in each family was not available. 
Information on fathers or brothers was also not recorded, and it was therefore not 
possible to confirm the reports that paternal history of fracture may be a more important 




The data presented in this chapter demonstrate a strong genetic component to 
BMD at multiple skeletal sites in postmenopausal twins, with heritability estimtes 
ranging from 0.60 to 0.98. These estimates were independent of potential demographic 
and environmental confounders such as age, menopause duration, weight, and use of 
HRT. In unrelated women from the general population, a positive f4mily history of 
fracture in a female first-degree relative is associated with reduced BMD at both the 
spine and hip, and with 2-fold increased risk of any osteoporotic fracture. There appears 
to be evidence for site specificity in this fracture risk as family history of wrist fracture 
was associated with a 4-fold increased risk of fracture at this site. The increases in 
fracture risk remained after adjustment for BMD, suggesting that other factors common 
within families (both genetic and environmental) may play an important role in the 
develoPment of osteoporotic fractures. 
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CHAPTER IV 
INFLUENCE OF VITAMIN D RECEPTOR GENOTYPE ON BONE MINERAL 
DENSITY IN PRE- AND POSTMENOPAUSAL WOMEN 
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IV. I Summary 
This chapter examines the relationship between polymorphisms at the VDR gene 
locus and bone mass in a study of 95 postmenopausal DZ twin pairs and in 1003 
unrelated women from the general population. Twin subjects were genotyped for a 
synonymous TaqI polymorphism. in the 3' region of the VDR gene and for a FokI 
polymorphism in the 5' coding region. The unrelated women were genotyped only for 
the 3' TaqI VDR gene polymorphism 
Within the DZ twins the TaqI polymorphism was associated with BMD at all 
skeletal sites measured, with a 7-10% difference in BMD between the homozygous 
genotypes. Weaker evidence for finkage between this polymorphism and BN41D was also 
demonstrated at all sites apart from the lumbar spine. There was no evidence of linkage 
disequilibrium (LD) between the TaqI and FokI polyrnorphisms in the DZ twins, and 
there was no association between this latter marker and BMD. 
In the women from the general population, there was no significant relationship 
between the TaqI polymorphism and BMD in both pre- and postmenopausal women. 
These findings were unaltered after adjustment for potential confounders such as age., 
weight, HRT use, smoking status and dietary calcium intake in both the twin subjects and 
the unrelated women. 
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IV. 2 Introduction 
At the onset of this thesis, Morrison et al (1994) had just reported on the 
relationship between VDR gene alleles and bone mass. In this study of predominantly 
premenopausal twins (64 MZ and 49 DZ pairs), BMD was measured using DXA at the 
lumbar spine and hip. VDR genotype was assigned using PCR and restriction 
endonuclease digestion with the enzymes Bsml, Apal and TaqI. In this group, VDR 
genotype was specifically associated with BMD at the spine, and to a lesser extent at the 
hip, with the allele "B" (or "t") linked to low bone mass. Subjects of the VDR genotype 
"BB" were found to have a 10- 15% reduction in BMD when compared to subjects with 
the "bb" genotype (equivalent to approximately I SD of the age-matched population 
distribution). A population based association study in 311 randomly selected unrelated 
women was also reported (Morrison et aL 1994), showing that women with the BB 
genotype were over represented in those subjects with BMD measurements 2 SD below 
the peak adulthood value (i. e. T score < -2). From these data it was subsequently 
estimated that the VDR locus was a major determinant of bone mass, explaining up to 
75% of the genetic variation in BMD. 
Because of the probability of type 1 errors, preliminary linkage and association 
studies require confirmation in different populations and enhance the candidacy of the 
locus. Having previously identified a genetic contribution to BMD and fi7acture risk in 
females from the UK population, the primary aim of this study was to examine the 
relationship between VDR genotype and BMD in these women in an attempt to replicate 




In total, 95 white, Caucasian female DZ twin pairs, concordant for 
postmenopausal status were studied. These subjects were aged 50-69 years of age and 
were recruited from the St. Thomas' Adult Twin Registry. All subjects were healthy and 
not known to be suffering from any disease affecting bone metabolism. BMD 
measurements at multiple skeletal sites were available for all subjects. VDR TaqI and 
FakI genotypes were obtained using standard techniques. 
Unrelated women from the Chingford Study were also studied. BMD 
measurements were available in all subjects at the lumbar spine and hip. Genotype 
results for the VDR TaqI polymorphism, were available on the majority of subjects. 
IV. 3.2 Statistical analyses 
Two main analyses were perfonned: 
1) Modified IBS sib-pair linkage analysis within the DZ pairs. 
2) Association analysis within both the DZ twins and unrelated women. 
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IV4 Restdis 
IVAI Twin analysis 
D Relationship between BMD and TaqI genotype 
Full genotype and clinical information was available on all 95 DZ pairs. The 
genotype frequencies were similar to those previously reported in Caucasian populations 
(Morrison et al, 1994; Hustmyer et al, 1992) and were in HWE. Characteristics of the 
DZ twin group according to their VDR genotypes are shown in Table IV. 1. Although 
smaH variations occurred between the different genotype groups, no significant 
I 
differences were observed in age, BM, age at menopause, smoking status or HRT use, 
although the heterozygous genotype "Tt" had a significantly higher weight than the 
homozygous genotypes ("TT", "tt"). 
IBS analysis showed that 55 pairs were concordant and 40 pairs discordant for 
TaqI VDR genotype, and no significant differences in baseline characteristics were 
observed between the groups. The correlation in BMD between concordant pairs was 
higher than the correlation between discordant pairs at all skeletal sites (Table IV. 2), 4: 7 
with the correlation values in the concordant pairs approaching those seen in MZ twins 
from this cohort. The difference between the concordant and discordant pairs was 
significant (p < 0.05) at the femoral neck, the total body and distal radius, although 
results were non-significant at the spine. 
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Table IV. 1 Mean characteristics (SD) of 190 postmenopausal dizygotic twins 
according to VDR TaqI genotype 
TT 
(n = 75) 
Tt 
(n = 78) 
tt 
(n = 37) 
Age (yrs) 58.9(5.5) 58.3(5.8) 59.2(4.9) 
Height (cm) 162.0(5.6) 163.2(6.5) 160.0(6.3) 
Weight (kg) 63.6(9.1) 67.0 (12.8) 63.8(11.2) 
BMI (kg/rrý) 24.3(3.6) 25.2(5.1) 25.0(4.3) 
Age at menopause (yrs) 48.9(3.8) 48.8(5.6) 48.9 (5-21) 
Years since menopause (yrs) 10.0(6.3) 9.5(8.3) 10.3(7.6) 
No. ever use of HRT 38(51) 35(45) 12(32) 
Median duration HRT use (months) 24 (6,50)* 24 (9,51)* 12 (3,38)* 
No. ever smoked (%) 41(55) 40(51) 18(49) 
Lumbar spine BMD (g/cm) 0.94(0.15) 0.94(0.17) 0.84 (0.16) ## 
Femoral neck BMD (g/cmý) 0.73(0.11) 0.75(0.12) 0.68 (0.10) 
Ward's triangle BMD (g/cm) 0.58(0.13) 0.58(0.14) 0.49 (0.11) 
Total hip BMD (g/cm) 0.85(0.11) 0.87(0.13) 0.79 (0.13) 
Total body BMD (g/cm) 1.06(0.10) 1.07(0.15) 0.99 (0-11) 
Distal radius BMD (g/cm) 0.43(0.06) 0.43(0.07) 0.39(0.07) 
* interquartile range 
#P<0.05 (vs TT/tt) ## P<0.05 (vs TT/Tt) 
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Table IV-2 Intraclass correlation coefficients for skeletal site BMD in DZ twin 
pairs concordant and discordant for VDR TaqI genotype 
VDR Genotype 
Site Concordant (n = 55) Discordant (n = 40) 
Lumbar spine 0.36 0.33 
Femoral neck 0.52 0.31 
Ward's triangle 0.39 0.26 
Total hip 0.42 0.27 
Total body 0.46 0.25 
Distal radius 0.46 0.25 
Analysis of all 190 sub ects as independent subjects showed a significant j 
association between VDR genotype and BMD at all skeletal sites other than the distal 
radius (Table IV. 1, Figure IVA). The "genotype group "tt" had lower BN4D than the 
other 2 genotypes, with the "T" affele appearing to be dominant over the "t" allele. The 
difference between the homozygous genotypes was 7-10% across sites, equating to 
approximately 0.5-0.6 SD. These findings were similar when all 190 twins were analysed 
as individuals with adjustment for similarity or when I twin from each pair was randomly 
selected (n = 95 subjects). Results were also essentially unaltered after adjustment for 
age, weight, menopause duration and use of HRT. From the ANOVA analysis it 
appeared that the proportion of trait variance explained by VDR genotype was 4.5% at 
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Relatio between BMD and Fokl geno 
Genotype results were available on 159 postmenopausal individuals, xvith fiA 
data available for 69 DZ pairs. Reasons for lack of genotype data included absence of 
available DNA and failure of the PCR on at least 3 occasions. Genotype frequencies did 
not differ significantly between those observed in the total group of 159 subjects (FF 
44%, Ff 41.5%, ff 14.5%) and the sub-group of 69 DZ pairs (FF 45.6%, Ff 40.6%, ff 
13.8%). In both groups the genotype frequencies were again in HWE, with estimated 
allele frequencies of F=0.65 and f=0.35. These were similar to those previously 
reported in other Caucasian populations. 
Characteristics of the DZ twins according to their FokI genotype are shown in 
Table IV. 3. Although subjects with the "FF" genotype had lower BMD at both the 
lumbar spine and femoral neck when compared to the other two genotypes, these 
differences were not significant. Adjustment for potential confounders such as age, 
menopause duration, BMI, HRT use and smoking did not alter these findings. Subjects 
with the 'Tf ' and ((ff ') genotypes had significantly higher BNU when compared to those 
with FF genotype (p = 0.003 in both instances). This suggests a dominant pattern of 
inheritance for higher BMI associated with the 'T ' allele - 
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Table IV-3 Mean characteristics (SD) 
genotype 
of 138 DZ twins according to FokI 
FF 
(n = 63) 
Ff 
(n = 56) 
ff 
(n = 19) 
Age (yrs) 59.1 (5.5) 58.7(5.3) 59.5(7.0) 
BMI (kg/m`) 23.7(3.2) 25.7 (4.4) 25.5 (4.1) 
Menopause age (yrs) 47.9(5.5) 48.6(3.7) 50.0(3.7) 
Menopause duration (yrs) 12.0(7.2) 9.5(5.6) 11.2(8.8) 
No. ever use of HRT 25(40) 18(32) 4(21) 
No. ever smoked (%) 34(54) 28(50) 9(47) 
Lumbar spine BMD (g/cm) 0.91(0.16) 0.93(0.16) 0.92(0.16) 
Femoral neck BMD (g/cm) 0.71(0.11) 0.74(0.11) 0.73(0.11) 
Ward's triangle BMD (g/cm) 0.55(0.14) 0.56(0.13) 0.55(0.13) 
Total hip BMD (g/cm) 0.83(0.12) 0.86(0.12) 0.82(0.12) 
Total body BMD (g/cm) 1.03(0.11) 1.06(0.12) 1.05(0.10) 
Distal radius (g/cm) 0.42(0.07) 0.44(0.07) 0.41(0.07) 
P=0.003 (Ff vs FF, ff vs FF) 
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IBS analysis demonstrated 43 pairs concordant for FokI genotype and 26 pairs 
discordant. Both groups were comparable in their baseline characteristics. N0 
relationship was observed in the DZ twins between their FokI IBS status and the intra- 
class correlation coefficients in BMD at the lumbar spine, femoral neck or any of the 
other skeletal sites measured using DXA (Table IVA). Within-pair correlations were 
actually greater in twins discordant for FokI genotype rather than in those concordant, 
providing evidence against linkage of this polymorphism to BMD. 
Table IVA Intra-class correlation coefficients for skeletal site BMD in 69 DZ 
pairs concordant and discordant for VDR FokI genotype 




Lumbar spine 0.23 0.56 
Femoral neck 0.34 0.51 
Total hip 0.37 0.43 
Ward's triangle 0.26 0.44 
Total body 0.28 0.56 
Distal radius 0.21 0.61 
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Because an association between BNH and FokI genotype had been demonstrated, 
analysis was also perfonned looking at the intra-class correlations in BNII against their 
FokI IBS status. This showed that the intra-class correlation in BNE for concordant 
pairs was significantly higher than that seen in discordant pairs (0.52 vs 0.29, p=0.01). 
RvplatiopýW jp between the FokI and TaqI Polymorphisms 
TaqI and FokI genotype results were available in total on 156 DZ subjects. The 
distribution of subjects within the genotype groups is shown in table IV. 5. The two loci 
appeared to segregate independently, with no evidence of linkage (X2 = 6.76, P=0.16). 
Formal statistical analysis also revealed no evidence for a significant interaction between 
the two loci acting on BMD (P > 0.10). The mean BMD values at the lumbar spine and 
femoral neck for each genotype group are shown in Figure IV. 2. 
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Table IV. 5 Distribution of subjects between the 2 VDR genotypes 
FokI Genotype 
TaqI Genotype FF Ff ff 
TT 31(27) 24(26) 8(9) 
Tt 31(29) 23(27) 11(10) 
Tt 7(12) 17(12) 4(4) 
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IV. 4.2 Population analysis 
Premenppausal bone mass 
In total, 213 women responded as being premenopausal at the initial interview. 
Subsequently 21 women were classified as peri- or post-menopausal and excluded from 
analysis due to current or previous use of HRT for menopausal symptoms. A further 
two women were also excluded due to previous hysterectomy, and although they had not 
experienced symptoms their menopausal status remained uncertain. 
VDR genotype results were available on 141 women. The reasons for 
incomplete results included DNA not being available (i. e. subjects withdrawing from 
study prior to phlebotomy for DNA) or a persistent failure of the PCR assay. There 
were no significant differences between the 141 women with full results and the 49 
without genotype results. 
Characteristics of the premenopausal study population are shown in Table IV. 6. 
No significant differences were observed between VDR genotype and baseline 
characteristics. An association was again observed between VDR genotype and weight. ) 
although in this population subjects with the "tt)' homozygous, genotype were 
significantly heavier than those with the "TT" genotype (p = 0.03). This genotype group 
was also heavier than the heterozygous, genotype "Tt", although the results did not quite 
reach statistical significance (p = 0.07). 
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Table IV. 6 Mean characteristics (SD) of 190 premenopausal 
stratification by TaqI VDR genotype in 141 subjects 
women with 
VDR Genotype 








Age (yrs) 47.4(2.1) 47.6(2.2) 47.3(2.0) 47.7(2.5) 
Height (cm) 162(6) 162(5) 161(6) 163(7) 
Weight (kg) 66.0(12.7) 64.7 (8.6) * 64.6 (12.8) # 70.5 (14.8) 
BMI (kg/m) 25.0(4.5) 24.5(3.0) 24.9(5.0) 26.5(5.3) 
Calcium intake 
(mg/day) 
475(223) 486(218) 476(225) 483(227) 
No. ever smokers 76(40%) 24(45%) 28(42%) 8(35%) 
Lumbar spine BMD 
(g/cm) 
1-06(0-13) 1.06(0.12) 1.04(0.13) 1.05(0.11) 
Femoral neck BMD 
(g/cm) 
0.83 (0.11) 0.82(0.10) 0.82(0.11) 0.83(0.09) 
0.03 (vs tt) P=0.07 (vs tt) 
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Crude baseline BMD values at both the spine and hip did not differ significantly 
between the TaqI genotypes. These findings were unaltered after adjustment for the 
observed difference in body weight. Adjustment for other potential confounders such as 
age, smoking status and dietary calcium intake also did not alter these results. 
Postmenopausal bone mass 
In total, 725 women reported being postmenopausal at the initial interview. 
Characteristics of these women are shown in Table IV. 7. TaqI genotype results were 
available on 432 of these (60%). Reasons for lack of genotype results are similar to 
those previously reported for those of the premenopausal women. 
No significant differences in crude BMD at either the lumbar spine or hip were 
observed between the TaqI genotypes. VDR genotype did, however, appear to be again 
associated with body weight, although here the heterozygote genotype "Tt" was 
significantly heavier than the hornozygote genotype TT (p < 0.05). Adjustment for this 
observed difference in weight did not, however, alter the negative relationship between 
VIDR genotype and BMD. Results were also unaffected by adjustment for age, 
menopause duration, dietary calcium intake, smoking status and ever use of HRT. 
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Table IV. 7 Mean characteristics (SD) of 725 postmenopausal women with 
stratification by TaqI VDR genotype in 432 subjects 
VDR Genotype 
Variable Total group 
(n---725) 
TT 





Age (yrs) 56.7(5.1) 56.2(4.8) 56.5(5.1) 56.4(5.3) 
Height (cm) 161(6) 161(6) 162(6) 161(6) 
Weight (kg) 67.3(11.7) 65.5(9.8) 68.2 (11.5) 65.7(11.8) 
BMI (kg/mý) 25.8(4.3) 25.2(3.5) 26.1(4.1) 25.4(4.1) 
Menopause duration 
(yr) 
8.5(5.9) 7.6(5.9) 8.6(6.2) 7.8(5.5) 
Calcium intake 
(mg/day) 
481(240) 485(260) 489(233) 472(209) 
No. ever smokers 338(47%) 77(50%) 87(41%) 29(43%) 
No. ever use HRT 187(26%) 28(18%) 51(24%) 15(22%) 
Lumbar spine BMD 
(g/cm) 
0.94(0.16) 0.92(0.15) 0.95(0.13) 0.93(0.17) 
Femoral neck BMD 
(g/cm) 
0.74(0.12) 0.73(0.12) 0.73(0.11) 0.74(0.11) 




vvelatio between TaqI VDR genotvr)e and BMD 
The data from the twin analysis demonstrated evidence for association and 
supportive evidence of linkage between a TaqI polymorphism in the 3' region of the 
VDR gene and bone mass at several skeletal sites of differing bone composition and 
skeletal loading. The genotype "tt" was specifically associated with a 7-10% reduction 
in MM (equivalent to 0.5 SD) when compared to the other genotypes, and results were 
unaffected after adjustment for potential environmental confounders. These results were 
similar in both the twin-based analysis and in the association-based analysis that ignored 
the effects of pairing, although at the lumbar spine a significant VDR TaqI genotype- 
BMD relationship was only observed in the assoeiation analysis. The population analysis 
failed, however, to show a similar relationship between TaqI VDR genotype and BMD at 
either the spine or femoral neck. There was no association in either pre- or 
postmenopausal subjects, and the results were again unaffected by potential 
environmental confounders. 
These results demonstrate that the effect of the VDR locus on BMD is several 
orders of magnitude lower than the initial estimate of Morrison et al (1994), perhaps 
explaining less than 5% of trait variance with only a 0.5 SD difference in BMD between 
the homozygous genotypes. The validity of the Australian twin data figures is now, 
however, questioned due to partial retraction of their original findings (Morrison et a], 
1997) as some of the genotyping contained errors. Reanalysis of this work is still 
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reported to demonstrate a borderEne effect between VDR genotype and BMD in the 
twin subjects, although no precise estirnate has to date been published. 
To date, only one other study (Hustmyer et aL 1994) has been pubfished where 
the relationship between BMD and VDR genotype has been specifically examined In 
twins (86 MZ and 39 DZ predominantly premenopausal pairs). In this study, BMD was 
measured at several sites (lumbar spine, hip, forearm), and VDR genotype was 
determined with individual digestion of genomic, DNA with 3 restriction endonucleases 
(Taql, Bsml, Apal), and Southem blot hybridisation with a radiolabelled 1.4 kb VDR 
cDNA. The study was originafly only powered to detect aI SD difference in BMD 
between the homozygous genotypes, as described by Morrison et al (1994), although 
larger numbers would be required to detect smaller differences similar to those observed 
in this thesis. Only an association-based analysis was performed on all twins independent 
of their zygosities and pairings. Results were subsequently stratified for menopausal 
status and HRT use. Overall, there was no significant association identified between any 
of the three RFLPs and BMD. In addition, in DZ twins discordant for genotype no aflele 
was specifically associated with either lower or higher BMD values. 
Following the report by Morrison et al (1994), a large number of population- 
based studies have subsequently been published examining the relationship between the 
3'-VDR polymorphisms and BMD. Both positive and negative associations have been 
observed, and the reasons for the conflicting results are again not inunediately apparent. 
Studies up to 1995 were summarised by Peacock (1996), with more recent publications 
detaed by both Cooper and Urnbach (1996) and Gong et al (1999). Cooper and 
Umbach (1996) used a meta-analytic approach to assess quantitatively the association 
between VDR and BMD from 16 of these published studies up to July 1996. There was 
strong evidence of study-to-study heterogeneity in effect size at both the spine and hip. 
tso 
They reported that there appeared to be a modest effect of VDR genot,, pe on BNfD,, 
with a reduction of about 2% in the "BB" compared to "bb" genotype groups. The 
magnitude of any effect seemed most marked in younger subjects and appeared to reduce 
with age. Interestingly, removal of the Australian twin data (Morrison et al. 1994) 
reduced these effect size estimates that were then no longer significant. Gong et al 
(1999) identified 75 articles and abstracts that had been published up to the end of 
December 1996. In totaL 34.3% of these studies reported a significant association 
between VDR genotype and spine BMD, with 43.1% reporting an association with 
femoral neck BMD. Despite obvious limitations of publication bias, they claim that these 
results are greater than one would predict by chance and support the finding of a 
significant relationship between VDR genotype and BMD. In general the positive 
studies were again more commonly seen in studies of younger subjects. 
Power calculations for the sample sizes required for many of the published 
studies would have been based on the prediction that the VDR gene explained up to 75% 
of the genetic variance acting on BNM (Morrison et al, 1994). Work from this thesis, 
and from the meta-analysis of Cooper and Umbach (1996) would suggest, however, that 
the effect attributable to the VDR locus is much smaller and that many of the early 
studies were therefore too small and probably under-powered to detect such modest 
genetic effects. Other studies have speculated that dietary intakes of calcium and 
vitamin D may also affect the relationship between VDR genotype and BMD (Dawson- 
Hughes et al, 1995; Krall et al, 1995; Graafmans et al, 1997; Kiel et al, 1997; Ferrari et 
al, 1998), although this has not been observed in all studies (Gamero et al, 1996b). 
Vandevyver et al (1997) have also noted an effect after stratification for BNU, ,, N-Ith a 
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VDR genotype effect at the femoral neck only observed in elderly non-obese subjects 
(BMI < 30 kg/m). 
One possibility for the conflicting results from the association studies could be 
due to LD between the TaqllBsmI polymorphisms and either other sequence changes in 
the VDR gene or with another locus mapping near to this chromosomal region 12q 12- 
14. This concept is supported by the findings of 3 studies demonstrating association 
between VDR genotype and bone mass, but where the association was with the alternate 
allele (Salamone et al, 1996; Houston et al, 1996; Uitterlinden et al, 1996). To date, no 
study has examined the association between the 3' poly-A sequence and BMD, despite 
the knowledge of strong LD between this and the BsmI VDR polymorphism. Potential 
candidate genes mapping to chromosome 12 that could have effects on bone mass, either 
directly or indirectly, include the insulin-like growth factor type I (IGF-1), type 11 
coUagen al (COL2Al), and nitric oxide synthase. 
p between FokI geno1ype and BMD R. Celationshi 
Analysis of a FokI polymorphism in the 5" region of the VDR gene failed to show 
any evidence of either linkage or association between the FoU polymorphism and bone 
mass in the postmenopausal twins. To date, only five published studies have examined 
the relationship between the FokI polymorphism and BMD using an association based 
analysis in unrelated individuals (Gross et al, 1996; Arai et al, 1997; Harris et al, 1997; 
Eccleshall et al, 1998; Ames et al, 1999). These studies and their results are summarised 
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No consistent trend in the results is apparent across studies, suggesting that any 
effect attributable to this polymorphism is modest and variable. Ames et al (1999) 
observed a relationship between calcium absorption and FokI genotype, with subjects of 
the 'TF"' genotype having a mean calcium absorption 41.5% greater than those of the 
"T' genotype and 17% greater than the "Ff ' heterozygotes. This suggested that the 
effect of this polymorphism on BMD could also be influenced by dietary calcium intake. 
As the FokI polymorphism mps to the 3' region of the VDR gene, it was 
reassuring to note there was no observed evidence of LD with the TaqI RFLP. There 
was therefore no need to look for evidence of interaction between the two 
polymorphisms. 
k between VDR genolypes and bo_ Relationsh dy weig 
The findings of an association between the TaqI polymorphism and weight in 
both the twin and population samples, and between the FokI polymorphism and BMI in 
the twins are of interest. Harris et al (1997) also demonstrated that white women with 
the "ff 'genotype were significantly heavier (on average 8kg) than women with the other 
two genotypes. A similar trend was also observed by Eccleshall et al (1998), with 
women of the "Ff 'and "ff' genotypes tending to be non-significantly heavier than those 
of the 'TF' genotype (4kg and 2 kg respectively). Other published studies have not, 
however, consistently observed this observation. 
Interestingly, the mouse VDR knockout was shown to have evidence of impaired 
growth and faure to thrive in the post-weaning stage, suggesting an effect of this locus 
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on growth (Yoshiizawa et al, 1997). The VDR locus has also been shown to influence 
weight in infancy, suggesting a role in the control of body size (Keen et al, 1997). It is 
not clear from this data whether the VDR genotype association with weight relates to 
either fat or lean mass, or whether the influence is independent of any known association 
with BMD. Model-fitting analysis of twin data in 57 MZ and 55 DZ pairs has 
demonstrated strong genetic regulation of fat mass, lean mass and BMD, although 
associations between these traits was largely mediated via environmental factors (Nguyen 
et al. 1998). Multivariate analysis in a larger sample of twin pairs would allow the effect 
attributable to the VDR locus to be quantified and determined (Martin et a], 1997). 
Limitations 
The twin-based modified sib-pair linkage analysis had modest power due to the 
small sample size of 95 pairs and the fact that only an IBS classification was used. The 
, 31-. absence of parental information on the twin subjects also greatly reduces the 
infonnativeness of the IBS classification (Bishop and Williamson, 1990), as does the low 
heterozygosity indices for the biaJlelic genetic markers: TaqI (H = 0.48) and FoU (H = 
0.46). The collection and use of parental genotype infon-nation and/or the use of more 
informative markers (Le. microsateflite polymorphisms rather than a bia. Hefic RFLP) 
would have increased the infonmtiveness of the linkage analysis. 
The association-based analysis in the twins utilised only data from one member 
of each pair, to reduce the bias from using correlated samples. By effectively halving the 
sample size, this approach does not maximise the potential of the data and increases the 
185 
risk of a type 11 error. A different approach would have been to utilise the generallsed 
estimating equation (Zeger and Liang, 1986). This method takes into account the 
dependence of measurements within twin pairs in estimating the significance of the 
differences and utilises aH the inforynation. Association-based approaches also appear to 
have increased power compared to linkage to detect loci having modest effects on 
disease risk (Risch and Merikangas, 1996). 
The population sample had adequate power (80%) to detect an effect on BMD 
attributable to the VDR locus of 0.5 SD. Compared to the twins, who were recruited 
nationally, the unrelated women were all from a single geographical region of NE 
London. Although it is possible that a localised environmental agent may be masking or 
overriding the effect of the VDR gene on BMD in this group, no significant dfferences 
in common environmental factors were observed. The lack of calcium intake data in the 
twins may, however, have been important and should be assessed. It is possible that the 
VDR gene effect on BMD is only seen in twins, although the negative findings of 
Hustmyer et al (1994) would not support this hypothesis. 
In the twin analysis, discrepant results were observed between the twin-based and 
individual-based analyses at the 1wnbar spine. The lumbar spine BMD values may have 
been influenced by degenerative disease (Masud et al, 1993), and this could have 
specifically affected the twin-based analysis as there is an independent genetic component 
acting on this trait (Sambrook et al, 1999). Unfortunately spinal radiographs were not 
available on the twin subjects to evaluate the presence and extent of degenerative 
change. 
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A final potential limitation was that this study examined each VDR polymorphism 
individuafly. The TaqI polymorphism, was chosen because of documented strong LD 
between it and the BsmI site (Morrison et aL 1994), presence of an invariant (control) 
site for restriction endonuclease digestion, and also because of cost. Results from 
Uitterlinden et at (1996) suggest that haplotype analysis may be more infon-native. and 
this is supported by recent studies in other fields (Nickerson et al, 1998; Keavney et al. 
1998). Lack of parental infonnation would mean that it would not be possible to 
unambiguously assign haplotypes, so these would need to be estimated using derived 
population frequencies. Haploptypic analysis of quantitative traits such as BMD would 
require larger sample sizes than available in this study, and raises concems about multiple 
testing issues (Altshuler et al, 1998). 
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IV6 Concimions 
Within postmenopausal DZ twins a TaqI polymorphism in the 3' region of the 
VDR gene appeared associated with BMD across spine, hip and total body sites. with the 
"t" allele specifically associated with low bone mass. Weaker evidence for fink-age 
between the VDR locus and BMD at all sites other than the lumbar spine was also 
demonstrated. Analysis of the 5' FokI polymorphism in the DZ twins failed to find any 
association or linkage with BMD at any of the skeletal sites. A population- based analysis 
in pre- and postmenopausal women failed to replicate these findings, with no significant 
association between the TaqI genotype and BMD at either the spine or hip. The reason 
for these conflicting results was not clear, although environmental differences between 
the groups could have contributed and ffirther research should explore the role of 
potential gene-gene and gene-environment interactions acting on BMD. 
There also appeared to be a consistent relationship between VDR genotype and 
aspects of body weight in both study groups. The TaqI genotype was significantly 
associated with body weight in both the twin and population based analyses, whilst in the 
twins the FokI genotype was significantly associated with body mass index, with 
additional supportive evidence for linkage. It remains to be determined whether this 
association with weight relates to body size or whether there is a relationship between 
VDR genotype and either fat or lean mass. 
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CHAPTER V 
INFLUENCE OF VITAMIN D RECEPTOR GENOTYPE ON EARLY- 
POSTMENOPAUSAL BONE LOSS AND OSTEOPOROTIC FRACTURE 
189 
vi Summary 
The previous chapter has demonstrated an association between a Taql 
polymorphism in the 3' region of the VDR gene with BMD in postmenopausal DZ twins. 
Similar findings were not, however, observed in unrelated women from the LJK general 
population. As earlier work in this thesis had suggested a familial risk to fracture that 
was independent of BMD, this chapter has examined whether the VDR TaqI genotype 
was associated with osteoporotic fracture and with rates of menopausal bone loss. 
Longitudinal measurements of BMD at spine and hip were available on women 
who were within 5 years of a natural menopause. Significant bone loss occurred at these 
skeletal sites over an average of 3-4 years, although there was no association between 
the TaqI VDR genotypes and this bone loss. Prevalent osteoporotic fractures were 
assessed at spine, hip and wrist in aH subjects. OveraH, these was no increase in total 
fracture risk between the TaqI VDR genotypes, although the small number of fractures 
at each site precluded site-specific analysis. 
These data therefore exclude the VDR gene having a major influence on 
determining rates of change in BMD in postmenopausal women or on increasing risk of 
osteoporotic fracture. Future work should be targeted to identify other genes influencing 
risk of osteoporosis, and to examine for possible gene-gene interactions. 
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V. 2 Introduction 
Epidemiological studies have demonstrated that BMD in later life is a strong 
predictor of subsequent fracture (Cummings et aL 1990; Cummings et al, 1993). When 
studying individuals with and without fractures there is still considerable misclassification 
and overlap of low and normal bone density results, with an average of only 0.5 standard 
deviations between cases and controls. In addition, and more importantly. BMD still 
fails to explain a considerable portion of the variance in fracture risk (Ott 1993). Data 
from Chapter III of this thesis and from other epidemiological studies (Cummings et al, 
1995; Fox et al, 1998) have demonstrated a familial risk to fracture that is independent of 
BMD. This suggests that genetic factors may also be acting on other intermediate traits 
that may ultimately increase the risk of fracture. 
In this chapter, the relationships between TaqI VDR genotype and both 
longitudinal measures of menopausal bone loss, and osteoporotIC-related fractures has 
been examined in a population-based analysis. 
V. 3 Methods 
Data was available on all 1,003 women from the Chingford Study. For the study 
of early postmenopausal bone loss, analysis was performed on a subset of women who 
were within 5 years of a natural menopause and where annual measurements of BMD 
were available for longitudinal assessment of bone loss. DNA and VDR TaqI genotN, pe 
results were available on the majority of subjects. 
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Standard statistical analytical techniques were utilised to examine the 
associations between VDR genotype and the phenotypic traits of interest. 
Differences in demographic variables between VDR genotypes were initially 
compared using ANOVA for quantitative traits and chi-squared test for quahtative 
traits. Adjustments for potential environmental and demographic confounders were 
made using ANCOVA. Conditional logistic regression analysis was used to estirnate 
the odds ratio and 95% test based confidence intervals for fracture risk associated 
with the individual VDR genotypes under dominant, recessive and co-dominant 
inheritance models. Adjustment for other potential confounding variables associated 
with fracture risk was also performed using conditional logistic regression. 
V. 4 Results 
Early postmenopausal bone loss 
Full results (3 or more scans and TaqI genotype) were available on 125 women. 
For this total group the mean (95% confidence interval) rate of change from the lumbar 
spine was - 1.1 O/o/yr (- 1.32, -0.88) and from the femoral neck was -0.76 
%/yr (- 1 . 08, - 
0.45). These rates of change were both statistically significantly different from zero. 
No significant differences were observed in the baseline characteristics between 
the 3 VDR genotypes (Table V. 1). Overall, rates of bone loss at the spine and hip did 
not differ significantly between the VDR genotypes, and these findmgs were unaltered 
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after adjustment for potential confounders (i. e. age, menopause duration. weight. 
smoking status, initial BMD) or after stratification for dietary calcium intake. 









Age (yrs) 52.8(3.7) 52.5(3.5) 52.6(3.3) 
Age at menopause (yrs) 50.5(3.7) 50.2(3.4) 50.4(2.8) 
Menopause duration (yrs) 2.2(l. 3) 2.3(l. 4) 2.2(l. 4) 
Height (cm) 161(6) 161(18) 162(5) 
Weight (kg) 66.0(11.0) 67.0(13.3) 66.6(14.1) 
BMI (kg/m) 25.3(4.2) 25.6(4.1) 25.3(4.7) 
Change in spine BMD (%/yr)* -1.31 (0.14) -1.09 (0.17) -1.01 (0.30) 





Full genotype results and vahdated fracture data were available on 595 women. 
The distribution of VDR genotypes did not differ significantly between subjects Nvith and 
without prevalent osteoporotic fractures, or when analysis was restricted specifically to 
vertebral or wrist fracture (Table V. 2). The "t" allele was not associated with an 
increased risk of fracture under recessive or dominant inheritance patterns, and these 
findings were not altered after adjustment for potential confounders such as age, BMI, 
and hip BMD (Tables V. 3 and V. 4). 
Table V. 2 Distribution of subjects (%) according to their VDR 
genotype and fracture status 








TT 199(36.7) 19(35.8) 11 (37.9) 4(44.4) 
Tt 257(47.4) 27(50.9) 15(51.7) 4(44.4) 
tt 86(15.9) 7(13.3) 3(10.4) 1(11.2) 
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Table V. 3 Odds ratios (95% CI) for fracture associated with the 
tt genotype vs the TT/Tt genotypes 
Fracture status Crude OR 
Any fracture 0.67 (0.31,1.45) 
Vertebral fracture 0.62 (0.18,2.08) 
Wrist fracture 1.09 (0.24,5.06) 
Table VA Odds ratios (95% CI) for fracture associated with the tt/Tt 
genotypes vs the TT genotype 
Crude OR 
Any fracture 1.07 (0.64,1.79) 
Vertebral fracture 0.93 (0.43,2.00) 
Wrist fracture 0.57 (0.18,1.78) 
I "- 
V. 5 Discussion 
Relationft between Taal VDR genotype and postmenopausal bone loss 
These data did not demonstrate any significant association between Taql VDR 
genotype and rates of change in BMD at either spine or hip. Adjustment for potential 
confounders also did not alter these negative findings. Rates of bone loss at both skeletal 
sites were normally distributed and it was not possible to identify a sub-group of women 
who would be classified as "fast bone losers". Although rates of change in BMD were 
modest they were significantly different from zero. 
These results contrast with the cross-sectional population study by Morrison et al 
(1994) that suggested an association between VDR genotype and rates of change in 
BMD. Extrapolation of these data demonstrated similar BMD values for the 3 BsmI 
genotypes at the onset of the menopause, with the regression slope of BMD against time 
appearing steeper for the "BB" genotype group compared to either the "bb" or "Bb" 
groups. Subsequent population based studies with longitudinal DXA data have, 
however, not supported these observations (Kroger et al, 1995; Berg et aL 1996; 
Gamero et al, 1996b; Jorgensen et al, 1996; Hansen et al, 1998). Several studies have, 
however, observed significant associations between VDR genotype and markers of bone 
turnover (Kruger et al, 1995; Howard et al,, 1995; Tokita et al, 1996). These findings 
are, however, not consistent between studies (Gamero et al, 1996b; Tsai et al, 1996; 
McClure et al, 1997; Kung et al, 1998). 
1% 
Several studies have examined the relationship between VDR genotNpe and W 
BMD response to calcium and/or vitamin D in therapeutic trials. At the hip. rates of 
change correlated with VDR genotype in a study of 229 postmenopausal women 
receiving calcium supplements (Krall. et al, 1996), and in a study of 81 postmenopausal 
women receiving 400 IU vitamin D3 (Graafmans et al, 1997). In these studies, the 
genotype "BB" appeared more responsive to therapy with either calcium or vitamin D. 
No data on lumbar spine BMD were available in these studies, probably reflecting the 
subjects' age and the fact that degenerative spinal disease would have affected 
longitudinal BMD measurements. Two smaller studies have, however, observed an 
association between rates of change in lumbar spine BMD and VDR genotype in subjects 
receiving calcium supplements (Ferrari et al, 1995) and I a-hydroxyvitamin D3 
(Matsuyama et al; 1995). There was no consistent genotype association in these two 
studies, with the study by Ferrari et al (1995) observing a correlation between change in 
spine BMD and dietary calcium intake only in the heterozygous genotype "Bb", whilst 
the study by Matsuyama et al (1995) noted an increased therapeutic response in the 
haplotype "bbaaTT" compared to the others. These findings suggest a gene-environment 
mteraction influencing rates of change in BMD- Adjustment for dietary calcium intake 
did not influence the results presented in this chapter. Two of the population-based 
studies quoted earlier did stratify their analyses according to either calcium intake 
(Garnero et aL 1996b) or calcium intake and serum 25-hydroxyvitamin D3 (Hansen et al, 
1998), although this did not alter their negative findings. The mean dietary intake of 
calcium was between 800-900 mg/day in these studies compared to pre-treatment intakes 
of less than 650 mg/day in the studies by Feffari et al (1995) and Krafl et al (1995). This 
suggests that the VDR genotype relationship with bone loss may only be apparent in 
subjects with low dietary intakes of calcium. 
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The number of subjects available for analysis limits the findings in this Chapter. 
Despite this, the study had approximately 70% power to detect a I% difference in rates 
of change in BMD between the homozygous genotypes. Although larger studies , vould 
be requffied to have more power, the present study precludes the VDR gene locus as 
having a major and probably clinically important influence on rates of change in BMD. 
The modest rates of bone loss observed in this study, the duration of follow-up, and the 
precision error associated with the DYA BMD measurements also precluded identifyirýg 
small differences between the genotypes. Although forearm BMD measurements using 
SPA have a low precision error, this predominately cortical bone site does not respond as 
greatly to oestrogen deficiency as trabecular bone at the spine. Studies of longer 
duration wiU be required to identify smaU differences in rates of change between the 
genotypes, although again whether these would be clinically important is uncertain. 
Relatiopýlju between TgqIjzenolyN and osteo-porotic fracture 
Overall, no relationship was observed between VDR genotype and history of 
prevalent fracture. As earlier work in this thesis has suggested site specificity to fracture 
risk, analysis was also performed examining the genotype-association with both prevalent 
vertebral and wrist fractures. The number of subjects with osteoporotic fractures at 
these two skeletal sites was sna, and results showed no association. It was not possible 
to demonstrate an increased fracture risk for the "T" allele under either recessive or 
dominant inheritance models. 
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To date, only one smaH study has identified an association bemeen VDR 
genotype and vertebral fracture in 25 Japanese patients (Yangi et al, 1996). Increased 
fracture risk was associated with the "B" affele, with a co-dominant or additrve 
inheritance model. Beavan et al (1996) and Young et al (1996) both reported that hip 
fracture prevalence correlated with population frequency of the "B" or 'T' allele, and this 
could explain in part the ethnic differences observed in fracture rates. They note that the 
"B" ("'t") allele is rare in Asian subjects, although Yangi et al (1996) reported a 14-fold 
increased fracture risk associated with the "BB" genotype. The low population 
frequency means it can only explain a small proportion of Japanese osteoporotic fracture 
cases. 
A large number of other studies have also examined the genotype distributions in 
subjects with and without vertebral fracture, finding no significant association (Melhus et 
aL 1994; Lim et al, 1995; Looney et al, 1995; Berg et al, 1996; Houston et al, 1996; 
Francis et al, 1997, Vandevyver et al, 1997; Ensrud et al, 1999). Nguyen et al (1994) 
estirmted that studies of greater than 300 subjects may be required to detect loci having 
modest effects on fracture (i. e. relative increase in risk of 1.4). Individually these studies 
may have been under-powered, although pooling of results provides a total sample size 
of more than 1000 subjects. Accepting that there may be differences in study design and 
patient entry criteria, overall this analysis shows no difference in VDR genotype 
frequencies between the control subjects and vertebral fracture cases (Figure V-1). 
These results would therefore suggest that the VDR locus does not influence the risk of 
vertebral fracture, although further studies will be required to examine this relationship in 
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Fractures (n= 368) Controls (n=996) 
V-6 Conclusions 
In a population-based analysis, VDR Taql genotype was found to not be 
associated with rates of early postmenopausal bone loss from either the spine or hip. 
Although the study design had limitations relating to sample size and duration of foflo, ýN - 
up, these results would suggest that the VDR locus does not have a major influence on 
early postmenopausal bone loss at these skeletal sites. 
VDR genotype was also not found to be related to risk of prevalent osteoporotic 
fractures, assessed as any fracture at either spine, hip or wrist occuning after the age of 
35 years. Unfortunately the relatively young age of the cohort and the small number of 
fractures reported precluded site-specific analysis. Comparison with other published data 
would support these negative findings, as there was no consistent increase in fracture risk 
observed across studies. Overall these data would also suggest that the VDR locus is 
not a major candidate gene for determining osteoporotic fracture. 
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CHAPTER VI 
CANDIDATE GENE ANALYSIS IN OSTEOPOROSIS: POPULATION BASED 
ASSOCIATION STUDIES OF THE OESTROGEN RECEPTOR, TYPE I 
COLLAGEN al AND INTERLEUKIN 1 RECEPTOR ANTAGONIST GENES 
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VI. I Summary 
It would appear that the VDR gene locus contributes only modestly to the 
population variance in BMD,, and this chapter has therefore examined the association 
between three additional candidate genes (oestrogen receptor, type I collagen cc I, and 
mterleukin-I receptor antagonist) and osteoporosis risk traits. Selection of these 
candidate genes was based on knowledge of bone cell biology and presumed disease 
pathophysiology. In addition, evidence for interaction between these loci and the VDR 
gene has also been explored. 
OveralL there was no association between polymorphism at the oestrogen 
receptor locus and osteoporosis related traits of BMD or early menopausal bone loss. At 
the IL- I RN locus, however, a polymorphic VNTR was associated with differential rates 
of bone loss at the lumbar spine but not at the hip. No relationship was observed 
I- - A. between the IL-IRN VNTR and baseline BMD at these two skeletal sites. At the 
COLIAl locus a significant association between BMD and fracture risk was observed. 
Carriage of at least one copy of the COLIAI "s" allele was associated with reductions of 
0.25 SD in BMD at both spine and hip, and a 2-3 fold increased risk of any osteoporotic 
fracture. There was also evidence of interaction between the VDR locus and the 
COLIAI, with fracture risk markedly increased in subjects who had at least one copy of 
ý1- - 44 91) me s aflele and who were heterozygous for the TaqI polyniorphism. 
These data therefore suggest that osteoporosis is a complex disease as several 
genes influence disease risk with evidence of gene-gene interactions. 
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VI-2 Oestrogen receptor 
VI. 2.1 Introduction 
Oestrogen appears to play an important role in maintaining bone mass in both 
adult men and women by suppressing bone remodelling and maintaining a balance 
between osteoblastic and osteoclastic activity. The skeletal action of oestrogen appears 
to be mediated through its intracellular receptor (ER), which has been shown to be 
expressed in bone (Eriksen et aL 1988). Studies of the ERoc-knockout mouse (Lubahn 
et al. 1993) and from an ERa human gene mutation (Smith et aL 1994) provide direct 
evidence for the ER having effects on the regulation of bone mass. 
Although gross germline structural mutations within the ER gene appear rare, 
polymorphic variation in the ER gene may predispose to osteoporosis. This chapter 
therefore examines the association between ER(x gene polymorphisms and bone-related 
traits. Because of the importance of oestrogen in the attaimnent of peak bone mass and 
the bone loss that occurs in the oestrogen-deficient state, the polyrnorphisms were 
examined against pre- and postmenopausal bone mass and early menopausal bone loss at 
both the lumbar spine and hip. 
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VI. 2.2 Methods 
Two groups of women were selected fi7om the Chingford study population 
cohort. Group I consisted of postmenopausal women who were within 5 years of a 
natural menopause and currently not on HRT or other medication known to affect bone 
metabolism Longitudinal BMD data were available on these women over 5 years. 
Group 2 consisted of premenopausal women who had regular menstruation, absence of 
menopausal symptoms and no current use of HRT. 
ERa genotypes were determined as described in Chapter 11 using PCR and 
restriction enzyme digestion with PvuII and XbaI. TaqI VDR genotypes were also 
available on these subjects as previously detailed. Chi-squared analysis was perfom-&d to 
test for LD between the two ER polymorphisms. Haplotype analysis was subsequently 
performed, with direct comparisons between the variable means of the common haplotype 
combinations using two-sided Student mest. 
VI. 2.3 Results 
Full results were available on 202 women at the PvuII locus and 193 women at 
the XbaI locus. In total, 188 of the women had genotypic information at both loci. The 
genotype distribution at these two loci in these 188 women is shown in Table VT. I 
below, and denionstrates strong LD between the loci (X' = 59.4, p<0.001). 
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Table VIA Distribution of subjects (%) at the PvuII and XbaI loci in 188 
women 
PVUII locus 
XbaI locus pp Pp pp 
xx 22(11.7) 12(6.4) 4(2.1) 
xx 22(11.7) 64(34.0) 10(5.3) 
xx 5(2.7) 21(11.2) 28(14.9) 
Table VI. 2 Oestrogen receptor gene haplotypes in 188 women 
PvuII genotype 
XbaI genotype PP Pp pp 
xx 292 213 39 3 
xx 19 2 - 3,4 
xx 1ý 1 194 414 
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The distribution of genotypes did not differ significantly between the groups of 
pre- and postmenopausal women. 
With evidence of LD between the two lociý it was possible to assign 4 
haplotypes: Px = 1, PX - 2, pX = 3, px = 4. In the absence of parental data and that the 
fact that each genotype was assigned independently, inference was made of the 
haplotypes for aH subjects apart from the cases where subjects were heterozygous at 
both the PvuII and XbaI loci (Pp/Xx). Haplotypes 2 and 4 appeared the most common 
in this group of Caucasian women (Table VI. 2). 
Characteristics of the women according to their PvuII and XbaI genotypes are 
shown in Tables VU and VIA respectively. There was no association between ER 
genotypes and bone mass at spine or hip, both in the total group and after stratification 
by menopausal status. In addition, there was also no association with rates of early 
postmenopausal bone loss at these sites. Non-significant findings were also observed 
with haplotypic analysis against these traits (Figures VI. I). 
There was no evidence of interaction between the TaqI VDR gene polymorphism 
and each of the ER polymorphisms on BMD or rates of change in BMD (Tables VII. 5 
and VII. 6), or when the analysis was repeated using constructed ER haplotypes. 
207 




(n = 51) 
Pp 
(n = 107) 
pp 
(n = 44) 
Age (yrs) 50.8(5.0) 50.5(4.1) 50.7(4.5) 
Height (cm) 162(5) 162(6) 161 (7) 
Weight (kg) 65.9(10.4) 68.6(13.9) 67.9(12.6) 
BMI (kg/m) 25.0(3.8) 26.0(5.3) 26.2(4.2) 
No. subjects postmenopausal 25 48 22 
Menopause duration (yrs) 2.8(2.1) 2.9(1.6) 3.9(3.2) 
Age at menopause (yrs) 51.8(3.2) 50.2(3.1) 50.4(3.1) 
No. ever smoking (%) 26 59 22 
Premenopausal lumbar spine BMD (g/cm) 1.05(0.12) 1.07(0.13) 1.05(0.08) 
Postmenopausal lumbar spine BMD (g/cm) 0.98(0.17) 0.96(0.14) 0.98(0.12) 
Premenopausal femoral neck BMD (g/cmý) 0.80(0.11) 0.82(0.11) 0.82(0.09) 
Postmenopausal femoral neck BMD (g/cm) 0.76(0.17) 0.77(0.12) 0.80(0.12) 
Change in lumbar spine BMD (%/yr) -1.1 (1.1) -0.7(l. 6) -1.0(1.6) 
Change in femoral neck BMD (%/yr) -0.7(2.0) -0.6(2.2) -0.6(2.3) 
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(n = 55) 
Age (yrs) 50.3(4.5) 50.5(4.1) 50.7(4.7) 
Height (cm) 162(5) 162(6) 163(7) 
Weight (kg) 66.4(12.4) 67.1 (13.2) 69.4 (12.3) 
BMI (kg/m) 25.3(5.2) 25.6(4.9) 26.2(4.2) 
No. subjects postmenopausal 14 52 32 
Menopause duration (yrs) 3.7(2.1) 3.1 (2.6) 2.9(1.7) 
Age at menopause (yrs) 51.7(2.0) 50.7(3.1) 51.3 (3.3) 
No. ever smoking (%) 17 41 24 
Premenopausal lumbar spine BMD (g/cm) 1.06(0.12) 1.07(0.13) 1.05(0.09) 
Postmenopausal lumbar spine BMD (g/cm) 0.98(0.13) 0.96(0.17) 0.98 (0.11) 
Premenopausal femoral neck BMD (g/cm) 0.79(0.12) 0.83(0.11) 0.83(0.10) 
Postmenopausal femoral neck BMD (g/cm) 0.77(0.13) 0.78(0.15) 0.77(0.12) 
Change in lumbar spine BMD (%/yr) -0.9(0.9) -0.9(l. 7) -0.8(1.5) 
Change in femoral neck BMD (%/yr) -0.5(2.8) -0.8(2.0) -0.5(1.9) 
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VI. 2.4 Discussion 
The data presented in this chapter failed to show an association between tvvo 
biaRelic polymorphisms of the oestrogen receptor gene and osteoporosis. Specificafly. 
no relationship was seen between ERcc genotype and premenopausal bone mass. and 
between ERa genotype and early postmenopausal bone loss. Two common haplotypes 
were identified, although no relationship was seen when these were also analysed against 
the osteoporosis traits. 
These findings contrast with other studies that have demonstrated association 
between ERcc gene polyrnorphisms and BMD in postmenopausal women (Sano et al, 
1995; Kobayashi et al, 1996), premenopausal women (Mizunuma et al, 1997; Willing et 
al, 1998), and niales (Ongphiphadhanakul et al, 1998). Negative studies have, however, 
also been reported (Mizunuma et al, 1997; Gennari et al, 1998; Han et al, 1999), and 
there appears to be no consistent trend in either the genotype/haplotype associated with 
lower BMD or with the skeletal site affected in the associations studies reported (Table 
VI. 7). The majority of studies have been conducted in subjects of Oriental descent, and 
. r- -- further studies are required in Caucasians and Blacks to determine whether the ERct 
gene contributes to the racial differences that are observed in BMD and osteoporotic 
fracture risk. In addition, no study has examined for a relationship between ERct 
genotype and osteoporotic fracture, with the majority of studies concentrating on women 
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In two of the studies summarised. in Table VI. 7, genotype associations Nvere also 
observed with markers of bone tumover (Sano et aL 1995; Mizunuffia et al. 1997). 
although direct assessment of change in BMD over 3 years failed to demonstrate any 
significant relationship (Willing et al, 1998). In this latter study, subjects were pre- and 
pen-menopausal and it therefore remains to be confirmed whether the ER gene has any 
effect on differential rates of bone loss in the postmenopausal period. 
In this chapter there was no evidence of interaction between the ERcc gene 
polymorphisms and the TaqI VDR polymorphism on BMD or rates of change in BMD. 
Studies analysing the BsmI VDR polymorphism have, however, shown an association 
between this and the ER PvulI polymorphism on spine BMD (Gennari et al, 1998, 
Willing et al, 1998) and rates of growth in childhood (Suarez et al, 1998). In the study 
lby Wifling et al (1998) there was, however, no evidence of interaction between the two 
loci acting on rates of change in BNM. Although there is strong evidence of LD 
between the BsmI and TaqI VDR polymorphisms, (Morrison et aL 1994), the interaction 
between the VDR locus and ER gene may be specific for the BsmI polymorphism. 
Limitations 
The study design had approximately 70% power to detect either a difference of 
0.5 SD in BMD or aI% difference in rates of change in BMD between the homozygous 
genotypes. For the study to have had 90% power (a = 0.05), the total sample size 
needed would have been more than 300 subjects. By restricting analysis to 
premenopausal and to postmenopausal women not using HRT, the study could not 
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address the issue as to whether environmental factors such as exogenous oestrogen in the 
form of HRT may have interacted with ER genotype (Deng et aL 1998; \Villing et A 
1998). In addition, it would be interesting to have analysed the relationship between ER 
genotype and the ages at menarche and menopause, parity, and to have examined for a 
possible interaction with use of the oral contraceptive pill. 
The study design was also limited by the fact that the PvuII and Xbal 
polymorphisms were assessed individually. In the absence of parental data this meant 
that haplotypes could only be inferred, with the genotype PpXx not being able to be 
included in analyses. A more detailed assessment of ER gene polymorphisms including 
the TA repeat in the promoter region may be required to accurately define the sequence 
diversity in the gene and to assess the degree of LD across the gene. This will be 
particularly important as the PvuII and XbaI polymorphisms are intronic and their 
functional significance is unclear. Data from other candidate genes for cardiovascular 
disease have already highlighted the sequence diversity in coding and non-coding regions 
(Rieder et al, 1999) and the potential for haplotype analysis (Keavney et al, 1998). The 
recent discovery of the ERP gene (Enniark et al, 1997) and polymorphic, association with 
BMD in Japanese women (Ogawa et al, 2000) is also of interest. These data suggest 
that the the ERP gene should be further examined for its relationship with BMD and 
fracture risk in larger groups. 
Because of the age of the subjects very few of them had experienced osteoporotic 
fracture thereby precluding fonnal analysis. In fact, only 8 subjects had sustained such 
fractures and these were evenly distributed across the ERa genotypes. 
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VI. 2.5 Conclusions 
In this chapter the ER gene has been evaluated as a candidate gene for the 
development of osteoporosis. Pre- and postmenopausal women (within 5 years of a 
natural menopause) were included in this analysis. Genotype information was available 
for the PvuII and XbaI ER gene polymorphisms and the TaqI VDR polymorphisms. 
There was no evidence of association between the ER RFLPs and BMD at spine or hip 
in both the pre- and postmenopausal women. In addition, there was no relationship 
between these RFLPs and longitudinal assessment of bone loss at both skeletal sites. 
The study identified two common ER haplotypes (PX and px), although there was no 
haplotypic association with BMD or bone loss. There was also no evidence of 
interaction between the VDR and ER loci. These data would therefore suggest that the 
ERoc gene is not a major candidate gene for the development of osteoporosis, and the 
results would preclude a significant locus effect on BMD and early menopausal bone 
loss. Further studies in older subjects will be required to determine whether this locus 
has any effect on fracture risk. 
VI. 3 Type I Collagen a] 
V13.1 Introduction 
Type I collagen is the major protein constituent in bOne and in a few individuals 
with severe osteoporosis, coding sequence defects similar to those observed in 
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osteogenesis imperfecta have been demonstrated (Spotila et al, 1991). These structural 
mutations are, however, rare and unlikely to account for more than a small minonty of 
the chnical cases seen (Spotila et aL 1994). 
During the course of this thesis, work from Grant et al (1996) demonstrated an 
association between a COLIAI polymorphism and both low BMD and vertebral fracture 
risk in two UK patient groups. In this chapter, the relationship between this COLIA I 
polymorphism, and BMD, osteoporotic fracture risk and biochemical markers of type I 
collagen resorption has been examined in a cross-sectional analysis of women from a 
separate UK population cohort. 
VI. 3.2 Methods 
The study design was a nested case-control study selected from the Chingford 
study population cohort. Cases were subjects with either (i) self-reported personal 
history of appendicular fracture in the I 0-year period preceding the study's onset (1978- 
1988), or (ii) prevalent vertebral deformity consistent with fracture on lateral 
thoracolumbar spinal radiographs. Controls had no fracture history and no radiographic 
evidence of vertebral fracture. 
BMD data were available at the lumbar spine and hip in all subjects. COLIAI 
and TaqI VDR genotype results were available as previously detailed in Chapter 11. As 
previous work had suggested a donfmant pattern of risk associated with the rarer -s" aflele 
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(Grant et al, 1996), statistical analysis was planned to combine the `Ss" and '*ss*' genotýpe 
groups. 
in a subgroup of women from the total cohort population urinary coUagen cross- 
links pyridinoline and deoxypyridinoline results were available for analysis against 
COLIA1 genotype. Dr. Ian James from St. Bartholomew's Hospital London had 
performed these assays on fasting early morning urine samples. The urinary collagen 
cross-links were assayed using ion-pair reversed-phase high-performance liquid 
chromatography (I]PLC) in the presence of I -octanesulphonic acid (James et al. 1990). 
Inter and intra assay variations were less than 10% for both pyridino line and 
deoxypyridinoline. This assay had been validated against standard gradient systems, 
where correlations of 0.95 (pyridinoline) and 0.92 (deoxypyridino line) were observed 
between the two techniques in 27 normal women. Preliminary analysis suggested that 
urinary collagen. cross-link values were not normally distributed and for subsequent 
analysis natural logarithmic transformation was required to normalise the data. 
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VI. 3.3 Results 
Complete clinical and genotype data were available on 185, predominanti-v 
-postmenopausaL women with a mean age (SD) of 54.3 (4.6) years. 55 women had 
evidence of validated prevalent fractures at either the lumbar spine or appendicular sites. 
Descriptive details of the fracture cases and controls are shown below in Table VI. 8. 
Table VI. 8 Mean characteristics (SD) of 185 women according to prevalent 
fracture status 
Variable Fracture Cases (n--55) Controls (n= 13 0) 
Age (yrs) 56.4 (5.2) * 53.4(4.0) 
BMI (kg/m) 26.7(4.7) 25.6(3.8) 
Menopause duration (yrs) 
[medain, interquartile range] 
8 (4,12) 4(2,5) 
No. subjects postmenopausal (%) 52(95%) 122(94%) 
No. subjects with ever use of HRT 15 (27%) 6(0.5%) 
No. subjects ever smoking 21(38%) 59(45%) 
Lumbar spine BMD (g/cmý) 0.88 (0.15) 0.97(0.15) 
Femoral Neck BMD (g/cm) 0.70 (0.12) 0.76(0.13) 
*<0.0001 (vs controls) 
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Table VI. 9 Mean characteristics (SD) of 185 women according to COUAI 
genotype 
Variable SS Ss ss 
(n-- 113) (n=67) (n=5) 
Age (yrs) 54.0 54.8 55.0 
(4.6) (4.5) (6.3) 
Body Mass Index (kg/mý) 26.0 25.8 26.4 
(5.2) (3.9) (3.2) 
Menopause duration (yrs) 4 4 5 
[median, interquartile range] C7--1 
(2,5) (2,8) (4,5) 
No. subjects postmenopausal (%) 106 63 5 
(94%) (94%) (100%) 
No. subjects with ever use of HRT 11 9 1 
(10%) (13%) (20%) 
No. subjects ever smoking 46 30 4 
(41%) (45%) (80%) 
No. subjects with fracture 28 27 * 0 
(25%) (40%) (0%) 
Lumbar spine BMD (g/cm 2) 0.965 0.912 0.924 
(0.163) (0.147) (0.087) 
Femoral neck BMD (g/CM2) 0.754 0.726 0.757 
(0.146) (0.105) (0.097) 
P=0.03 
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In total, twenty-one women reported previous or current use of HRT, with a 
median (interquartile range) duration of therapy of 9 (39 12) months. BMD vvas 
significantly reduced in the fracture cases compared to those without any history of 
prevalent fracture at both the spine and the hip. 
The COLIAI genotype frequencies observed in the total group were similar to 
those previously reported in white Caucasoids (Grant et al, 1996) and were in HWE: SS 
61.1%, Ss 36.2%, ss 2.7%. No significant differences in demographic characteristics 
were observed between the women in the COLIAI genotype groups (Table VI. 9). 
Analysis of the relationship between COLIAl genotype and BMD showed that 
BMD was lower in heterozygous, subjects ("Ss") at both the spine and the hip when 
compared to the homozygous genotypes "SS" and "ss" (Table VI. 9). A pattem 
suggesting a dominant genetic effect associated with presence of the "s" allele was 
observed only at the spine. BMD was significantly reduced at the lumbar spine in 
subjects with the "s" allele ("Ss/ss" combined vs "SS"), mean difference (95% Cl) 0.047 
gkmý (0.001,0.093), P=0.02 (Figure VI. 2). A similar trend was also seen at the 
femoral neck, although this difference was non-significant, mean Merence 0.026 g/CM2 













Figure VI. 2 Relationship between COLIAI genotype and mean BMD 






In totaL fuH genotype results at both the COLIAl and VDR loci and BMD data 
were available on 151 subjects. As these genes are on different chromosomes ý was 
reassuring to observe that there was no evidence of co-segregation of genotypes. There 
was also no evidence for an interaction between the loci acting on BNID at either the 
spine or hip. 
As previously stated 55 validated fractures were observed; 28 vertebral 
deformities/fractures and 27 appendicular. The risk genotypes ("Ss/ss") were higher in 
the prevalent fracture cases compared to non-fracture cases, with frequencies of 49% vs 
33% respectively (Fisher's exact tests P=0.04). The "Ss/ss" genotypes were associated 
with an increased risk of any fracture compared to the homozygous "SS" (Table VI. 10). 
Site-specific analysis also demonstrated a consistent trend of fractures being more 
commonly associated with the "s") allele at both the spine and appendicular sites, 
although these findings were not statistically significant for the individual skeletal sites 
due to small numbers. 
Table V1.10 Odds ratio (95% CI) for risk of prevalent fracture vertebral 
and appendicular) associated with carriage of the "s" allele 
COLIAI Genotype OR (crude) OR (adjusted 
SS 1.00 1.00 
Ss/ss 1.95 (1.01,3.78) 1.82 (0.91.3.61) 
adjusted for femoral neck BMD 
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Stratification of results by TaqI VDR genotype identified a subset of women with 
the heterozygous genotype "Tt" who were at significantly increased risk of fi-acture, 
odds ratio 5.59 (1.53,20-36). No increase in fracture risk associated with the carriage of 
"s" alUele was observed for women of the homozygous VDR genotypes *'TF' or -tt- 
(Figure VI. 6). Adjustment for confounders such as age, weight, BMD or calcium mtake 
did not appreciably alter this risk. 
Mean values for urinary collagen cross-links in the COL IAI genotype groups are 
presented in Table VIA 1. Pyridinoline concentrations were significantly elevated in 
1. subjects with the "Ss/ss" genotypes compared to the homozygous "SS . Levels of 
deoxypyridinoline did not, however, differ significantly between the genotype groups. 
. 
Again, there was no evidence of any interaction between the COLIAI and VDR genes 40- 
acting on the urinaq coUagen cross-links. 
Table V1.11 Relationship of COLIA1 genotype to mean (SD) urinary 
collagen cross-links 
Variable SS (n = 48) Ss/ss (n = 34) 
Pyridinoline/creatinine (mnoYmmol) 44.6(24.5) 54.1 (24.5) 
Deoxypyridinoline/creatinffie (nmol/mmol) 13.3(7.0) 15.0(7.2) 
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Figure VI. 3 Interaction between TaqI VDR and COLIA1 genotypes 
on total fracture risk 
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VI. 3.4 Discussion 
Type I collagen is the major protein constituent of bone and is therefore a strong 
and plausible candidate gene for the regulation of BMD. The results presented in this 
chapter show an association between a single base pair polymorphism (G-->T) within the 
regulatory region of the COLIAl gene and risk of osteoporosis. The "s" allele výas 
associated with reduced BMD at the spine with a more modest reduction also observed 
at the hip. These findings are simflar to those observed in the two other populations 
studied from Aberdeen and London (Grant et aL 1996) and suggest that the genetic 
effect associated with the COLIAI locus is strongest at the spine. The "risk" genotypes 
("Ss/ss") were over-represented in subjects with prevalent fi7acture when compared to 
non-fracture cases, where presence of the "s" aflele was associated with almost a 2-fold 
increased risk of any fracture when compared to the alternate aflele. The increased 
fracture risk associated with the "s" allele appeared largely independent of BMD, 
suggesting that the COLIAI locus may also have effects on bone structure or quality. 
The earlier study by Grant et al. (1994) had shown an association between the 
COLIAI genotype and vertebral fracture (55 cases) with an ahnost 3-fold increased risk 
ICI 55 (. 4 ý5 of fracture associated with the ", d ss genotypes. The data from this chapter 
would indicate a consistent increased risk for any fracture although larger studies would 
be required for site specific analysis. During the course of this work other studies have 
also examined the relationship between the COLIAI locus and osteoporosis. A study m 
1,778 postmenopausal women (age range 55-80 years, mean age 66 years) from the 
Netherlands demonstrated a significant effect of the COLIAI locus on BMD and fracture 
risk (Uitterlinden et A 1998). In this study the COLIA1 locus explained onl)- 0.3-0.4% 
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of the population variance in BMD with any effect only being apparent in subjects aged 
over 70 years. This may indicate some relationship between this polymorphism and age- 
or menopause related bone loss, and may also explain the preliminary observations from 
another cross-sectional study that the genetic effect on BMD associated with the 
COLIAl locus was stronger in postmenopausal compared to premenopausal women 
(Garnero et al, 1998). Two smaller studies have, however, demonstrated an association 
between COLIAI genotype and BMD in prepubertal girls (Sainz et al, 1999) and 
premenopausal women (Hampson et al, 1998). In the study by Uitterlinden et al (1998), 
carriage of the "s" allele was associated with an increased risk of peripheral fractures, 
although in contrast to the findings by Grant et al (1996) no increase in the risk of 
prevalent vertebral fractures was observed. This increase in fracture risk was not altered 
by adjustment for BMD, again perhaps suggesting some influence of this genotype on 
bone structure and quality. Data from other case-control studies was conflicting, with 
both positive (Langdahl et at, 1998; Roux et al, 1998) and negative (Liden et al, 1998, 
Hustmyer et al, 1999, Willing et al, 1997) associations being reported. It is interesting to 
observe that in the positive association studies there was no relationship between 
COLIAl genotype and BMD, again suggesting a possible influence of this locus on bone 
quality or structure. To date, no studies have examined the relationship between the 
COLIAI genotype and QUS parameters. 
Case-control studies cannot confer a causal association between a genetic locus 
and a risk trait. The replication of the findings from Grant et al (1996) by work from this 
thesis and the other studies above (Uitterlinden et al, 1998; Roux et al, 1998; Gamero et 
A 1998; Langdahl et al, 1998) provides stronger evidence and reduces the risk of t3pe I 
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errors. Demonstration of a functional significance associated with the COLIAI 
polymorphism. which is located in a putative Spl binding site domain of the gene*s 
promoter would strengthen the candidacy of this locus. The observation that 
pyridinoline levels were increased in the "at risk"" genotype groups could suggest an 
association with collagen. turnover. Deoxypyridinoline which is reported to be more 
specific for type I collagen resorbed from bone was not however significantly elevated in 
subjects with the "s" allele, suggesting that the COLIAI locus rather than being bone 
specific, may have regulatory effects on total body turnover of type I coflagen. This 
could indicate a possible relationship between this locus and type I collagen in skin, 
which would be of interest in view of the association observed in some studies between 
skin thickness and osteoporosis (Brincat et al, 1987; Pedersen et al, 1995). Langdahl et 
al (1998), however, found no relationship between urinary and serum markers of 
coRagen turnover and COLIAI genotype. 
The data from the larger cross-sectional studies suggest a stronger effect of this 
locus on BMD with increasing age, and this could reflect an effect of the COLIA I locus 
on differential rates of bone loss. This would be supported in part by the findings 
presented in this chapter demonstrating an association with coflagen turnover. 
Longitudinal studies will be required to directly assess the relationship between the 
COLIAI locus and menopausal bone loss. 
The finding of a potential interaction between the COLIAl and VDR locus is of 
rather than being interest. It appeared specific for the heterozygous genotype '*Tt 
associated with carriage of either the "T" or "t" alleles under difFerent inheritance 
219 
patterns. The COLIAl polymorphism is situated in a Spl binding site in the promoter 
region of the gene. The Spl transcription factor gene maps to the same chromosomal 
region as the VDR gene on chromosomal 12, and there is therefore a plausible biological 
hypothesis for an interaction. Because of issues relating to power and multiple 
comparisons these findings would need to be replicated in further studies to exclude the 
possibility of type I error. Environmental factors may also needed to be taken into 
account, although in this analysis results remained significant after inclusion of dietary 
calcium intake in the logistic regression model. 
To date, only one study bas presented genotype information for the two loci in 
the same population (Willing et al, 1997). In total, 66 women from the lower quartile of 
hip BMD measurements and 63 from the upper quartile were examined. There was no 
association between femoral neck BMD and either COLIAI or VDR genotypes when 
analysed independently. No data was presented, however, for whether there was any 
I interaction between the two loci. 
2-10 
VI. 3.5 Conclusions 
These data demonstrate that the COLIAI gene polymorphism is associated with 
reduced spinal BMD and an increased risk of prevalent fracture. The increase in fracture 
risk was largely unaltered after adjustment for BMD, suggesting the locus may also have 
effects on bone structure or quality. Urinary pyridinoline, a marker of type I collagen 
resorption, was elevated in sub ects with the risk genotypes "Ss" and "ss". There was j 
evidence of interaction between the COLIAI and VDR loci acting on fracture risk, 
although this was not seen for either BMD or markers of collagen turnover. The 
functional significance of the COLIAl polymorphism remains to be detern-tined. 
Longitudinal studies will be required to evaluate whether this gene could have a potential 
clinical role in the identification of a subset of women geneticafly predisposed to 




Interleukin I receptor antagonist 
Introduction 
Oestrogen. deficiency is associated with an increase in local production of various 
cytokines and growth factors within the bone marrow and bone ceRs, and these 
inflammatory factors appear to play an important role in the development of 
postmenopausal osteoporosis (Ralston, 1994). IL-I is a powerful stimulant of bone 
resorption and is recognised as an inhibitor of bone formation (Dinarello, 1991). The 
observed postmenopausal increase in IL- I activity results from an effect of oestrogen on 
the production of both IL-1 and the IL-1 inhibitor, IL-Ira. These and other data 
therefore raise the possibility that the interleukin I receptor antagonist gene is a potential 
candidate gene for the genetic regulation of early postmenopausal bone loss. In this 
chapter, therefore, the relationship between bone mass, early postmenopausal bone loss 
and an IL- I RN VNTR has been studied. 
VI. 4.2 Methods 
From the Chingford study population cohort, 125 women were selected for the 
present study if they were within 5 years of a natural menopause and at their baseline 
examination were currently not on HRT or other medication known to affect bone 
metabolism. Longitudinal measurements of BMD over 5 years were available on 
subjects at spine and hip. 
232 
I RN and TaqI VDR genotype results were avai. lable as previously det"ed iri 
Chapter 11. For analysis, the IL-IRN alleles were collapsed into a biallelic sý-stem based 
on the number of repeats. The IL- I RN genotype Al (4 repeats) was grouped with genotýpe 
A3 (5 repeats), and compared with genotypes A2 (2 repeats) and A4 (3 repeats). This 
reduces the problems associated with small numbers of subjects in several genotype groups, 
and has a plausible biological basis as the larger affeles will have probably arisen because of 
mutation from a common ancestral allele with fewer repeats. Where ANOVA values were 
significant (p < 0.05), the Bonferroni test for mWtiple cornparisons, was used to search for 
evidence of differences between individual genotype groups. Analysis for allele specific 
effects was perforrned. using carriage of the collapsed allele classes under dominant and 
recessive risk models, with comparisons between the variable means using two-sided Student 
t-test. 
VI. 4.3 Results 
Characteristics of the 125 women entered into the study are shown in Table 
VI. 12. Full clinical and genotype results were available on 108 of these women. No 
significant differences were observed between subjects with genotype results and those 
where DNA was either unavailable or attempts at PCR unsuccessful. 
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Table V1.12 Mean characteristics (SD) of study population and 
stratification by RARN genotype 
Total AlAl AIA2 A2A2 AIA3 A2A3 
group (n=45) (n=49) (n=7) (n=3) (n=4) 
(N=125) 
Age (yrs) 53.1 52.2 53.2 52.6 53.0 55.8 
(3.5) (3.4) (4.0) (2.8) (4.0) (1.5) 
Age at menopause (yrs) 50.4 49.8 50.2 50.6 50.0 51.5 
(3.1) (3.1) (3.9) (3.4) (4.0) (1.0) 
Menopause duration (yrs) 2.7 2.4 3.0 2.0 3.0 4.3 
(1.7) (1.8) (1.6) (1.8) (0.0) (0.5) 
BMI (kg/M2) 26.0 26.4 26.1 25.4 24.7 23.8 
(4.8) (4.7) (5.3) (3.9) (3.1) (2.1) 
No. ever smoking (%) 54 20 23 0 1 3 
(43) (43) (47) (0) (33) (75) 
Lumbar spine BMD (g/CM2) 0.969 0.960 0.985 0.888 0.982 0.912 
(0.144) (0.145) (0.139) (0.118) (0.082) (0.123) 
Femoral neck BNM (g/crn 2) 0.763 0.748 0.775 0.699 0.741 0.743 
(0.130) (0.129) (0.131) (0.100) (0.170) (0.110) 
Change in lumbar spine BMD -1.1 -1.4 -0.7 -1.6 -1.8 -0.9 
(%/Yr) (1.5) (1.5) (1.5) (0.8) (0.5) (1.9) 
Change in femoral neck BMD -0.50 -0.9 0.0 -1.2 -0.4 -2.0' 
(%/Yr) (22) (2.3) (2.2) (0.9) (1.4) H 
only I subject in this group with annual rate of hip loss data 
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Analysis of the genotypes in the 108 women showed evidence of three afleles 
which corresponded both in size and in frequency to those previously identified (Table 
V1.13). From these three observed alleles, five out of the six possible genotypes were 
seen (Table VI. 12). There was no significant difference between these 5 genotype 
groups in anthropomorphic or environmental variables known to influence bone niass. 
Table V1.13 IL-IRN alleles identified through DNA amplification of 108 
unrelated individuals (comparison with published data) 
Allele Size 
(bp) 






Al 410 4 65.8 73.6 
A2 240 2 31.0 21.4 
A3 500 5 3.2 3.6 
A4 325 3 - 0.7 
A5 595 6 0.7 
Current study Tarlow et al. 1993 
Collapsing of the IL- I RN VNTR into a biallefic system gave nse to three 
genotype groups: AIAI and AIA3 (n = 48), AIA2 and A2A3 (n = 53), and 
A2A, 2- (n = 
7). No effect of IL-IRN genotype class was observed on baseline BMD at either the 
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lumbar spine or femoral neck. There was, however, a significant association bemeen 
rates of change in BMD at the lumbar spine and the collapsed IL- I RN genotypes. This 
remained significant after adjustment for age, weight and baseline BMD. and also after 
adjustment for multiple testing using the Bonferroni test statistic. Subjects ý, vho , vere 
heterozygous for the A2 allele (genotypes AIA2 and A2A3) tended to have reduced 
rates of spinal bone loss when compared to subjects with the genotypes AIAI and AI A3 
(Bonferroni adjusted P value = 0.06). There were, however, too few subjects with the 
genotype A2A2 to observe a clear allele dose effect across the genotype groups. 
Combinffig the A2 heterozyous and hornozygous, genotype groups, demonstrated 
that presence of at least one copy of the A2 alIele was associated with reduced spinal 
bone loss (mean rate of change ± SD = -1.38 ± 1.48 %/yr) when compared to non- 
carriage of the A2 aflele (mean rate of change = -0.81 ± 1.46 %/yr), P<0.05 (Figure 
VIA). Similar, but non-significant, trends were also seen at the femoral neck with 
reduced rates of bone loss associated with carriage of at least one copy of the A2 allele, 
(-0.85 ± 2.25 %/yr vs -0.23 ± 2.12 %/yr, P=0.18). These findings were essentially 
unaltered after adjustment for the potential confounders as listed above. 
VDR TaqI and IL-lRN genotype results were available on 99 subjects. There 
was no evidence of an interaction between the loci acting on either BMD or with rates of 










Carriage of A2 allele 
Figure VIA Relationship between carriage of the IL-IRN A2 allele and 




The data from this chapter demonstrate that the interleukin I receptor antagonist 
locus is a potential candidate gene for the development of postmenopausal osteoporosis. 
Allelic variation of the IL-IRN gene was associated with differential rates of bone loss 
from the lumbar spine, and may indicate a specific effect of this locus on trabecular bone. 
The functional significance of these findings is not clear. The VNTR is due to a 
86 bp repeat within intron 2 of the gene and this may be of functional significance as the 
sequence is reported to contain three potential protein binding sites; an a-interferon 
silencer A, a 0-interferon silencer B and an acute phase response element (Tarlow et al, 
1993). Polymorphic VNTR repeats have been shown to influence gene expression at the 
insulin locus (Vafiadis et al, 1997), although it is unknown if the IL- I RN VNTR has any 
direct effect on either osteoclast or osteoblast function. The physical number of repeats 
may also be important and could affect transcriptional activity and RNA stability. The 
data from this analysis suggest that the A2 allele may be associated with reduced rates of 
spinal bone loss, and hence reduced osteoclast activity. This contrasts with other studies 
that have shown the A2 aflele to be associated with disease severity in several 
inflammatory diseases (Blakemore et al, 1994; Mansfield et al, 1994; Blakemore et al, 
1995). One possible explanation could relate to the menopausal status of subjects as 
many of the disease associations have been documented in younger subjects. In the 
analysis presented in this chapter, the study was restricted to postmenopausal v, -omen 
and this may suggest that the A2 allele is specificafly associated with reduced 
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inflanunatory activity in the oestrogen deficient state. Further studies -vvill need to 
examine whether there is allele specific expression of IL- Ira that is modified b-.. - hormonal W 
status. In the absence of functional data on IL-lra activity, however, an alternative 
hypothesis is that the IL-IRN VNTR is in LD with a disease causing gene nearby on 
chromosome 2, and that the degree of LD could have differed between the patient 
groups studied. 
To date, fewer studies have exanýined cytokine polymiorphisms for their 
relationship with osteoporosis and associated risk traits than has been seen with the VDR 
and COLIAI loci. A CA microsateflite repeat polymorphism of the interleukin 6 gene 
has been associated with BMD in two separate studies (Murray et al, 1997; Tsukamoto 
K et al, 1999). Replication of study findings is important in genetic association studies to 
confirm original findings and exclude type I errors. 
Limitations 
The subjects represented in this analysis had a mean age of 53 years and would 
have already experienced some age related bone loss. The lack of an association 
between IL-IRN genotypes and baseline BMD suggests that the genetic effect of the 
locus on osteoporosis risk is not mediated through a major effect on peak BMD although 
testing specifically in premenopausal subjects would provide confirmation. Longitudinal 
epidemiological studies show continued bone loss in elderly subjects (Jones et al, 1994). 
and it remains to be determined if the demonstrated association between the 
IL- I RN 
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locus and spinal bone loss persists into later life. This could result in significant 
differences in BMD between the two common alleles in the elderly, translating into 
differential fracture rates. The design of the study to examine menopausal bone loss 
rather than fracture meant that a relationship with osteoporotic fracture could not be 
accurately assessed. The lack of an association at the hip my suggest separate genetic 
mechanisms at the different skeletal sites, although the greater variability in loss rates and 
the lower absolute values at this site could have precluded identification of any effect. 
VI. 4.5 Conclusions 
In summary, these data demonstrate an association between a polymorphic 
VNTR in intron 2 of the ILI -RN gene and menopause related bone loss from the lumbar 
spine. A similar trend was observed at the femoral neck, although this faded to reach 
statistical significance. This suggests that this genetic locus may play a central role in the 
regulation of trabecular bone turnover in the oestrogen deficient state. There was no 
relationship between IL-IRN genotype and bone mass at either skeletal site, suggesting 
that this locus does not have a major influence on the attainment of peak BMD. There 
was also no evidence of interaction between IL- I RN and VDR TaqI genotypes acting on 
either BMD or rates of change in BMD at both spine and hip. Future studies should 
detennine whether the relationship between IIL-IRN genotype and rates of change in 
spine BMD extends beyond the first five years of the menopause and whether 
it 
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241 
VII-I Summary 
Clinical observations suggest an inverse relationship between osteoporosis 
and osteoarthritis (OA), with OA cases having increased BMD and possibly a 
reduced fracture risk. As twin and family based studies have indicated a genetic 
predisposition to OA, this could support a hypothesis that osteoporosis and OA may 
share a common genetic aetiology. At the onset of this thesis, the VDR gene had 
been identified as a potential candidate gene for the determination of osteoporosis. 
This chapter has analysed whether the VDR TaqI polymorphism has any influence on 
the risk of OA at both the knee and spine in unrelated women. The hypothesis under 
test would predict that the allele associated with higher BMD would also be 
associated with an increased risk of OA. 
Two nested case-control studies were performed in postmenopausal women. 
VDR genotype frequencies were found to differ significantly between knee OA cases 
and controls (Fisher's exact test p=0.03), and between spinal OA cases and controls 
(Fisher's exact test p=0.02). No relationship was observed, however, between 
VDR genotype and presence of Heberden's nodes on clinical examination. Carriage 
of the VDR "T" affele was associated with an almost 3-fold increased risk of OA at 
either knee or spine when compared to the "t" allele, with a dominant inheritance 
pattern of risk suggested. Findings were essentially unaltered after adjustment for 
confounders such as age, weight, and BMD, and after stratification for presence of 
OA at other sites. 
These data suggest that VDR genotype is a marker for OA at both spine and 
knee, and this relationship is independent of any genotypic association with BmD. The 
data also highlight that other candidate genes may have influences on risks of 
osteoporosis and OA. 
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VU. 2 Introduction 
OA is a common age related and chronic skeletal condition associated Xvith 
considerable morbidity and mortality, although at present the aetiOlop. - and 
pathogenesis of this condition remain largely unknown. OA of the knee and hip 
appears to be beneficial for bone mass, with OA cases having a 5-10% greater bone 
mass compared to controls (Dequeker, 1996). There is also evidence that OA is 
associated with underlying abnormalities in bone structure and mineralisation, 
findings that are independent of body weight and skeletal loading (Gevers et al, 
1989). Family studies have suggested a strong genetic component to OA, with 
higher prevalence rates in first-degree relatives of index cases and familial 
aggregation (Kellgren et al, 1963; Felson et al, 1998; Hirsch et al, 1998). A recent 
population based UK twin study has also demonstrated a clear genetic effect for 
radiological OA at the knee and band in women, with up to 65% of the variance 
being explained by genetic factors (Spector et al, 1996). Twin studies also support a 
significant genetic contribution to spinal degenerative change seen on magnetic 
resonance imaging (Battie et al, 1995; Sambrook et al, 1999). 
As evidence exists for a strong genetic component to both OA and 
osteoporosis, this raises the possibility that common genetic factors may influence 
the development and/or protection against both conditions. To address this issue, 
this chapter examines whether allelic variation at the VDR locus may also be 
associated with an altered risk of OA in postmenopausal women and whether this 
risk is independent of BMD. 
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VII-3 Methods 
VII. 3.1 Subjects 
The study design was to perform two nested case-control studies (knee OA and 
spinal OA) within postmenopausal women the Chingford Study population. BMD 
results and TaqI VDR genotype results were available as previously described m Chapter 
ii. 
V11.3.2 Knee and spinal radiographs 
Antero-posterior weight bearing knee radiographs had been performed at baselme 
using standard procedures. Grading was performed blind by a single observer (Dr 
Debbie Hart) according to the methods of Kellgren & Lawrence where a scale of 0 to 4 
is used (0 representing no disease and 4 representing severe disease) (Kellgren and 
Lawrence, 1963). Radiological definition of OA is the currently accepted standard for 
epidemiological studies of OA in populations (Spector et al, 1993). Knee OA was 
defined as present if a grade of 2 or more was given (definite osteophyte ± narrowing), 
and controls were classified as having no OA with a grade of :! ýl - The intra-observer 
reproducibility for this technique was good with a kappa score of over 0.8. Presence of 
Heberden's nodes was determined by clinical hand examination (Egger et al, 1995). 
Standard lateral radiographs of the thoracic (T4-12) and lumbar (LI-4) spine 
were also obtained at baseline using standard techniques and graded for presence of 
osteophytosis according to published criteria on a scale of 0 to 3: (0 = none, I =-- 
. iinW9 2= definite, 3= severe). Spinal OA was defined as present in subjects with a 
grade 2! 1 in at least one of the two levels scored (Orwol] et aL 1990). 
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VII. 3.3 Statistical Analysis 
Differences in demographic variables between OA cases and controls, and 
between VDR genotypes were initially compared using analysis of variance and chi- 
squared test. VDR genotype frequencies were compared between OA and control 
groups using Fishers exact test. Conditional logistic regression analysis was used to 
estimate the odds ratio and 95% test based confidence intervals for developing a 
radiological feature of OA for the individual VDR genotypes, with the homozygous 
VDR genotype "tt" set as baseline. Adjustment for other potential confounding 
variables was also performed using conditional logistic regression. 
VII. 4R es ults 
Relatiogft between T; YqI VDR genoMe and knee OA 
In total, 501 women from the total cohort were postmenopausal and had graded 
knee radiographs. Full genotype results were available on 351 (70%) women: 82 
subjects with knee OA and 269 with normal radiographs. The mean age ± SD for the 
total group of 351 women was 55.3 ± 5.0 years. No significant differences were 
observed between sub ects with genotype results and those where DNA was unavailable. j 
The characteristics of the women according to the absence or presence of knee OA are 
shown in Table V-H. 1, and are similar to those of the whole cohort except for age, 
menopause status and duration. Within the 351 women with fuH results, there were 
significant differences between the cases and controls for potential confounders such as 
age, BNE, use of HRT, and hip BMD. Subdivision of women according to their 
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radiological grading for OA demonstrated that the majority of cases had minor discase: 
63 (76.8 %) were grade 2,15 (18.3 %) grade 3 and 4 (4.9 %) grade 4. For controls, 
201 (74.7 %) were grade 0 and 68 (25.3 %) grade 1. 
Overall, VDR genotype frequencies were in HWE and similar to those observed 
in other Caucasian groups and in the whole cohort. Table VH. I shows that there were 
no significant differences in the baseline characteristics between the VDR genotypes 
within this total group or after stratification by Kellgren and Lawrence OA grade. 
The frequencies of the TaqI genotypes were found to differ significantly between 
the OA cases and controls using Fisher's exact test (P = 0.03) with the -tt" genotype 
frequency being reduced with worsening OA status, although the number of subjects 
with severe OA (grade > 3) was too small for formal analysis (Table VII. 2). 
The crude and adjusted odds ratios (95% Cl) for knee OA in the "TT" and "I't- 
VDR genotype group compared to the homozygous genotype "tt" are shown in Table 
VII. 3. 
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Table VITA Mean characteristics (SD) of women according to their knee 
OA status 
Variable Controls OA Cases 
Total Grade 0 Grade I Total Grade 2 Grade 3 Grade 4 
(n=269) (n=201) (n=68) (n=82) (n=63) (n= 1 -5) (n=4) 
Age (yrs) 54.4 54.1 55.4 58.3* 58.1 58.1 62.5 
(4.8) (4,8) (4.6) (4.7) (4.6) (5.2) (1.9) 
BMI (kg/M2) 25.0 24.5 26.2 28.0* 27.7 28.4 30.8 
(3.6) (3.5) (3.8) (4.0) (3.7) (4.5) (4.9) 
Age at menopause 47.8 47.9 47.1 47.7 47.7 48.1 46.5 
(Yrs) (5.0) (4.9) (5.3) (4.7) (4.8) (4.8) (4.1) 
No. ever use of 78 57 21 15 t to 5 0 
HRT (%) (29%) (28%) (31%) (18%) (16%) (33%) (0%) 
No. ever smokers 112 83 29 37 29 6 2 
N (42%) (41%) (43%) (45%) (46%) (40%) (50%) 





(0.11) (0.12) (0.13) (0.14) (0.10) (U. UB) 
- 
P<0.001 (cases vs controls) 
P=0.05 (cases vs controls) 
tP=0.008 (cases vs controls) 
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Table VII. 2 VDR genotype distribution (%) according to Kellgren and 
Lawrence OA Grade 
Genotype Grade 0 
(n = 201) 
Grade I 
(n = 68) 
Grade2 
(n = 63) 
Grade 3 
(n = 15) 
Grade 4 
(n = 4) 
TT 74 (36.8 %) 24 (35.3 %) 19 (30.2 %) 10 (66.7 %) 0(0%) 
Tt 87 (43.3 %) 36 (52.9 %) 38 (60.3 %) 4(26.7%) 4(100%) 
tt 40(19.9%) 8(11.8%) 6(9.5%) 1 (6.6%) 0(0%) 
Table VII. 3 Effect of VDR Genotype on Risk of Knee OA - Odds Ratio 
(95% Cl) 
Genotype Frequency in CIA Frequency in controls OR OR 
cases (%) (%) (Crude) (Adjusted 
TT 29(35.4%) 98(36.4%) 2.42 2.82 
(0.94,6.21) (0.98,8.10) 
Tt 46(56.1 %) 123(45.7%) 3.15 2.98 
(1.26,7.83) (1.09,8.12) 
tt 7(8.5 %) 48(17.9%) 1.0 1.0 
Adjusted for age, BMI, femoral neck BMD, use of IIRT 
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As risk of knee OA appeared to be associated with presence of the "T-' aflele 
with a dominant inheritance pattern, analysis was subsequently performed on the 
genotypes "IT' and "Tt" combined against the "tt" homozygous group set at 
baseline. Crude analysis showed an odds ratio of 2.82 (1.16-6.85, p=0.02) for risk 
of knee OA in association with the "'F' allele. This increase in risk remained after 
- -1. adjustment as previously detailed with an odds ratio of 2.60 (1.01-6.71, p<0.05). 
No significant relationship was observed between VDR genotype and nodal 
arthritis, as determined by the presence of Heberden's nodes. In addition there was 
no difference in genotype frequencies in the subset of knee OA cases who also had 
clinical nodes present compared to knee OA alone. 
Relatiopft between TaqIl VDR genolypg and MinW OA 
In total, 757 women from the total cohort were postmenopausal and had 
graded spinal radiographs. Full genotype results were available on 495 (65%) 
women: 104 subjects with spinal OA and 391 with normal radiographs. Site specific 
analysis showed that 63 subjects had evidence of OA changes in the thoracic spine 
only, 25 had changes only at the lumbar spine, with 16 subjects having changes at 
both levels. The characteristics of the women according to the absence or presence 
of spine OA are shown in Table V-H. 4, and are similar to those of the whole cohort 
except for age, menopause status and duration. No significant differences were 
observed between subjects with genotype results and those where DNA was 
unavaidable. 
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Table VIIA Mean characteristics (SD) of women according to their spinal 
OA status 
Controls 
(n = 391) 
Spinal OA Cases 
(n = 104) 
Age (yrs) 55.6(5.2) 5 7.5 (5.1) 
BMI (kg/m) 25.1(3.5) 27.3 (13.5) 
Menopause duration (yrs) 8.0(6.0) 9.4(5.9) 
No. ever use of HRT 103(26%) 22(21%) 
No. ever smokers (%) 175(45%) 48(46%) 
BMD Lumbar spine (g/cm) 0.93(0.15) 0.98 (0.17) 
BMD Femoral neck (g/cm) 0.73(0.12) 0.75(0.12) 
P<0.001 (cases vs controls) 
tP-0.003 (cases vs controls) 
250 
Again, overaH the VDR genotype frequencies in this subgroup of 495 women C7 
were in HWE. There were no significant differences in the baseline characteristics as 
measured in Table VIIA between the VDR genotypes within this total group or after 
L-+r 
.., atification by presence of spinal OA. 
The frequencies of the TaqI genotypes were found to differ significantly 
between the OA cases and controls using Fisher's exact test (P = 0.01). The crude 
and adjusted odds ratios (95% CI) for spinal OA in the 'ITT" and -Tt- VDR 
genotype groups compared to the homozygous genotype "tt" are shown in Table 
V11.5. 
Table VII. 5 Effect of VDR Genotype on Risk of Spinal OA - Odds Ratio 
(95% Cl) 
Genotype Frequency in OA Frequencyin OR OR 
cases (%) controls (%) (Crude) (Adjusted 
TT 37(36%) 139(36%) 2.62 2.93 
(I. 11,6.19) (1.16,7.3 9) 
Tt 60(58%) 183(47%) 3.23 3.36 
(1.41,7.41) (1.34.8.39) 
tt 7(6%) 69(17%) 1.0 1.0 
Adjusted for age, weight, femoral neck BMD 
251 
Risk of spinal OA again appeared to be associated with presence of the *F' 
allele with a dominant inheritance pattern. Analysis was therefore subsequentlý, 
performed on the genotypes "TT" and "Tt" combined against the "tt" homozygous 
group set at baseline. Crude analysis showed an odds ratio of 2.97 (1.32-6.67) for 
risk of spinal OA in association with the "r' allele. This increase in risk was 
marginally increased after adjustment as previously detailed with an odds ratio of 
3.19 (1.32-7.72). This analysis was also Performed after exclusion of subjects with 
prevalent knee OA. The risk of spinal OA associated with the "T" allele remained 
increased, with a crude odds ratio of 2.45 (1-01,5.89). These findings were also 
essentially unaltered after adjustment for age, weight and BMD. 
VII. 5 Discussion 
These results demonstrate associations between a TaqI polymorphism of the 
VDR locus and early knee OA and spinal OA in women from the general population. 
The "T" affele, which has previously been associated with high bone mass in some twin 
and population studies, is associated with a nearly 3-fold increased risk for development 
of OA at the two skeletal sites when compared to the alternate allele. The pattem of risk 
was observed to be co-dominant, with the homozygous genotYPe "TT" and the 
heterozygous genotype "Tt" both having an equivalent increased risk of OA. This 
relationship cannot be explained on the basis of age, as no significant deviation from the 
expected genotype frequencies was observed in the total group after stratification by age. 
This relationship was also independent of other factors such as weight and BMD that 
have been shown to influence OA risk and were found to differ between the cases and 
controls. 
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The finding that there was no relationship between the VDR locus and nodal 
arthritis also suggests that differing genetic mechanisms may underlie the 
develoPment of Heberden's nodes and associated generalised OA. There may also 
be some evidence for site specificity, as the findings at the spine appeared 
independent of the observed association at the knee. 
It has been proposed that the increase in bone density observed in OA 
indicates that the latter disease might initially be a subchondral bone disorder rather 
than a defect in cartilage, with an increase in subchondral stiffness (Radin et a], 
1970). This would make the subchondral. bone less deformable to impact loading 
and would result in more force being transmitted to overlying tissue, thereby 
predisposing to articular cartilage loss. The finding that there was no association 
between VDR genotype and BMD in this subset of women, and that the observed 
increase in OA risk associated with VDR genotype was independent of BMD 
suggests, however, that the molecular mechanisms are likely to be more complex 
than a simple direct action on bone strength with consequent cartflage damage. 
Serum levels and dietary intake of vitamin D have been shown to correlate 
with progression of hip and knee OA, with this relationship being independent of any 
effect of vitamin D on BMD (McAlindon et aL 1996; Lane et aL 1999). Vitamin D 
has been shown to stimulate synthesis of proteoglycan by mature articular cartilage in 
vitro (Corvol et al, 1981), and this suggests that vitamin D, through its receptor, may 
directly affect articular cartilage metabolism. Vitamin D also has effects on the 
immune system and altered fimction of the VDR may result in immuno-modulation 
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(Hewison, 1992). This may be relevant as low levels of inflamniation have been 
associated with knee osteoarthritis. (Sipe, 1995; Spector et a]. 1997). Unfortunately, 
serum measurements of vitamin D metabolites were not available on these subjects 
and it was therefore not possible to test this hypothesis that VDR genotype may 
cause alterations in vitamin D homeostasis that could result in an OA phenotype. 
Analysis was also not performed to test for an association between VDR genotype 
and serum markers of iifflammatory activity such as Greactive protein levels in these 
subjects. 
The current study cannot exclude the possibility that the TaqI polymorphism. may 
be in LD with a nearby novel susceptibility locus on chromosome 12 that has effects on 
both bone and cartilage metabolism. Potential candidate genes for the development of 
OA that map to this chromosomal region include the COL2AI IGF- I loci that have both 
been implicated in OA and osteoporosis (Dequeker et al, 1993; Bleasel et al, 1995). A 
genome-wide linkage scan for OA in 481 families with a least one affected sibling pair 
(disease status defined as prevalent joint replacement for OA) has recently failed to 
identify linkage with chromosome 12 (Chapman et al, 1999). A finiher study in 27 
sibships with distal. interphalangeal OA gave initial linkage to a marker mapping to 
12q24, although further typing of microsatellite markers in the region failed to replicate 
these findings (Leppavuori et al, 1999). Linkage studies may, however, have lin-ýted 
power to detect loci having modest effects on disease risk (Risch and Merikangas, 1996) 
and association studies could offer a more powerful approach. 
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The COL2AI gene maps <920 kb from the VDR locus, and mutations of this 
locus have been demonstrated in familial forms of OA and chondrodysplasias (Pedeutor 
et al, 1994). These mutations are, however, rare and unlikely to account for the Tnaj ori t-v 
of clinical cases observed in the general populatiom Several small association and 
affected sib pair (AS) linkage studies have failed to identify any association between the 
COL2AI locus and OA in the general population (Hull et al, 1989; Vikkula et aL 1993; 
Priestly et al, 1991; Loughlin et al, 1994; Aerssens et al, 1998). A recent population- 
based study in 786 subjects aged 55 to 65 years has also identified an association 
between allelic variation at the IGF-I locus and radiographic OA at several sites 
including knee, hip, hand, and spine (Meulenbelt et al, 1998). 
During the course of this work, several studies have also been published that have 
examined the relationship between VDR genotype and OA. Uitterlinden et al (1997) 
examined 846 subjects (405 males, 441 females) aged above 55 years. Their results 
showed that carriage of the haplotype "baT" was associated with a 2-fold increased risk 
of OA, and is consistent with this Chapter's results. Earlier work from this group had. 
however, suggested that the "baT" haplotype was actually associated with reduced bone 
mass in this population so the pathophysiological mechanisms are uncertain (Uitterlinden 
et al, 1996). In the study reported by Aerssens et al (1998), no relationship was 
observed between BsmI genotype and hip OA. in this study disease status was defined 
by need for hip replacement and therefore represents a more severe, and probably more 
symptomatic, end of the disease spectrurn. The negative findings at the hip may reflect 
site-specificity in the VDR-OA association, or that the gene influences susceptibility 
rather than severity of disease. 
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Two studies have specifically examined the relationship between VDR genotype 
and spinal OA. Jones et al (1998) studied spinal degenerative disease assessed on plain 
radiographs (L 1 -4) in I 10 men and 172 women aged over 60 years (average age 69 
years). Compared to the homozygous genotype "tt", subjects with the genotype **TT" 
had a 55% reduction in risk of disc space narrowing and a 59% reduction in the seventy 
of osteophytosis. No data were available for OA at peripheral sites. Videman et al 
(1998) studied 85 pairs of MZ male twins (Le. 170 sub ects) aged 35 to 69 years xvith j 
magnetic resonance imaging (MRI) of the thoraco-lumbar spine. Association analysis 
was performed using data for afl subjects, taking account of the fact that MZ twins were 
being studied through the use of the generalised estimating equation. Taql and Fokl 
genotypes were both significantly associated with MRI measures of spinal degenerative 
change, with the "t" and 'T' alleles associated with increased disease. 
The concept that genes regulating BMD may also have an association with risk of 
OA is also supported by several studies. Polymorphisms of the oestrogen receptor gene 
have been associated with both osteoporosis, (Sano et al, 1995; Kobayashi et al. 1996) 
and generalised OA (Ushiyama et al, 1998). In the ASP linkage study, an OA 
susceptibility locus was detected mapping to a region on chromosome IIq (Chapman et 
al, 1999). This region has also previously demonstrated significant linkage with a locus 
implicated in the regulation of bone mass from studies examining rare familial bone 
diseases (Gong et al, 1996; Johnson et al, 1997) and nomial variation of BMD within 
sibships (Koller et al, 1998). The recent hand OA linkage study also provided c%ldence 
for linkage with chromosome 2q, a region harbouring the IL-I gene farnih, cluster 
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(Leppavuori et al, 1999). This suggests that the IL- I RN locus may also be a candidate 
for OA and warrants further study. Work is ongoing from these latter linkage studies to 
refine the linkage region and to then attempt positional cloning of the novel disease 
susceptibility loci. 
Limitations 
The study's results are limited to early knee and spinal OA in women as the 
number of subjects with severe OA was too smaff. At the knee, the majority of cases had 
osteophytosis with very few having significant loss of joint space. Additional, larger 
studies would be required to confinn if the observed relationship between VDR genotype 
and knee OA was dependent on differing genetic influences on either osteophyte 
development or cartilage loss. Similarly at the spine, the majority of cases had early 
disease as assessed by spitW radiographs. Improved phenotypic resolution would have 
been achieved with spinal MRI in this early disease state, although this was not available 
on subjects. Numbers were also too small for analysis to be performed on thoracic and 
lumbar spines separately. 
The cross-sectional nature of the study design meant that prevalent OA was 
assessed and it was not Possible to address issues on disease incidence or progression. 
Longitudinal studies would again be needed to determine whether this locus has any 
inflUence on the progression ofjoint damage at t site. 
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The finding of haplotypic association with knee OA (Uitterlinden et aL 1997). 
and association between the FokI afleles and spirW MRI characteristics (Videman et al. 
1998) highlights the need for more extensive genotyping of the VDR gene. Haplot,, -pe 
analysis of a qualitative trait such as OA would be feasible, but large numbers of subjects 
would be required for adequate statistical power. 
The data in this chapter demonstrated an association between TaqI VDR 
genotype and both spine and knee OA, although no association was observed between 
presence of Heberden's nodes. Although correlations exist between presence of OA at 
different sites, it is not clear if this equates to the same disease process. It is unclear 
from this analysis whether the observed associations at the spine and knee reflect a 
common genetic influence on the same pathological process or independent effects at the 
two sites. Statistical adjustment or stratification of analyses may support site- specificity, 
although multivariate modelling of data in a large number of MZ and DZ twins would 
provide a more powerful tool to address this issue (Martin et al, 1997). 
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VII. 6 Conclusions 
The data presented in this chapter have shown a relationship between early knee 
and spinal OA and a VDR TaqI polymorphism, in unrelated women from the general 
population. The risk of OA was increased nearly Mold in those with the VDR 
genotypes "TT" and "Tt" when compared to those with the "tt" genotype. These 
findings suggest a dominant inheritance pattern of risk associated with carriage of the 
"T" affele. The risk of OA associated with VDR genotype was statistically independent 
of BMD, suggesting that the pathophysiological mechanisms underlying these results are 
likely to be more complex than a sirnple direct action on bone strength and consequent 
cartilage damage. 
Findings in other populations have confirmed associations between the VDR 
gene and both knee and spinal OA, and further research should now be aimed at 
characterising the molecular basis to this relationship between the VDR protein and 
cartilage/bone metabolism. The data also suggest that candidate genes associated with 
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viii. I Summary 
The data presented in this thesis have confirmed that genetic factors appear to 
play an important role in determining both bone strength and fracture risk in women from 
the UK. The heritability estimates from the classical twin analysis suggest that up to 98 
% of the population variance in total body BMD was accounted for by genetic factors. 
At specific skeletal sites the proportion of variance attributable to genetic factors ranged 
-C-- - trom 60 to 85 %, being highest in sites composed predominantly of trabecular bone. The 
population-based analysis used family history of fracture as a surrogate of genetic risk, 
and demonstrated a familial component to BMD and individual fracture risk. The data 
also suggested site-specificity in fracture risk, particularly at the wrist. In total, four 
candidate genes were analysed for association with BMD and related osteoporotic traits. 
Overall, the results suggested that the effect of individual genes on disease risk was 
modest, with potential and complex interactions between other candidate genes and 
enviromnental factors. 
Extending the findings from this thesis would enable a more detailed insight into 
the genetic actiology and architecture of osteoporosis. Modeffing and path-based 
analysis of the twin data would allow a breakdown of the genetic components acting on 
BMD, examining for common or site-specific influences. In addition it would also enable 
the interaction between BMD and risk of OA to be further explored. For these týpes of 
analyses a larger number of twin subjects would be needed to have adequate power, and 
this forms the basis of ongoing research at St. Thomas' Hospital. Collection of further 
twins would also allow the heritability for fracture risk at individual sites to be estimated. 
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Assessment of subjects from the Chingford Study continues, with data collection 
up to 8 to 10 years. It should now be possible to determine the number of incident 
fractures that have occurred over this time period, and due to the age of the cohort it is 
anticipated that a large number of these will be of the distal forearm. It should then be 
possible to examine the relationship between family history of fracture and risk of 
incident fracture, thereby reducing the potential bias with assessment of prevalent 
fracture. Collection of additional longitudinal BMD measurements would also allow a 
more accurate estimation in rates of change in BMD, reducing the effects of the precision 
of the DXA machines. Candidate gene association analyses could be repeated against 
these extended and recalculated rates of change, although results may be statistically 
rather than clinicaRy significant. 
To explore ftu-ther the relationship between OA and osteoporosis, additional 
genotyping of the Chingford cohort for the ER, IL-IRN and COLIAI gene 
polymorphisms would be required. These genotypes were initially obtained on a subset 
of women from the total cohort, although the findings with the VDR gene suggest 
ftirther analysis should be perfonned. With the availability of longitudinal OA data, it 
should also be possible to examine for genetic associations with either disease incidence 
or progression although power may be limited due to small numbers. With more 
comprehensive genotype information, the study could assess more accurately for gene- 
gene mteractions. It may also be possible to examine for gene associations with response 
to therapy, particularly HRT. 
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Future work should also be directed towards examining other candidate genes in 
this cohort, thereby allowing ftirther assessment of epistatic interaction between loci. 
During -the course of this work a number of genes in addition to the four that have been 
described have been analysed for polymorphic association with BMD and fi7acture risk. 
These include transforming growth factor 01 (Langdahl et al, 1997), calcitonin receptor 
(Taboulet et aL 1998), apolipoprotein E (Shiraki et aL 1997), osteocalcin (Dohi et aL 
1998), and parathyroid hormone (Hosoi et aL 1999). Many of these studies are small 
and have been conducted predominantly in subjects of Oriental descent. Confirmation of 
these findings in other ethnic and racial groups will be required in further studies. 
At present choice of candidate genes has been determined by a prior knowledge 
of bone pathophysiology. The number of potential candidates will increase as scientific 
knowledge increases about the control and regulation of osteoclasts and osteoblasts, and 
their interaction with the bone matrix. Studies in knockout mice have identified bone 
phenotypes, suggesting important roles of these genes in bone metabolism and 
development (Iotsova et al, 1997; Kuro-o et al, 1997; Mizuno et al, 1998; Xu et al, 
1998). Given the homology between the murine and human genomes, research is 
centred on examining whether the equivalent genes have similar effects in man. 
Identification of the gene defects responsible for rare familial bone diseases has also 
revealed additional candidates such as core-binding factor Al (Mundlos et al, 1997) and 
cathepsin K (Gelb et al, 1996; Johnson et al, 1996). Recent quantitative trait linkage 
analysis studies in mice (Klein et al, 1998; Higuchi et al, 1999) and humans (Devoto M et 
al, 1998; Niu T et al, 1999) have also identified chromosomal regions that may harbour 
novel susceptibility loci for low BMD and osteoporosis. Interestingly, som of these 
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linkage regions in the human studies are consistent both between study populations and 
with homologous regions identified in the mouse studies. Further work mdll be required 
to isolate the susceptibility genes in these regions, although this will be expedited by 
progress in the Human Genome Project. 
Once further candidate genes have been identified, it will be possible to screen for 
mutations and polymorphisms to assess the degree of genetic diversity. This has been 
undertaken for at least 175 candidate genes for cardiovascular disease (Cargill et al, 
1999; Halushka et al, 1999), with future predictions that over 1,000 genes wifl have soon 
I- - been analysed. It may then be possible to undertake large association studies with 
common allelic variants of multiple candidate genes (Kruglyak 1999). The challenge will 
be in interpreting the significance of results derived from this type of analysis. In 
addition, development of analytical methods will be required to explore the potential 
mteractions between genes and environmental factors. Large collections of well- 
characterised population groups will also be necessary. 
With an improved knowledge about the genetic determination of osteoporosis, 
what are the potential benefits to patients? Gene targets and molecular mechanisms may 
ultimately lead to novel drug discovery programmes, although this process may take 
some time to yield successful results. Knowledge that family history of fracture is an 
important clinical risk factor is important, and is recognised. in guidelines for disease 
management and assessment with DXA. Accurate genotype information on several 
candidate genes may also aid identification of subjects at increased fracture risk, although 
the sensitivity and specificity for such assessments wifi need to be determined prior to 
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wide-spread clinical use. Gene polymorphisms that predict response to current therapies 
(i. e. vitamin D, HRT, bisphosphonates) may also aflow the targeting of treatment to 
those most likely to respond and benefit. Gene therapy is also often highlighted as a 
potential goal for this type of research, although at present this remains some distance in 
the future. 
In conclusion, this thesis has demonstrated a significant genetic contribution to 
osteoporosis and fracture risk in postmenopausal women. Future work may identify 
additional susceptibility genes and examine their influence on disease risk, thereby 
providing an improved understanding of the molecular mechanisms underlying the 
development of osteoporosis. This will hopefully ultimately lead to improved preventive, 
diagnostic and treatment options for subjects with osteoporosis. 
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APPENDIX A 
TWIN STUDY QUESTIONNAIRE 
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50 
Draft Research Unit 
E N E R A L Q U E S T I O N N A I R E 
2 0 P R 0 D U C T 1 0 N TH 
PART 
Study Type Centre Code Study No Date (Day[Month[Year) 
STH 1 
Interviewer Code Visit Month Date Of Birth (Day/Month/Yeax) 
A. About You 
Sumame 
First Name(s) 
Sex 0 Male 0 Female 
Handedness 0 Right 0 Left 0 Ambidextrous 
Eflu& Origin (Select one) 
0 Caucasian 0 Asian 0 Oriental 0 Black 0 Other 
Town of Birth Country of Birth 
hrs min 
How long since you last ate or drank anything other than water? [I]. E: l 
GTT Time 0- Time finished glucose drink (to be drunk within 5 minutes) 
120 Time (minutes) 
FSHA and Oestradiol 0- No 0 Yes 
Testosterone 0 No 0 Yes 
1/9 
314 
Draft Study Type Centre Code Study No Vsit ', I nth 
T 11 S'ý TH 
B. You and Your Twin 
Give Your Birth Weight in kg 





n M-^'+ Vr%^%Al 
Sister 
0 Older than twins 





What type of delivery? 
Normal 
U LJVI IL [-. I I%jVT 0 Younger than twins 0 Caesarean 0 Anything else or unknown or sister 
0 Premature (over 4 weeks) C N/A 
0 Don't Know 
C. Zygosity Score (score for each question given in parentheses) 
In childhood, were you and your twin described as 
0 As alike as peas in a pod (1) 
0 Of ordinary likeness (2) 
0 Don't Know (3) 
Who could tell you apart at school age? 
0 Parents (1) 
0 Brothers/Sisters (2) 
0 Close school friends (3) 
0 Strangers (4) 
0 Don't Know (5) 
Did you share the same room as children? 
0 Yes 
0 No 
0 Half of the time as child 
0 Reared apart since birth 
The Examination 
At school, did people have trouble telling you apart? 
0 Yes (1) 
0 No (2) 
0 Don't Know (3) 
Total 





0 If total <5 Monozygous 
0 If total =8 Dizygous 
0 Unkown = 6,7 and >8 
If yes, until what age did you share the same home? years 
Present height cms Lifetime maximum height cms 
, kg Weight 
kg r The weight You were when aged 20 
111 
Lowest weight aged 20 or ove 
Maximum weight you have been not including pregnancy 













Draft SIT H 
initial systolic blood presure Initial diastolic blood pressure 
G6p stren 
- 
gth best of 3 recordings on 







I CITIS culs 
Repeat systolic blood presure Repeat diastolic blood 
Dolonmeter score of the fore head 
Thigh Measure. Measure the distance from where the leg meets the body 
down to the top of the knee cap and then half this distance and measure 
around the leg at this half way distance 
Quad Measure. Measure 15cms up from the bottom of the knee 
cap and then measure around the leg. 
E. Medical History 
Left thigh Right thigh 
cms CrIls 
Left quads Rightquads 
cms cmS 
Do you have any of the foHowing rheumatic diseases? 
Sle/Lupus Psoriatic arthritis 
Ankylosing Spondyliis 0 Polymyalgia rheumatica 
Fibromyalgia 0 Other 
0 Gout 0 None of the above 
Do you suffer, or have you suffered, from any of the following soft tissue rheumatic problems? 
0 Frozen shoulder 
0 Housemaids knee 
0 Tennis elbow 
0 Carpal tunnel syndrome 
0 Other 
0 None of the above 
Have you any of the following operations? Year of first operation 
0 Hip replacement -----------------IIII 
0 Knee replacement 
----------------- T 
0 Arthoscopy -------------------- 
0 Other knee surgery ----------------- 
" Elbow replacement ---------------- 
" Shoulder replacement -------------- 
0 Laminectomy ---------------- 3/9 
316 





F. Occupational History 
FEMALE OCCUPATION 
VI V2 V3 IIIN HIM IV 
Housewife Retired Permanently University Secretary 
Disabled Lecturer Teacher Factory Waitress Cleaner 
Student Polytechnic Clerical Skilled Chartered 
Lecturer Usher K Unemployed Accountant Receptionist Day Assistant 
PR Nursery Telephone Doctor Shop I Operator Factory 





V1 V2 V3 1 11 IIIN IHM IV V 
Divorced LongTerm Permanently University Teacher Shopworker Caretaker Assembler Road 
Unemployed Disabled Lecturer S'. k'CCPcr 
Single Polytechnic Policeman Ambulance Packer 
If unemployed Chartered Lecturer Dustman 
Dead less than 1 yr Accountant CivilServant Skilled Prison 
or retired Computer Officer Porter 
record Doctor Prog Accountant Builder 
husband's Postman 







Present occupation (select one using the above as a guide) 
V1 V2 V3 1 11 IIIN HIM IV V Years in present employment 
a] 
000000000 
Partners present occupation 
vl V2 V3 1 11 MIN HIM IV V 
000000000 
Enter as per coding using the twins own assessment of amount of knee bending (as a guide: typical clerical work 
would be classed as'minimal', typical nursing duties would be classed as'moderate', child rearing and 
farming would be class, fied as' 
lot') 
Knee Bending Score for Present Employment 






Studv Type Centre Code Study. N*o 
D raft 
:TSTH 
occupational History (continued) 
Leave blank if no previous employment 
past occupation I 
vi V2 V3 1 11 IIIN HIM IV V Years in this employment 000000000 
Knee Bending Score for Past Employment I 
0 None 0 Minimal 0 Moderate 0 Lot 0 All the Time/Continuously 0 N/A 
past occupation 2 
V1 V2 V3 1 11 IIIN HIM IV V Years in this employment 
000000000 
Knee Bending Score for Past Employment 2 
0 None 0 Minimal 0 Moderate 0 Lot 0 All the Time/Continuously 0 N/A 
Past occupation 3 
V1 V2 V3 1 11 IIIN HIM IV V Years in this employment 
000000000 
Knee Bending Score for Past Employment 3 




-70ý -- -- -tLUdyTvpe CentreCode Study No Draft 
--- -- I V, sit Month 
TSTH 
G. Exercise History 
As a guide: 
Ask about the twin's sporting activities, determine the time spent in each, and classify them using the tables, bearing in mir, ý that s activity should cause breathlessness or sweating, moderate activity should not. The classification of each spix- ar% ac -0, history obtained from the twin. d: r,, z0 


















Martial Arts X 
Boxing X 
Are you currently undertaking any regular physical activity once a week for at least one year? 
If No, please go to question XX 
How many minutes per week do you spend in vigorous weight-bearing activity? 
How many minutes per week do you spend in moderate weight bearing activity? 
How many minutes per week do you spend in vigorous non-weight bearing activity ? 
How many minutes per week do you spend in moderate non-weight bearing activity? 
0 No 0 Yes 
At your Most Active Between 20 and 30, did you do at least I year of Regular Physical Activity 
0 No 0 Yes 0 N/A 
The year you did most regular physical activity between 20s and 30s 
How many minutes per week did you spend in vigorous sport in your 20s? 
How many minutes per week did you spend in moderate sport in your 20s? 
How many rninutes per week did you spend in vigorous non-weight bearing activity in your 
20s? 
How many actual hours per week do you spend on your feet at work and play? 





11. Reproductive History 
Study Type Centre Code Study No Visa Month 
LSý TH 
1ýis section is for females, only. If the twins are male, go to section I (Family Size) 
Ii 
H, l ljow old were you when you had your first menstrual penod? '; 
H. 2 What is your menopausal status? 
0 Definitely Pre-menopausal 
() Definitely Post-Menopausal 
C) Probably Post-Menopausal if you have had a hysterectomy and are ov*er the age of 54 
0 Possibly Post-Menopausal if you have had a hysterectomy and are age*d 50-54 years 
0 Possibly Pre-menopausal if you had hysterectomy and are ag*ed 45-49 years 
0 Probably Pre-Menopausal if your menopausal status is unknown and you are less than 45 years old 
or started HRT before the menopause 
NOTE: take blood for FSH and OESTRADIOL if twin falls into any "probable" or "possible" category. 
H. 3 How old were you when you had your last regular period ? years 
HA What day of your menstrual cycle are you currently on? 
I st day of last period Use -I if HRT started before regular 
periods ceased 
H. 5 How many pregnancies have you had (including n-ýiscarriages, still births and terminations)? 
H. 6 How many children were you involved in bringing up, including adopted? 
(For foster children, 
10 years fostering =I child equ, valent) 
M Have you had a hysterectomy? 0 No 0 Yes 
0 Partiai 0 Don't Know 
H. 8 If yes, how old were you? years 
H-9 What was the main reason for the hysterectomy/endometrectomy? 




H. 10 Have you had any ovaries removed, with the hysterectomy or at any other time? 
0 None 
7/9 
One 0 Both 0 Partiai 
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---------------/Study Type CentreCode S tudy Draft ýNit Morith 
TSTH 
Which of the following gynaecological operations have you had9 
Dand C0 Ovarian Cyst 0 Sterilization Other C None 
I 
H. 12 Have you ever taken the Oral Contraceptive Pill (OCP)? 
No 0 Yes current 0 Yes, Ex-User 0 Don't Know 
13 if yes, how old were you when you First went on to the OCP? 
H. 15 Have you ever had Hormone Replacement Therapy (HRT)? 0 No 
H. 14 How long were you on the OCP. 1 mnths 
I j Yes, Current C Yes, Ex-User 0 Don't Know 
H. 16 If yes, how old were you when you first went on to HRT7 
H. 17 How long were you on HRT? months (If less than 1 month, enter as 1) 
H. 18 Enter the ROUTE and TYPE of HRT. Use the longest route if more than one type has been used. 
HRT TYPE HRT ROUTE HRT PREPARATION 
I= Premarin 2 1 
2= Prempac C 2 2 
3= Estroderm TTS 1 1 
4= Nuvelle 2 1 
5= Hormonin 2 
6= Progynova 2 
7= Lival / Tibolone 2 3 
8= Other n/a n/a 
9= Don't Know n/a n/a 
0= n/a n/a n/a 
Route 
1) Patch 0 2) Oral 0 3) Vaginal 0 4) N/A 0 
Prep'aration 
1) Oestrogen Only 0 2) Oestrogen and Progesterone, 0 3) Oestrogen, Progesterone, Androgen 0 4) Unspecified 0 N/A 0 
Select one only 
H. 19 What was the main reason you began taking HRT? H. 20 Were there other reasons you began taking HRT? 
0 Menopausal symptoms (flushing, sweating, palpitations) 0 Menopausal symptoms (flushing, sweating, palpitations) 
0 Depression 0 Depression 
0 Low Sex Drive 0 Low Sex Drive 
0 Worry about Osteoporosis/Thin Bones 0 Worry about Osteoporosis/Thin Bones 
0 To Improve General Health 0 To Improve General Health 
0 Had a Hysterectomy 0 Had a Hysterectomy 
0 Ovaries had been removed 0 Ovaries had been removed 
0 Tiredness 0 Tiredness 
0 Headaches - 
0 Headaches 
0 Joint or Bone Pain 0 Joint or Bone 
Pain 
0 Twin did and she felt better 0 Twin did and she 
felt better 
0 Advice of doctor 0 Advice of doctor 
0 Other 0 Other 
0 N/A Q/0 0 N/A 
CP/ 7 121 
0 
ýýdy Type Centre Code Study. No isit Month Draft 
T TH 
Select one only 
H, 21 What was the main reason you stopped taking the HRT? H-22 Were there any other reasons that you stopped taiL, -,, - HRT' 
(D Did not find that the HRT helped the symptoms 
0 Menopausal Symptoms came to and end 
0 Advice of Doctor 
Side effects - return of periods 
Sore or swollen breasts 
0 Nausea 
0 Water Retention 
0 Skin Rash or Irritation 
0 Weight Gain 
0 Twin Sister Stopped 
0 Other 
0 N/A 
0 Did not find that the HRT helped the symptoms 
C Menopausal symptoms came to an end 
0 Advice of doctor 
0 Side effects - return of periods 
0 Sore or swollen breasts 
0 Nausea 
0 Water retention 
0 Skin rash or irritation 
0 Weight gain 
0 Twin sister stopped 
0 Other 
0 N/A 
H. 23 Were I are your periods regular? (5 days difference or more = irregular) 0 No 0 Yes 0 Don't Know 
H. 24 If yes, how many days was your menstrual cycle (usually)? 
H. 25 How many days did/do you bleed each cycle? 
H. 26 Excluding pregnancies and the menopause, have you had any episodes where your periods stopped for more than six months? 
0 No 0 Yes 0 Don't Know 
H. 27 If yes, how many months in total did you miss your period? months 
H. 28 How many children did you breast feed? 
H. 29 How many months in total (for all children) did you breast feed? months 
H. 30 Do/did you get menopausal symptoms (e. g. sweating, flushing)? 
0 No 0 Yes 0 N/A 
?0 No 0 Yes 0 N/A H. 31 Do/did you experience depression as a symptom of the menopause. 
Family Size 
This section is for rnale twins 
I How many children were you involved in bringing up (including adopted) EE 
9/9 





Twin Research Unit 
"N QUEST IONNAI RE PART 
PR0DUCT0NSTH 
To be completed by the research nurse 
Study Type Centre Code Study No VIsItMonth 
STH 




J. I Have you had hypertension? 0 No 0 Yes 0 During pregnancy 
J. 2 Have you had Ischernic Heart Disease (including angina, heart attack)? 0 No 0 Yes 
J. 3 Have you ever lost the use of an arm, leg, your vision or ability to speak? 
0 No 0 Yes (less than 24 hrs) 0 Yes (more than 24 hrs) 
JA Can you walk a mile at your own pace on a flat level, not up or downhill, without stopping? 0 No 0 Yes 
J. 5 If not, what makes you stop? 
0 Discomfort in calves 0 Discomfort in chest 0 Breathlessness 0 Other (Le non cardiac reason) 0 N/A 









Pulmonary Disease Lung Function Measurements and Medication 
J. 7 Vitalograph machine number (if not taken leave blank) 
J. 8 Expected FEN I- calculated using the lung function calculator 
(FEV = Forced Expiration Volume) 
J. 9 Number of blows into the vitalograph 
J. 10 Measured FEV I- recorded from x axis at I sec. 
The highest recording is taken ( If 
between 2 lines estimate downwards) 
II Measured FVC - recorded from x axis at 6 second. (if between 2 lines estimate downwards) 
[I 
(FVC = Forced Volume Capacity) 
J. 12 Room Temperature degrees c. 
J. 13 In the past 2 weeks, have you had a cold or 'flu-like illness'? 0 No 0 Yes 
J. 14 Have you ever had asthma? 0 No 0 Yes (whether treated with medication or not) 
J. 15 If yes, what medication are you currently taking for it? 
0 Steroidal (blue) 0 Non-steroidal (brown) 0 Other 
J. 16 How often are you taking medication for asdima? 
0 PRN (less than once a day) 0 OD 0 BID 0 TIDS 0 QDS 0 PRN (more than QDS) 




1. sa l, lontn 
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K. Hair and Teeth 
K. I Number of second or adult teeth lost (through decay) K. 2 Age you lost all second or adult teeth 
El 0 1-5 El 6-10 11-20 over 20 
K. 3 Original young adult hair colour 





Fý Strawberry blonde (reddish-fair) 
[I Light/brown/fair/mousey 
Fý Other 
KA Age you noticed more than one white hair 
K. 5 Age at which you tmed mostly white 
K. 6 Age you tumed completely white 
L. Fracture History and Osteoporosis 
Complete this section if # bone. If no #, go to section M 




arm not wrist 
ankle 
leg not ankle 
Severity of injury I 
Major injury (RTA) 
Minor injury 
fall < ht of chair 
Age of fracture I 
yrs 
Site of fracture 2 Site of fracture 3 Site of fracture 4 
[I spine [I spine El spine 
F-I wrist 0 wrist 0 wrist 
[I hip 0 hip El hip 
F-I arm not wrist El arm not wrist 0 arm not wrist 
El ankle 0 ankle ankle 
E] leg not ankle [I leg not ankle leg not ankle 
Severity of injury 2 Severity of injury 3 Seventy of injury 4 
[] Major injury (RTA) [I Major injury (RTA) [: 1 Major injury (RTA) 
E] Minor injury [I Minor injury [I Minor injury 
fall < ht of chair fall < ht of chair fall < ht of chair 





Have you been diagnosed as having osteoporosis? [I No [I Yes 
C: l Don't know 
If yes, what treatment did/do you have? 
M No treatment 
D Don't know 
El HRT 
El Bisphosphonates (Didronel or Fosamax) 
C] Calcium and Vitamin D 
M Other treatments 
3/13 




arm not wrist 
ankle 
El leg not ankle 
Seventy of injury 5 
ED Major injury (RTA) 
[I Minor injury 
fall < ht of chair 




Draft , 3tudy Type Centre Code Study No 
IT S'T H Diabetes 
Do you have diabetes? 
[I No 
Yes, insulin dependent Type 1, treated with insulin from diagnosis 
Yes, non insulin Type 2 
Have/had diabetes unsure what type 
Gestational diabetes 
Other Endocrine 
Have you ever had thyroid disease? [I No [I Yes Hypothyroid or Hyperthyroid disease Don't know 
Cancer 












Have the following ever or frequently(at least once a week) changed colour in C1 Yes C3 No C1 Yes No the cold weather? 
If yes at what age did this begin? yrs yrs , 
Is this still a problem? C1 Yes C1 No 0 Yes C3 No 
If not, (i. e not happened within the last 12 mths) at what age did it end? 
--Lyrs 
EE yr-S 
0 None El None Do you remember a sequence of colour changes in your hands or feet? If colour One colour One colour 
changes included/white/blue-purple then score. If not, cross none. 
Two colours Two colours 
More than two colours El More than two colour 
Is the colour change accompanied by numbness? 0 Yes EJ No Cý Yes C1 No 
Is the colour change accompanied by pain? 0 Yes 0 No 
I 
El Yes No 
Does anyone else in the family (other than your twin) notice these symptoms? 
Parents Other sib Children 
C1 No Yes [I Don't know No Yes F-I Don't know / N/A ED No [I Yes 
Joint disease 
Have you ever been diagnosed as having Arthritis of the knee(s)? No 
[I Yes [] Don't know 
Have you ever been diagnosed as having Arthritis of the Hip(s)? No 
[I Yes C3 Don't know 
Have you ever been diagnosed as having Arthritis of the Hand(s)? ED No 
[I Yes El Don't know 
Do you have Rheumatoid Arthritis? 
ED No [3 Yes (Confirmed by blood test) C3 Yes (Not confirmed by blood test) Don't know 












Have you ever had pain or stiffness in the foll 
Left hand Right hand Left Knee 
[] No No No 
Cl Yes Yes Yes 
Age the pain or stiffness stated in these joints 
Left hand Right hand Left knee 
I- I 













-I-,.. - ., ýkkti 
Right hip Back Ne,: k Othc, - 
No No - No 
Yes Yes - Yes Yes 
Right hip Back Neck Other 
Left hand Right hand Left knee Right knee Left hip Right hip Back 
<5 days <5 days D<5 days El <5 days [I <5 days 0<5 days E] <5 days 
5-15 days 5-15 days [15-15 days [15-15 days [15-15 days 0 5-15 days E 5-15 days 
16-30 days 16-30 days 0 16-30 days [116-30 days El 16-30 days El 16-30 days F-I 16-30 days 
> 30 days > 30 days El > 30 days [I > 30 days [I > 30 days [I > 30 days Cl > 30 days 
Have you had pain in the last month in the following joints? 
Neck Other 
[] <5 days El <5 
C] 5-15 days CD 5-15 
D 16-30 days D 16-30 
Cl > 30 days C] > 30 
Left hand Right hand Left Knee Right knee Left hip Right hip Back Neck Other 
7- No D No El No D No D No D No Cl No D No [I No 
0 Yes Fý Yes F-I Yes D Yes D Yes D Yes El Yes El Yes D Yes 
Number of full days pain lasted in the following joints in the last month ( refers to continuous pain from first thing in the morning to 
the last thing at night). If <I day enter 0 or enter number of days. 
Left hand Right hand Left knee Right knee Left hip Right hip Back Neck Other 
1 [1: 1 1--] FF E-1 
Is the pain in the following joints in the last year better, worse or same 
Left hand Right hand Left knee Right knee Left hip Right hip Back Neck Other 
D Better ED Better F-I Better F-I Better D Better D Better D Better ED Better 
D Better 
[I Same EDSame Fý Same Fý Same [I Same D Same ED Same D Same Cl Same 
ED Worse El Worse Fý Worse D Worse Cl Worse [I Worse ED Worse 
CD Worse E] Worse 
How many painful episodes have you had in the last year in the 
following joints? 
Left hand Right hand Left knee Right knee Left hip Right hip 
Back Neck Other 
None Fý None F-I None Fý None Fý None 
D None E] None None C1 None 
One F1 One D One Fý One Fý One 
D One 0 One One One 
2-4 EJ 2-4 [12 -4 Fý 2-4 
Fý 2-4 2-4 [12 -4 2-4 2-4 
D >5 E] >5 F-I >5 
Fý >5 Fý >5 >5 
Have you ever inj ured the following joints long enough to rest 
it for more than a week? 
Left hand Right hand Left Knee Right knee Left hip 
Right hip Back Neck Other 
Fý No D No D No [I No D No 
El No D No 7No No 
Yes D Yes Yes ED Yes D Yes 




, Study Type Centre Co(je sludý No 
I 
Do You get early morning stiffness in the following joints ? If yes, give the length of time (in minuEes) it lasLs 
If 
Left Hand No Yes (every morning) - 1/2 morn Y&1,, 2 N 
Right Hand El No Yes (every morning) -- 1/2 morn Y& 1/2 N 
Left Knee El No F-I Yes (every morning) 1/2 morn Y& 1/2 N mins 
Right Knee D No D Yes (every morning) 1/2 morn Y& 1/2 N mins 
Left Hip [I No D Yes (every morning) 1/2 morn Y& 1/2 N mins 
Right Hip No Yes (every morning) El 1/2 morn Y& 1/2 N mins 
Back No Yes (every morning) 1/2 morn Y& 1/2 N mins 
Neck El No Yes (every morning) 1/2 morn Y& 1/2 N mins 
Other [I No El Yes (every morning) El 1/2 morn Y& 1/2 N mins 
Joint Examination 
Is there definite evidence of boney artiocular sweUing affecting any of the DIP or PIP joints? 
0 Yes 0 No 
M. Drug History (See coding sheet) 














Age started Duration (months) Past Drug Code Age started 
Duration (months) 
I1 
1) ELI - 
F1 IE 
-ij 
2) 1 E-ij 








Draft ----study Type Centre Code Study No Visit 
LTL ýS TH 
N. Tobacco and Alcohol 
N. I Have you ever smoked cigarettes, cigars or a pipe? 
[] Never smoked 
Fj Yes, current smoker 
C] Yes ex-smoker 
N. 2 At what age did you start smoking? 
N. 3 Do you smoke at all nowadays? 0 Yes 0 No 
If you "Never Smoked", please go to question N. 7 
If you are a "Current" or 'Ex" smoker, continue with 
question N. 2 
NA If ex-smoker at what age did you stop altogether? 
N. 5 How many cigarettes do/did you usually smoke each day? 
N. 6 What is your Pack Year habit? (No. cigarettes per day smoked X No. years smoked) / 20 
N-7 What is your current average alcohol consumption? 
F-I Never 
El Social Occasions Only 
F-I 1-5 Units per week 
D 6-10 Units per week 
11 -15 Units per week 
16-20 Units per week 
21-40 Units per week 
More than 40 units per week 
Amount Unspecified 
N. 8 What is your lifetime average alcohol consumption? 
Never 
Social Occasions Only 
ED 1-5 Units per week 
Fý 6-10 Units per week 
[] 11 - 15 Units per week 
F1 16-20 Units per week 
El 21-40 Units per week 
f-I More than 40 units per week 




S, ýUdy Type Centre Code Study No 
Draft 
T STH 
0. About Your Relatives Where infomiatlon Is unavailable, please leave blank. 
Your Mother 
Year of birth Year of death Country of birth 
Your Father 
Year of birth 
Your Grandparents 
Year of death 
I 
Maternal grandmother's country of birth 
Paternal grandmother's country of birth 
Your Children 
Country of birth 
Maternal grandfather's country of birth 
Paternal grandfather's country of birth 
Please give, in birth order, including stillborn or premature babies that died soon after being born, 
applicable, year of death 





LI 0 Male 
3 






































Your Brothers and Sisters 
_-__-SýudyType 
CentreCode Study No 
TS T'H 
Please state, in birth order, your siblings year of birth and, if applicable, year of death 














male Female C-) Unknown 
0 Male C Female C Unknown 
Male Female Unknown 
'-'ý Female Unknown Male 11 ý 
Male C Female 0 Unknown 
Male 0 Female 0 Unknown 
Male 0 Female 0 Unknown 
I 
0 Male 0 Female 0 Unknown 
Male 0 Female 0 Unknown 




Sites of Fracture 
E-g of a maior iniurv include a road traffir arrripm nnA ý. n- C-il 
Xý M 
- Mother Age at fracture I Father Age at 
I fracture 
C] Spine El Major 
acycTILY 
0 Minor [I Don't know 
Fý Wrist [I Major Fý Minor C1 Don't know 
Cl Hip [3 Major [I Minor [I Don't know 
C] Arm. 
(not wnst) 
[I Major 0 Minor C1 Don't know 
C] Ankle Major 0 Minor 0 Don't know 
F1 Leg Major Minor 0 Don't know 
M Don't know 
Seventy 
Spine Major Minor Don't krc-, v 
Wrist Major Minor Don t knc,,,, 
Hip E: Major Minor Don't know 
Arm E 
-7-1 
' (not wrist) Major t know Minor Don 
Ankle Major C3 Minor Don't know 
Leg Major (: 1 Minor L- Don t know 
0 Don't know 
Any sister 












Major F-I Minor 0 Don't know 
0 Major El Minor Fý Don't know 
E] Major [I Minor El Don't know 
El Major El Minor El Don't know 
El Major [] Minor Fý Don't know 
[I Major El Minor F1 Don't know 







F-I Don't know 
Major 
oevenly 
CD Minor [I Don't know 
E] Major Cl Minor ED Don't kno%ý 
El Major Cl Minor 0 Don't knov, 
C] Major ED Minor Cl Don't knoy 
C] Major El Minor [I Don't knoy 
k ' D [I Major El Minor t nov on ED 
Not ai3plicable 




ED Minor F-I Don't know 
Wrist Fý Major Fý Minor 0 Don't know 
Hip 
Mi Fý Don't know Fý Major nor [I 
ED Arm 
(not wrist) FI Major El Minor M Don't know 
0 Ankle 
M Mi El Don't know Major nor 
0 Leg 
ED M M Minor C1 Don't know ajor 
0 Don't know 
C1 Not applicable 10/13 332 
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A'N YCHI LD 




F1 No Treatment 
fý HIRT 
C] Bisphosphanate 
7 Calcium and Vit D 
F] Other 




Calcium and Vit D 
D Other 
















E] Calcium and Vit D 
ED Other 
7 Don't Know 
Does anyone in the family have Arthritis of the knee? 
0 Yes 
Fl No 






0 Don't Know 
Yes 
No 
0 Don't Know 
0 Yes 
Cl No 
0 Don't Know 
Does anyone in your family have Arthritis of the hip? 
Yes 
No 
0 Don't Know 
Yes 
No 
Fý Don't Know 
0 Yes 
Fý No 
0 Don't Know 
M Yes 
f-I No 
M Don't Know 
ED Yes 
Fl No 
Fl Don't Know 
Does anyone in your family have Arthritis of the hands, including wrists? 
0 Yes 
0 No 
ED Don't Know 
Fý Yes 
F-I No 
El Don't Know 
El Yes 
Fý No 
Fý Don't Know 
Fý Yes 
El No 
El Don't Know 
ED Yes 
Cl No 
0 Don't Know 
Does anyone in your family have Thyroid Disease? 
0 Yes 
0 No 
0 Don't Know 
0 Yes 
ED No 
F1 Don't Know 
Cl Yes 
Fý No 
Fý Don't Know 
Fý Yes 
Fý No 
f-I Don't Know 
Fl Yes 
Fl No 
Fl Don't Know 
Does anyone in you family have Rheumatoid Arthritis? 
Yes (confirmed by 
blood test) 
0 Yes (not confirmed 
by blood test) 
El No 
0 Don't Know 
Yes (confirmed by 
blood test) 
Yes (not confirmed 
by blood test) 
F] No 
C3 Donl Know 
Yes (confirmed by 
blood test) 
Yes (not confirmed 
by blood test) 
D No 
0 Don't Know 
Yes (confirmed by 
blood test) 
Yes (not confirmed 
by blood test) 
Fý No 
Don't Know 
Yes (confirmed by 
blood test) 
C3 Yes (not confirmed 





S 'y Type Centrc Code 3LUUY NO Draft 
TIST: H 
MOTHER FATHER ANY SISTER 





unsure what type) 
Yes 
No 
0 Don't Know 
Y Yes 





unsure what type) 
Visit 
ANY BRCTHER ANý'CHIM 





unsure what tý? e) 
Yes 
No 
Don I Know 
Yes 
T-unsurc -, 'hat t,, -PC) 
Does anyone in your family have non insulin Dependent Diabetes Mellitus Type 2? 
Yes 
No 
Cl Don't Know 
Y Yes 
unsure what type) 
Yes 
No 
0 Don't Know 
ý Yes 
unsure what type) 
0 Yes 
ED No 
7 Don't Know 
Y Yes 
unsure what type) 





unsure what type) 
El Yes 
El No 
El Don't Know 
Y Yes 
unsure what type) 
El Yes 
0 No 
F-I Don't Know 
0 Yes 
(unsure what type) 
Treated by diet/tablet sat the beginning ma. ý 
have had to progress on to insulin 
:ý Yes 0 Yes 
E: No 0 No 
Don't Know Don't Know 
Yes Yes 





Fý Don't Know 
Y Yes 
unsure what type) 
ED Yes 
ED No 
0 Don't Know 
Y Yes 
unsure what type) 
Does anyone in your family suffer from Hypertension? 
Yes Fý Yes 0 Yes El Yes ED Yes 
No Fý No Fý No No No 
El Don't Know 0 Don't Know 0 Don't Know 0 Don't Know Don't Know 
Does anyone in your family have Ischemic Heart Disease ( including angin a, Heart attack)? 
Yes Fý Yes Fý Yes ED Yes Yes 
El No El No Fý No 0 No No 
0 Don't Know FI Don't Know 0 Don't Know M Don't Know E3 Don't Know 
Has anyone in your family had a stroke? 
Yes 0 Yes F-I Yes 
0 Yes C) Yes 
No El No 0 No 
0 No No 
Don't Know Fý Don't Know Fý Don't Know 
F-I Don't Know Don't Know 
Does anyone in your family have Asthma (however treated)? 
Cl Yes 0 Yes Fý Yes Yes 
Yes 
C1 No 0 No Fý No 
No No 
0 Don't Know C1 Don't Know [D Don't Know 






Study; jyype Centre Code stuclý No 
STH 
ANY SISTER ANY BROTHER 
Does/did your mother, any sister or any child have/had Breast Cancer? 
Yes -Lj Yes 
No No 
Don't Know Don't Know 
Does anyone in your farrdly have Colon Cancer? 





F1 Yes 0 Yes 0 Yes Yes Yes 
F] No 0 No No No No 
F] Don't Know 0 Don't Know Don't Know 0 Don't Know Don't Know 
Does anyone in y our family have Gasterectomy? 
FI Yes 0 Yes El Yes 0 Yes Yes 
n No 0 No 0 No 0 No 
El No 
n Don't Know F-I Don't Know F-I Don't Know 0 Don't Know 
0 Don't Know 
Does anyone in your family have Cholecystectomy? 
Fý Yes 0 Yes 
ED No FI No 
Fý Don't Know 0 Don't Know 
Fý Yes 
7 No 




Fý Don't Know 
F-1 Yes 
R No 
R Don't Know 
APPENDIX B 
CHINGFORD, STUDY QUESTIONNAIRE 
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Telephone - Home 






ý Previous occupation 
Husband occupation 
Hand dominance (1=1eft 2=right 3=both) 





















































gedical History cont. 
Weight (kg) 
Max -2, 
min 3 3= 
Age 20 34..., 




2=ex (how long 
stopped yrs) 
Max (per day) 37= 





O= Units (per wk) 4. 
Family History 
Any operations 














2=definite Fland Knee 
3=adopted 















JOINTS AFFECTED BY ARTHRITIS 
JOINT 
Name and address of contact: 
Relationship to patient: 
YEAR SYMPTOMS 
(also state if present) 
-10 
338 
Have you ever had back pain lasting more than a week? 
When/dates? I 
What problem? 
2. Have you ever seen a Dr. about back pain? 
What treatment did you have? ý- 
3. Have you noticed a loss of height, a stoop or a hump? 
How much height have you lost? inches. 
Have you ever taken steroid tablets? 
Dates 
I-I 
How long for? mths. 
5. Have you ever taken calcium tablets? 
Dates 11 How long for? mths. Dose I mg 
6. How many pints of milk do you drink in a week? 
7. How many times a week do you eat hard cheese? 
8. How many small pots of yoghurt do you eat a week? 
mg Calcium intake per week please leave 
9. Have any of the following relatives had: (1=yes O=No) 
Mother Grandmother(mothers side) Sister Aunt(mothers side) 
Fracture 
i 
of : El El p H 
Wrist F-I F-1 F-1 El 
Spine F-1 F-I El 
(add number next to box for amount of times fractured) 
10. Do any of the following relatives have: 
(1=Yes O=No) 
Sister Aunt(mothers side) 
F-I El 
Mother Grandmother(mothers side) 
lost height 
1: 1 Fý 
(add no. of inches lost next to box) 
stoop 0 El 
Hump D F-I 
11 F-I 
339 
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